CUMULATIVE SUPPLEMENT 12
DECEMBER 2002



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2002

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 12

December 2002

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

CUMULATIVE SUPPLEMENT 12
December 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DANBURY PHARMACEUTICALS INC (DANBURY PHARMA)	WATSON LABORATORIES INC (WATSON LABS)
DURAMED PHARMACEUTICALS INC (DURAMED)	DURAMED PHARMACEUTICALS INC SUB OF BARR LABORATORIES INC (DURAMED PHARM BARR)
DERMIK LABORATORIES INC (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
JANSSEN RESEARCH FDN (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC (JOHNSON AND JOHNSON)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
MCNEIL CONSUMER HEALTHCARE DIVISION (MCNEIL CONS)	MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIVISION MCNEIL PPC (MCNEIL CONS SPECLT)
MOVA PHARMACEUTICALS CORPORATION (MOVA)	CLONMEL HEALTHCARE LTD (CLONMEL HLTH)
NMC LABORATORIES INC	ALPHARMA US PHARMACEUTICAL DIV (ALPHARMA US PAHRM)
PARKE DAVIS PHARMACEUTICALS LTD (PARKE DAVIS PHARMS)	PFIZER PHARMACEUTICALS LTD (PFIZER PHARM LTD)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
THAMES PHARMACAL COMPANY INC (THAMES)	TARO PHARMACEUTICALS NORTH AMERICA INC (TARO PHARMS US)
WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waiver its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waivers its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity

1.4 TRAMADOL HYDROCHLORIDE TABLETS. Tramadol Hydrochloride 50 mg tablet products approved under section 505(j) are marked with a (*) because there are special considerations governing the substitution of these products. The tramadol hydrochloride 50 mg tablets marked with a (*) are therapeutically equivalent (AB) to RW Johnson's Ultram (Tramadol Hydrochloride) 50 mg tablets. However, because of RW Johnson's exclusivity and patent protection for the 25 mg titration dosing regimen, tramadol hydrochloride drug products approved under section 505(j) may not carry the labeling for the 25 mg titration dosing regimen. Ultram 50 mg tablets are scored for use in the 25 mg titration schedule; tramadol hydrochloride 50 mg tablets approved under 505(j) are not scored. Prescribers and dispensers should be aware of this scoring difference between Ultram and other tramadol hydrochloride tablets and take it into account when writing a prescription or practicing drug product selection.

1.5 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/22bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.
The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product

activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2001	JUN 2002	SEP 2002	DEC 2002
DRUG PRODUCTS LISTED	10166	10193	10329	10465
SINGLE SOURCE	2665 26.2%)	2400 (23.5%)	2399 (23.2%)	2420 (23.1%)
MULTISOURCE	7391 72.7%)	7687 (75.4%)	7824 (75.7%)	7939 (75.9%)
THERAPEUTICALLY EQUIVALENT	7105 69.9%)	7402 (72.6%)	7549 (73.1%)	7659 (73.2%)
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	285 (2.8%)	275 (2.7%)	280 (2.7$)
EXCEPTIONS[1]	110 (1.1%)	106 (1.1%)	106 (1.0%)	106 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	10	5	5	6
NUMBER OF APPLICANTS	574	574	582	598

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS2	Change. Miscellaneous deletion
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

		ACARBOSE						
		TABLET; ORAL						
		PRECOSE						
>D>		BAYER	25MG	N20482	004	MAY 29, 1997	DEC	CAHN
>D>			50MG	N20482	001	SEP 06, 1995	DEC	CAHN
>D>	+		100MG	N20482	002	SEP 06, 1995	DEC	CAHN
>A>		BAYER PHARMS	25MG	N20482	004	MAY 29, 1997	DEC	CAHN
>A>			50MG	N20482	001	SEP 06, 1995	DEC	CAHN
>A>	+		100MG	N20482	002	SEP 06, 1995	DEC	CAHN
		ACEBUTOLOL HYDROCHLORIDE						
		CAPSULE; ORAL						
		SECTRAL						
AB		ESP PHARMA	EQ 200MG BASE	N18917	001	DEC 28, 1984	JUL	CAHN
AB	+		EQ 400MG BASE	N18917	003	DEC 28, 1984	JUL	CAHN
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE						
AB		VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929	001	APR 22, 2002	APR	NEWA
		ACETAMINOPHEN; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		PHENAPHEN W/ CODEINE NO. 2						
		@ ROBINS AH	325MG;15MG	N84444	001		MAY	DISC
		SOLUTION; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+	ALPHARMA	120MG/5ML;12MG/5ML	N85861	001		MAY	CRLD
		TYLENOL W/ CODEINE						
		@ JOHNSON RW	120MG/5ML;12MG/5ML	N85057	001		MAY	DISC
		TABLET; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA		ABLE	300MG;30MG	N40452	001	AUG 01, 2002	AUG	NEWA
AA			300MG;60MG	N40459	001	AUG 01, 2002	AUG	NEWA
		@ PUREPAC PHARM	300MG;60MG	N86683	001		MAY	DISC
		ACETAMINOPHEN; HYDROCODONE BITARTRATE						
		SOLUTION; ORAL						
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA		KV PHARM	500MG/15ML;7.5MG/15ML	N40366	001	JAN 23, 2002	JAN	NEWA
		TABLET; ORAL						
AA		ABLE	325MG;7.5MG	N40464	001	OCT 23, 2002	OCT	NEWA
AA			325MG;10MG	N40464	002	OCT 23, 2002	OCT	NEWA
AA			325MG;5MG	N40478	001	NOV 08, 2002	NOV	NEWA
AA			500MG;10MG	N40473	001	NOV 06, 2002	NOV	NEWA
AA			500MG;5MG	N40477	001	NOV 06, 2002	NOV	NEWA
AA			650MG;10MG	N40476	001	OCT 23, 2002	OCT	NEWA
AA			750MG;7.5MG	N40469	001	OCT 25, 2002	OCT	NEWA
AA	+	MALLINCKRODT	660MG;10MG	N40084	003	JUL 29, 1996	JUL	CTNA
AA			750MG;10MG	N40468	001	OCT 31, 2002	OCT	NEWA
AA		UCB	500MG;10MG	N40210	001	AUG 13, 1997	JUN	CAHN
AA	+	WATSON LABS	750MG;10MG	N40094	004	MAR 22, 1999	OCT	CFTG

ACETAMINOPHEN; HYDROCODONE BITARTRATE
TABLET; ORAL
NORCO
AA + WATSON LABS 325MG;5MG N40099 001 JUN 25, 1997 MAY CTNA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
ACETAMINOPHEN AND PENTAZOCINE HCL
AB AMIDE PHARM 650MG;EQ 25MG BASE N76202 001 AUG 02, 2002 AUG NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
TABLET; ORAL
DARVOCET
@ AAIPHARMA LLC 325MG;32.5MG N16844 001 JUN CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE
TABLET; ORAL
DARVOCET-N 100
AB + AAIPHARMA LLC 650MG;100MG N17122 002 JUN CAHN
DARVOCET-N 50
AB AAIPHARMA LLC 325MG;50MG N17122 001 JUN CAHN

ACYCLOVIR
>A> CREAM; TOPICAL
>A> ZOVIRAX
>A> + GLAXOSMITHKLINE 5% N21478 001 DEC 30, 2002 DEC NEWA
TABLET; ORAL
ACYCLOVIR
AB NEOSAN PHARMS 400MG N74946 001 NOV 19, 1997 JUL CAHN
AB 800MG N74946 002 NOV 19, 1997 JUL CAHN

ADEFOVIR DIPIVOXIL
TABLET; ORAL
HEPSERA
+ GILEAD 10MG N21449 001 SEP 20, 2002 SEP NEWA

ALBUMIN CHROMATED CR-51 SERUM
INJECTABLE; INJECTION
CHROMALBIN
@ ISO TEX 100uCi/VIAL N17835 001 JUN DISC

ALBUMIN IODINATED I-125 SERUM
INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
@ MALLINCKRODT 6.67uCi/ML N17844 003 JUN DISC
@ 100uCi/ML N17844 002 JUN DISC

ALBUTEROL
AEROSOL, METERED; INHALATION
PROVENTIL
BN + SCHERING 0.09MG/INH N17559 001 JUN CRLD

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX	+ 3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996	MAR	CTEC

VENTOLIN HFA

BX	+ GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	MAR	CTEC

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB	SIDMAK LABS	EQ 4MG BASE	N76130 002	SEP 26, 2002	SEP	NEWA
AB		EQ 8MG BASE	N76130 003	SEP 26, 2002	SEP	NEWA

VOLMAX

AB	+ MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992	SEP	CFTG
AB	+	EQ 8MG BASE	N19604 001	DEC 23, 1992	SEP	CFTG

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP	+ GD SEARLE LLC	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	JUL	CAHN

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

	@ GENZYME	10 UNITS/ML	N20057 004	MAY 08, 1992	JUN	DISC

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

	+ DSM PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996	JUN	CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

INFUVITE ADULT

	+ SABEX 2002	2 IU/ML;20MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/ML;0.8MG/ML;0.72MG/ML;0.6MG/ML;600 IU/ML	N21163 001	MAY 18, 2000	AUG	CTNA

MULTI-12

	+ SABEX 2002	2 IU/ML;20MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/ML;0.8MG/ML;0.72MG/ML;0.6MG/ML;600 IU/ML	N21163 001	MAY 18, 2000	APR	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

	PHARMACIA AND UPJOHN	0.01MG/VIAL	N21212 001	JUN 11, 2002	JUN	NEWA
		0.02MG/VIAL	N21212 002	JUN 11, 2002	JUN	NEWA

		AMANTADINE HYDROCHLORIDE						
		SYRUP; ORAL						
		AMANTADINE HCL						
	AA	CAROLINA MEDCL	50MG/5ML	N75819	001	SEP 11, 2002	SEP	NEWA
		TABLET; ORAL						
>A>	AB	USL PHARMA	100MG	N76186	001	DEC 16, 2002	DEC	NEWA
		SYMMETREL						
>D>	+	ENDO PHARMS	100MG	N18101	001		DEC	CFTG
>A>	AB +		100MG	N18101	001		DEC	CFTG
		AMCINONIDE						
		LOTION; TOPICAL						
		AMCINONIDE						
	AB	ALTANA	0.1%	N76329	001	NOV 06, 2002	NOV	NEWA
		CYCLOCORT						
	AB +	FUJISAWA HLTHCARE	0.1%	N19729	001	JUN 13, 1988	NOV	CFTG
		OINTMENT; TOPICAL						
		AMCINONIDE						
	AB	ALTANA	0.1%	N76096	001	NOV 19, 2002	NOV	NEWA
		CYCLOCORT						
	AB +	FUJISAWA HLTHCARE	0.1%	N18498	001		NOV	CFTG
		AMIFOSTINE						
		INJECTABLE; INJECTION						
		ETHYOL						
		@ MEDIMMUNE ONCOLOGY	375MG/VIAL	N20221	002	SEP 10, 1999	JUN	DISC
		AMINO ACIDS						
		INJECTABLE; INJECTION						
		AMINOSYN 7%						
		@ ABBOTT	7% (7GM/100ML)	N17673	002		JUN	DISC
		AMINOSYN 8.5%						
		@ ABBOTT	8.5% (8.5GM/100ML)	N17673	004		JUN	DISC
		AMINOSYN II 3.5%						
		@ ABBOTT	3.5% (3.5GM/100ML)	N19438	001	APR 03, 1986	JUN	DISC
		BRANCHAMIN 4%						
		@ BAXTER HLTHCARE	4% (4GM/100ML)	N18678	001	SEP 28, 1984	JUN	DISC
		AMIODARONE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		AMIODARONE HCL						
	AP	ABBOTT	50MG/ML	N75955	001	OCT 18, 2002	OCT	NEWA
	AP	AM PHARM PARTNERS	50MG/ML	N75761	001	OCT 15, 2002	OCT	NEWA
	AP	BEDFORD	50MG/ML	N76018	001	OCT 15, 2002	OCT	NEWA
	AP	BEDFORD LABS	50MG/ML	N76299	001	OCT 24, 2002	OCT	NEWA
	AP	BEN VENUE	50MG/ML	N76088	001	OCT 15, 2002	OCT	NEWA
>A>	AP	BIONICHE (CANADA)	50MG/ML	N76217	001	OCT 15, 2002	DEC	CAHN
	AP	FAULDING	50MG/ML	N76108	001	OCT 15, 2002	OCT	NEWA
>D>	AP	PHARMAFORCE	50MG/ML	N76217	001	OCT 15, 2002	DEC	CAHN
	AP		50MG/ML	N76217	001	OCT 15, 2002	OCT	NEWA
		CORDARONE						
	AP +	WYETH AYERST	50MG/ML	N20377	001	AUG 03, 1995	OCT	CFTG

		AMIODARONE HYDROCHLORIDE						
		TABLET; ORAL						
		AMIODARONE HCL						
	AB +	EON	400MG	N75315 002	JUN 30, 2000	NOV	CFTG
	+		400MG	N75315 002	JUN 30, 2000	OCT	CRLD
>A>	+	TARO	100MG	N75424 002	DEC 18, 2002	DEC	NEWA
	AB		400MG	N76362 001	NOV 29, 2002	NOV	NEWA
		CORDARONE						
	AB	WYETH AYERST	200MG	N18972 001	DEC 24, 1985	OCT	CRLD
		AMLEXANOX						
		PASTE; DENTAL						
		APHTHASOL						
	+	GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	JUL	CAHN
		AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE						
		CAPSULE; ORAL						
		LOTREL						
		NOVARTIS	EQ 5MG BASE;20MG	N20364 004	MAR 03, 1995	AUG	CRLD
	+		EQ 10MG BASE;20MG	N20364 005	JUN 20, 2002	AUG	NEWA
		AMMONIUM LACTATE						
		CREAM; TOPICAL						
		AMMONIUM LACTATE						
	AB	CLAY PARK	EQ 12% BASE	N75774 001	MAY 01, 2002	MAY	NEWA
		LAC-HYDRIN						
	AB +	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG
		LOTION; TOPICAL						
		AMMONIUM LACTATE						
	AB	PADDOCK	EQ 12% BASE	N75575 001	JUN 11, 2002	JUN	NEWA
		LAC-HYDRIN						
	AB +	WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG
		AMOXICILLIN						
		FOR SUSPENSION; ORAL						
		AMOXICILLIN						
	AB	RANBAXY	200MG/5ML	N65113 001	NOV 29, 2002	NOV	NEWA
	AB		400MG/5ML	N65113 002	NOV 29, 2002	NOV	NEWA
>A>	AB	TEVA	200MG/5ML	N65119 001	DEC 04, 2002	DEC	NEWA
>A>	AB		400MG/5ML	N65119 002	DEC 04, 2002	DEC	NEWA
		AMOXIL						
	AB	GLAXOSMITHKLINE	200MG/5ML	N50760 001	APR 15, 1999	NOV	CFTG
	AB +		400MG/5ML	N50760 002	APR 15, 1999	NOV	CFTG
		TABLET, CHEWABLE; ORAL						
		AMOXICILLIN						
		@ APOTHECON	125MG	N64131 001	MAY 06, 1996	JUL	DISC
		@	250MG	N64131 002	MAY 06, 1996	JUL	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	GENEVA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002	JUN	NEWA
	AB		400MG/5ML;EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002	JUN	NEWA
>A>	AB	LEK SVCS	200MG/5ML;EQ 28.5MG BASE/5ML	N65098 001	DEC 16, 2002	DEC	NEWA
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	N65098 002	DEC 16, 2002	DEC	NEWA

AUGMENTIN '200'

AB	GLAXOSMITHKLINE	200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG

AUGMENTIN '400'

AB	GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
		400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA
AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA
AB	LEK SVCS	875MG;EQ 125MG BASE	N65093 001	NOV 21, 2002	NOV	NEWA
AB	RANBAXY	500MG;EQ 125MG BASE	N65109 001	NOV 04, 2002	NOV	NEWA
AB		875MG;EQ 125MG BASE	N65102 001	SEP 17, 2002	SEP	NEWA
AB	TEVA	500MG;EQ 125MG BASE	N65101 001	OCT 30, 2002	OCT	NEWA
AB		875MG;EQ 125MG BASE	N65096 001	OCT 29, 2002	OCT	NEWA

AMOXICILLIN AND CLAVULANATE POTSSSIUM

AB	LEK SVCS	500MG;EQ 125MG BASE	N65117 001	NOV 27, 2002	NOV	NEWA

AUGMENTIN '500'

AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG

AUGMENTIN '875'

AB +	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	GENEVA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA
AB		400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA

AUGMENTIN '200'

AB	GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG

AUGMENTIN '400'

AB +	GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG

TABLET, EXTENDED RELEASE; ORAL

AUGMENTIN XR

+	GLAXOSMITHKLINE	1GM;62.5MG	N50785 001	SEP 25, 2002	SEP	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

	SHIRE PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	AUG	CAHN

ADDERALL XR 15

	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JUN	NEWA
	SHIRE PHARM	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	AUG	CAHN

ADDERALL XR 20

	SHIRE PHARM	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	AUG	CAHN

ADDERALL XR 25

	SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JUN	NEWA
	SHIRE PHARM	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	AUG	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

		CAPSULE, EXTENDED RELEASE; ORAL						
		ADDERALL XR 30						
	+	SHIRE PHARM	7.5MG;7.5MG;7.5MG;7.5MG	N21303	003	OCT 11, 2001	AUG	CAHN
		ADDERALL XR 5						
		SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303	005	MAY 22, 2002	JUN	NEWA
		SHIRE PHARM	1.25MG;1.25MG;1.25MG;1.25MG	N21303	005	MAY 22, 2002	AUG	CAHN
		TABLET; ORAL						
		ADDERALL 10						
AB		SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522	007	FEB 13, 1996	FEB	CFTG
		ADDERALL 20						
AB		SHIRE LABS	5MG;5MG;5MG;5MG	N11522	008	FEB 13, 1996	FEB	CFTG
		ADDERALL 30						
AB	+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522	010	MAY 12, 1997	FEB	CFTG
		ADDERALL 5						
AB		SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522	009	MAY 12, 1997	FEB	CFTG
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB		BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422	001	FEB 11, 2002	FEB	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	N40422	002	FEB 11, 2002	FEB	NEWA
AB			5MG;5MG;5MG;5MG	N40422	003	FEB 11, 2002	FEB	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	N40422	004	FEB 11, 2002	FEB	NEWA
AB		COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444	001	JUN 19, 2002	JUN	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	N40444	002	JUN 19, 2002	JUN	NEWA
AB			5MG;5MG;5MG;5MG	N40444	003	JUN 19, 2002	JUN	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	N40444	004	JUN 19, 2002	JUN	NEWA
AB		EON	1.25MG;1.25MG;1.25MG;1.25MG	N40470	001	SEP 27, 2002	SEP	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	N40439	001	JUN 14, 2002	JUN	NEWA
AB			5MG;5MG;5MG;5MG	N40439	002	JUN 14, 2002	JUN	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	N40439	003	JUN 14, 2002	JUN	NEWA

AMPHOTERICIN B

		INJECTABLE, LIPID COMPLEX; INJECTION						
		ABELCET						
	+	ELAN PHARMS	5MG/ML	N50724	001	NOV 20, 1995	JAN	CAHN
	+	ENZON	5MG/ML	N50724	001	NOV 20, 1995	NOV	CAHN
		SUSPENSION; ORAL						
		FUNGIZONE						
		@ BRISTOL MYERS SQUIBB	100MG/ML	N50341	003		JUN	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

		INJECTABLE; INJECTION						
		AMPICILLIN AND SULBACTAM						
AP		ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074	001	MAR 19, 2002	MAR	NEWA
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074	002	MAR 19, 2002	MAR	NEWA
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076	001	MAR 19, 2002	MAR	NEWA
		UNASYN						
AP	+	PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608	002	DEC 31, 1986	MAR	CFTG
AP	+		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608	001	DEC 31, 1986	MAR	CFTG
AP	+		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608	005	DEC 10, 1993	MAR	CFTG

AMPRENAVIR
CAPSULE; ORAL
AGENERASE
@ GLAXOSMITHKLINE 50MG N21007 001 APR 15, 1999 MAY DISC
@ 150MG N21007 002 APR 15, 1999 MAY DISC
SOLUTION; ORAL
@ GLAXOSMITHKLINE 15MG/ML N21039 001 APR 15, 1999 MAY DISC

ARIPIPRAZOLE
TABLET; ORAL
ABILIFY
OTSUKA 2MG N21436 006 NOV 15, 2002 NOV NEWA
5MG N21436 005 NOV 15, 2002 NOV NEWA
10MG N21436 001 NOV 15, 2002 NOV NEWA
15MG N21436 002 NOV 15, 2002 NOV NEWA
20MG N21436 003 NOV 15, 2002 NOV NEWA
+ 30MG N21436 004 NOV 15, 2002 NOV NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC
+ SABEX 2002 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
FOR SOLUTION; IV (INFUSION)
M.V.I. PEDIATRIC
+ AAIPHARMA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
INJECTABLE; INJECTION
M.V.I.-12
AP + AAIPHARMA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
DARVON COMPOUND
\+ AAIPHARMA LLC 389MG;32.4MG;32MG N10996 006 MAR 08, 1983 JUN CAHN
DARVON COMPOUND-65
AA + AAIPHARMA LLC 389MG;32.4MG;65MG N10996 007 MAR 08, 1983 JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
TALWIN COMPOUND
@ SANOFI SYNTHELABO 325MG;EQ 12.5MG BASE N16891 001 JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
DARVON W/ ASA
\+ AAIPHARMA LLC 325MG;65MG N10996 005 JUN CAHN

ASPIRIN; PROPOXYPHENE NAPSYLATE
CAPSULE; ORAL
DARVON-N W/ ASA
@ AAIPHARMA LLC 325MG;100MG N16829 001 JUN CAHN
TABLET; ORAL
@ AAIPHARMA LLC 325MG;100MG N16863 001 JUN CAHN

ATOMOXETINE HYDROCHLORIDE
CAPSULE; ORAL
STRATTERA
LILLY 5MG N21411 001 NOV 26, 2002 NOV NEWA
10MG N21411 002 NOV 26, 2002 NOV NEWA
18MG N21411 003 NOV 26, 2002 NOV NEWA
25MG N21411 004 NOV 26, 2002 NOV NEWA
40MG N21411 005 NOV 26, 2002 NOV NEWA
\+ 60MG N21411 006 NOV 26, 2002 NOV NEWA

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE; INTRAMUSCULAR
ATNAA
\+ @ US ARMY 2.1MG/0.7ML;600MG/2ML N21175 001 JAN 17, 2002 JAN NEWA
@ 2.1MG/0.7ML;600MG/2ML N21175 001 JAN 17, 2002 FEB NEWA

AZELAIC ACID
>A> GEL; TOPICAL
>A> FINACEA
>A> + BERLEX 15% N21470 001 DEC 24, 2002 DEC NEWA

AZELASTINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
OPTIVAR
\+ MURO 0.05% N21127 001 MAY 22, 2000 MAY CAHN

AZITHROMYCIN DIHYDRATE
TABLET; ORAL
ZITHROMAX

	+ PFIZER	EQ 500MG BASE	N50784 001	MAY 24, 2002	MAY	NEWA

AZTREONAM
INJECTABLE; INJECTION
AZACTAM

	@ BRISTOL MYERS SQUIBB	500MG/VIAL	N50580 001	DEC 31, 1986	JUN	DISC
	@	1GM/VIAL	N50580 002	DEC 31, 1986	JUN	DISC
	@	2GM/VIAL	N50580 003	DEC 31, 1986	JUN	DISC

BACITRACIN
INJECTABLE; INJECTION
BACITRACIN

>A>	AP AM PHARM PARTNERS	50,000 UNITS/VIAL	N65116 001	DEC 03, 2002	DEC	NEWA

BACITRACIN ZINC; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
BACITRACIN ZINC AND POLYMYXIN B SULFATE

	AT ALTANA	500 UNITS/GM;10,000 UNITS/GM	N65022 001	FEB 27, 2002	FEB	NEWA

BECLOMETHASONE DIPROPIONATE MONOHYDRATE
SPRAY, METERED; NASAL
VANCENASE AQ

	@ SCHERING	EQ 0.084MG DIPROP/SPRAY	N20469 001	JUN 26, 1996	OCT	DISC

BENDROFLUMETHIAZIDE
TABLET; ORAL
NATURETIN-10

	@ APOTHECON	10MG	N12164 003		JUN	DISC

NATURETIN-5

	+ APOTHECON	5MG	N12164 002		JUN	CRLD

BENZONATATE
CAPSULE; ORAL
TESSALON

	+ FOREST LABS	200MG	N11210 003	JUN 25, 1999	MAR	NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE
GEL; TOPICAL
DUAC

	+ STIEFEL	5%;EQ 1% BASE	N50741 001	AUG 26, 2002	AUG	NEWA

BENZTROPINE MESYLATE
TABLET; ORAL
BENZTROPINE MESYLATE

	AA COREPHARMA	0.5MG	N72264 001	FEB 27, 1989	MAY	CAHN
	AA	1MG	N72265 001	FEB 27, 1989	MAY	CAHN
	AA	2MG	N72266 001	FEB 27, 1989	MAY	CAHN
	AA + PAR PHARM	0.5MG	N88877 001	APR 11, 1985	AUG	CRLD
	AA +	1MG	N88894 001	APR 11, 1985	AUG	CRLD

AA +		2MG	N88895 001	APR 11, 1985	AUG	CRLD
	COGENTIN					
	@ MERCK	0.5MG	N09193 004		AUG	DISC
	@	1MG	N09193 003		AUG	DISC
	@	2MG	N09193 002		AUG	DISC
	BENZYL PENICILLOYL-POLYLYSINE					
	INJECTABLE; INJECTION					
	PRE-PEN					
	+ SCHWARZ PHARMA	60UMOLAR	N50114 001		JUL	CAHN
	BETAMETHASONE DIPROPIONATE					
	OINTMENT; TOPICAL					
	BETAMETHASONE DIPROPIONATE					
AB +	FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG	CRLD
	DIPROSONE					
	@ SCHERING	EQ 0.05% BASE	N17691 001		AUG	DISC
	BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE					
	CREAM; TOPICAL					
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE					
AB	ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002	AUG	NEWA
	BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE					
	TABLET; ORAL					
	KERLEDEX					
	@ LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992	JUN	DISC
	@	10MG;12.5MG	N19807 002	OCT 30, 1992	JUN	DISC
	BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE					
	SUSPENSION/DROPS; OPHTHALMIC					
	BETOPTIC PILO					
	@ ALCON	EQ 0.25% BASE;1.75%	N20619 001	APR 17, 1997	JUN	DISC
	BIPERIDEN LACTATE					
	INJECTABLE; INJECTION					
	AKINETON					
	@ ABBOTT	5MG/ML	N12418 002		JUN	DISC
	BISOPROLOL FUMARATE					
	TABLET; ORAL					
	BISOPROLOL FUMARATE					
AB	MUTUAL PHARM	5MG	N75474 001	OCT 25, 2002	OCT	NEWA
AB		10MG	N75474 002	OCT 25, 2002	OCT	NEWA
	BITOLTEROL MESYLATE					
	AEROSOL, METERED; INHALATION					
	TORNALATE					
	@ SANOFI SYNTHELABO	0.37MG/INH	N18770 001	DEC 28, 1984	JUN	DISC
	SOLUTION; INHALATION					
	@ SANOFI SYNTHELABO	0.2%	N19548 001	FEB 19, 1992	JUN	DISC

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN
@ ALLERGAN 0.2% N20613 001 SEP 06, 1996 AUG DISC

BROMOCRIPTINE MESYLATE
TABLET; ORAL
BROMOCRIPTINE MESYLATE
AB LEK SVCS EQ 2.5MG BASE N74631 001 JAN 13, 1998 JAN CMFD
PARLODEL
AB + NOVARTIS EQ 2.5MG BASE N17962 001 JAN CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SYRUP; ORAL
BROMANYL
@ ALPHARMA 12.5MG/5ML;10MG/5ML N88343 001 AUG 15, 1984 MAY DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SYRUP; ORAL
BROMANATE DM
@ ALPHARMA 2MG/5ML;10MG/5ML;30MG/5ML N88722 001 MAR 07, 1985 OCT DISC
BROMFED-DM
AA VERUM PHARMS 2MG/5ML;10MG/5ML;30MG/5ML N89681 001 DEC 22, 1988 NOV CAHN

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
BUPIVACAINE HCL KIT
@ ABBOTT 0.075% N19978 001 SEP 03, 1992 JUN DISC
@ 0.114% N19978 002 SEP 03, 1992 JUN DISC
@ 0.23% N19978 003 SEP 03, 1992 JUN DISC
BUPIVACINE HCL PRESERVATIVE FREE
AP INTL MEDICATED 0.25% N76012 001 JAN 09, 2002 JAN NEWA
AP 0.5% N76012 002 JAN 09, 2002 JAN NEWA
AP 0.75% N76012 003 JAN 09, 2002 JAN NEWA

BUPRENORPHINE HYDROCHLORIDE
TABLET; SUBLINGUAL
SUBUTEX
RECKITT BENCKISER EQ 2MG BASE N20732 002 OCT 08, 2002 OCT NEWA
+ EQ 8MG BASE N20732 003 OCT 08, 2002 OCT NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
TABLET; SUBLINGUAL
SUBOXONE
RECKITT BENCKISER 2MG;0.5MG N20733 001 OCT 08, 2002 OCT NEWA
+ 8MG;2MG N20733 002 OCT 08, 2002 OCT NEWA

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR
GLAXOSMITHKLINE 150MG N20358 003 OCT 04, 1996 JUL CRLD
+ 200MG N20358 004 JUN 14, 2002 JUL NEWA

BUSPIRONE HYDROCHLORIDE
CAPSULE; ORAL
BUSPAR

	@ BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000	JUN	DISC
	@	7.5MG	N21190 002	DEC 20, 2000	JUN	DISC
	@	10MG	N21190 003	DEC 20, 2000	JUN	DISC
	@	15MG	N21190 004	DEC 20, 2000	JUN	DISC

TABLET; ORAL
BUSPIRONE HCL

AB	EGIS	5MG	N75119 001	MAR 14, 2002	MAR	NEWA
AB		10MG	N75119 002	MAR 14, 2002	MAR	NEWA
AB	GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002	MAR	NEWA
AB		10MG	N75413 002	MAR 19, 2002	MAR	NEWA
AB		15MG	N75413 003	MAR 19, 2002	MAR	NEWA
AB	KV PHARM	5MG	N75572 001	FEB 27, 2002	FEB	NEWA
AB		10MG	N75572 002	FEB 27, 2002	FEB	NEWA
AB		15MG	N75572 003	FEB 27, 2002	FEB	NEWA
AB	MYLAN	5MG	N75272 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75272 002	MAR 01, 2002	MAR	NEWA
AB		30MG	N76008 001	JUN 28, 2001	MAY	CAHN
AB	PAR PHARM	5MG	N75467 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75467 003	FEB 28, 2002	FEB	NEWA
AB		15MG	N75467 004	FEB 28, 2002	FEB	NEWA
AB	PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002	MAY	NEWA
AB		10MG	N75388 002	MAY 09, 2002	MAY	NEWA
AB		15MG	N75388 003	MAY 09, 2002	MAY	NEWA
AB	TEVA	5MG	N75022 001	FEB 28, 2002	FEB	NEWA
AB		10MG	N75022 002	FEB 28, 2002	FEB	NEWA
AB		15MG	N75022 003	FEB 28, 2002	FEB	NEWA
AB	TORPHARM	5MG	N75521 001	APR 05, 2002	APR	NEWA
AB		10MG	N75521 002	APR 05, 2002	APR	NEWA
AB		15MG	N75521 003	APR 05, 2002	APR	NEWA
AB	ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002	MAR	NEWA
AB		10MG	N75385 002	MAR 01, 2002	MAR	NEWA
AB		15MG	N75385 003	MAR 01, 2002	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM

@ WALLACE LABS	15MG	N00793 002		OCT	DISC
@	100MG	N00793 005		OCT	DISC

BUTENAFINE HYDROCHLORIDE
CREAM; TOPICAL
MENTAX-TC

+	BERTEK	1%	N21408 001	OCT 17, 2002	OCT	NEWA

BUTORPHANOL TARTRATE
SPRAY, METERED; NASAL
BUTORPHANOL TARTRATE

>A>	AB	NOVEX	1MG/SPRAY	N75499 001	DEC 04, 2002	DEC	NEWA
	AB	ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002	MAR	NEWA

		CAFFEINE; ERGOTAMINE TARTRATE						
		TABLET; ORAL						
		ERCATAB						
		+ GENEVA PHARMS	100MG;1MG	N84294	001		JUN	CTEC
		WIGRAINE						
		@ ORGANON	100MG;1MG	N86562	001		JUN	DISC
		CALCIFEDIOL						
		CAPSULE; ORAL						
		CALDEROL						
		@ ORGANON	0.02MG	N18312	001		JUN	DISC
		@	0.05MG	N18312	002		JUN	DISC
		CALCIPOTRIENE						
		OINTMENT; TOPICAL						
		DOVONEX						
		+ BRISTOL MYERS SQUIBB	0.005%	N20273	001	DEC 29, 1993	FEB	CAHN
		SOLUTION; TOPICAL						
		+ BRISTOL MYERS SQUIBB	0.005%	N20611	001	MAR 03, 1997	FEB	CAHN
		CALCITRIOL						
		INJECTABLE; INJECTION						
		CALCIJEX						
>D>		+ ABBOTT	0.001MG/ML	N18874	001	SEP 25, 1986	DEC	CFTG
>A>	AP	+	0.001MG/ML	N18874	001	SEP 25, 1986	DEC	CFTG
>D>		+	0.002MG/ML	N18874	002	SEP 25, 1986	DEC	CFTG
>A>	AP	+	0.002MG/ML	N18874	002	SEP 25, 1986	DEC	CFTG
>A>		CALCITRIOL						
>A>	AP	AM PHARM PARTNERS	0.001MG/ML	N75836	001	DEC 31, 2002	DEC	NEWA
>A>	AP		0.002MG/ML	N75836	002	DEC 31, 2002	DEC	NEWA
>A>		CALCIUM CHLORIDE; ICODEXTRIN; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE						
>A>		SOLUTION; INTRAPERITONEAL						
>A>		EXTRANEAL						
>A>		+ BAXTER HLTHCARE	25.7MG/100ML;7.5GM/100ML;5.08MG/100 ML;535MG/100ML;448MG/100ML	N21321	001	DEC 20, 2002	DEC	NEWA
		CAPTOPRIL						
		TABLET; ORAL						
		CAPOTEN						
	AB	PAR PHARM	12.5MG	N18343	005	JAN 17, 1985	MAY	CAHN
	AB		25MG	N18343	002		MAY	CAHN
		@	37.5MG	N18343	006	SEP 17, 1986	MAY	CAHN
	AB		50MG	N18343	001		MAY	CAHN
		@	75MG	N18343	007	JUN 13, 1995	MAY	CAHN
	AB	+	100MG	N18343	003		MAY	CAHN
		@	150MG	N18343	004	JUN 13, 1995	MAY	CAHN
		CARBAMAZEPINE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		CARBATROL						
		@ SHIRE LABS	100MG	N20712	003	DEC 22, 1999	JUL	DISC

	@	200MG	N20712 001	SEP 30, 1997	JUL	DISC
	@	300MG	N20712 002	SEP 30, 1997	JUL	DISC
	+ SHIRE PHARM	100MG	N20712 003	SEP 30, 1997	SEP	CMFD
	+	200MG	N20712 001	SEP 30, 1997	SEP	CMFD
	+	300MG	N20712 002	SEP 30, 1997	SEP	CMFD
	SUSPENSION; ORAL					
	CARBAMAZEPINE					
AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002	JUN	NEWA
	TABLET; ORAL					
AB	APOTEX	200MG	N75948 001	FEB 27, 2002	FEB	NEWA
	TABLET, CHEWABLE; ORAL					
	+ TARO PHARM INDS	200MG	N75687 002	JUL 29, 2002	JUL	NEWA
	CARTEOLOL HYDROCHLORIDE					
	SOLUTION/DROPS; OPHTHALMIC					
	CARTEOLOL HCL					
AT	NOVEX	1%	N76097 001	FEB 06, 2002	FEB	NEWA
	CEFACLOR					
	TABLET, EXTENDED RELEASE; ORAL					
	CECLOR CD					
	@ LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	JUN	DISC
	CEFACLOR					
	TEVA	EQ 375MG BASE	N65058 001	SEP 04, 2002	SEP	NEWA
AB		EQ 500MG BASE	N65058 002	SEP 04, 2002	SEP	NEWA
	CEFADROXIL/CEFADROXIL HEMIHYDRATE					
	CAPSULE; ORAL					
	DURICEF					
	@ GALEN CHEM	EQ 250MG BASE	N50512 002		MAY	CAHN
	@ WARNER CHILCOTT	EQ 250MG BASE	N50512 002		JUL	CAHN
AB	+	EQ 500MG BASE	N50512 001		JUL	CAHN
	FOR SUSPENSION; ORAL					
	GALEN CHEM	EQ 125MG BASE/5ML	N50527 002		MAY	CAHN
		EQ 250MG BASE/5ML	N50527 003		MAY	CAHN
	+	EQ 500MG BASE/5ML	N50527 001		MAY	CAHN
	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527 002		JUL	CAHN
		EQ 250MG BASE/5ML	N50527 003		JUL	CAHN
	+	EQ 500MG BASE/5ML	N50527 001		JUL	CAHN
	TABLET; ORAL					
AB	+ GALEN CHEM	EQ 1GM BASE	N50528 001		MAY	CAHN
AB	+ WARNER CHILCOTT	EQ 1GM BASE	N50528 001		JUL	CAHN
	CEFAMANDOLE NAFATE					
	INJECTABLE; INJECTION					
	MANDOL					
	@ LILLY	EQ 10GM BASE/VIAL	N50504 004		JUN	DISC
	CEFORANIDE					
	INJECTABLE; INJECTION					
	PRECEF					
	@ BRISTOL	500MG/VIAL	N50554 001	MAY 24, 1984	JUN	DISC
	@	1GM/VIAL	N50554 002	MAY 24, 1984	JUN	DISC

	@	2GM/VIAL	N50554 003	MAY 24, 1984	JUN	DISC
	@	10GM/VIAL	N50554 004	MAY 24, 1984	JUN	DISC
	@	20GM/VIAL	N50554 005	MAY 24, 1984	JUN	DISC

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP	HIKMA	EQ 500MG BASE/VIAL	N65072 001	NOV 20, 2002	NOV	NEWA
AP		EQ 1GM BASE/VIAL	N65072 002	NOV 20, 2002	NOV	NEWA
AP		EQ 2GM BASE/VIAL	N65072 003	NOV 20, 2002	NOV	NEWA
AP		EQ 10GM BASE/VIAL	N65071 001	NOV 20, 2002	NOV	NEWA

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	RANBAXY	EQ 50MG BASE/5ML	N65082 001	MAY 31, 2002	MAY	NEWA
AB		EQ 100MG BASE/5ML	N65082 002	MAY 31, 2002	MAY	NEWA
	VANTIN					
AB	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992	MAY	CFTG
AB +		EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992	MAY	CFTG

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

	@ FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983	JUL	DISC

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

	@ HLR	EQ 500MG BASE/VIAL;1%	N50585 007	MAY 08, 1996	JUN	DISC
	@	EQ 1GM BASE/VIAL;1%	N50585 006	MAY 08, 1996	JUN	DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFTIN

AB	GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001	DEC 28, 1987	FEB	CFTG
AB		EQ 250MG BASE	N50605 002	DEC 28, 1987	FEB	CFTG
AB +		EQ 500MG BASE	N50605 003	DEC 28, 1987	FEB	CFTG
	CEFUROXIME AXETIL					
AB	APOTEX	EQ 250MG BASE	N65069 001	OCT 02, 2002	OCT	NEWA
AB		EQ 500MG BASE	N65069 002	OCT 02, 2002	OCT	NEWA
AB	RANBAXY	EQ 125MG BASE	N65043 003	FEB 15, 2002	FEB	NEWA
AB		EQ 250MG BASE	N65043 002	FEB 15, 2002	FEB	NEWA
AB		EQ 500MG BASE	N65043 001	FEB 15, 2002	FEB	NEWA

CELECOXIB

CAPSULE; ORAL

CELEBREX

	GD SEARLE LLC	200MG	N20998 002	DEC 31, 1998	AUG	CRLD
+		400MG	N20998 003	AUG 29, 2002	AUG	NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL					
CEPHALEXIN					
@ TEVA	EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988	APR	DISC
@	EQ 250MG BASE/5ML	N62867 001	APR 15, 1988	APR	DISC
TABLET; ORAL					
TEVA	EQ 500MG BASE	N63024 001	JAN 12, 1989	JUN	CTEC
KEFLET					
@ LILLY	EQ 500MG BASE	N50440 001		JUN	DISC
@	EQ 1GM BASE	N50440 002		JUL	DISC

CEPHALOGLYCIN

CAPSULE; ORAL					
KAFOCIN					
@ LILLY	250MG	N50219 001		MAY	DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION					
KEFLIN					
@ LILLY	EQ 20GM BASE/VIAL	N50482 007		JUN	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION					
CEFADYL					
APOTHECON	EQ 500MG BASE/VIAL	N62961 001	SEP 20, 1988	JUN	DISC
@	EQ 1GM BASE/VIAL	N62961 002	SEP 20, 1988	JUN	DISC
@	EQ 2GM BASE/VIAL	N62961 003	SEP 20, 1988	JUN	DISC
@	EQ 4GM BASE/VIAL	N62961 004	SEP 20, 1988	JUN	DISC

CERIVASTATIN SODIUM

TABLET; ORAL					
BAYCOL					
@ BAYER	0.2MG	N20740 003	JUN 26, 1997	JAN	DISC
@	0.3MG	N20740 004	JUN 26, 1997	JAN	DISC
@	0.4MG	N20740 005	MAY 24, 1999	JAN	DISC
@	0.8MG	N20740 006	JUL 24, 2000	JAN	DISC

CHLORAMPHENICOL

FOR SOLUTION; OPHTHALMIC					
CHLOROMYCETIN					
@ PARKEDALE	25MG/VIAL	N50143 001		JUL	DISC

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL					
CHLOROMYCETIN PALMITATE					
@ PARKE DAVIS	EQ 150MG BASE/5ML	N50152 001		JUN	DISC

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC					
CHLOROMYCETIN HYDROCORTISONE					
@ PARKEDALE	12.5MG/VIAL;25MG/VIAL	N50202 001		JUL	DISC

CHLORMEZANONE
TABLET; ORAL
TRANCOPAL

@ SANOFI SYNTHELABO	100MG	N11467 003			JUN	DISC
@	200MG	N11467 005			JUN	DISC

CHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
CHLOROTHIAZIDE AND RESERPINE

@ WEST WARD	250MG;0.125MG	N88557 001	DEC 22, 1983		AUG	DISC
@	500MG;0.125MG	N88365 001	DEC 22, 1983		AUG	DISC

CHLOROTHIAZIDE-RESERPINE

@ MYLAN	250MG;0.125MG	N87744 001	MAY 06, 1982		AUG	DISC
@	500MG;0.125MG	N87745 001	MAY 06, 1982		AUG	DISC

CHLORPHENESIN CARBAMATE
TABLET; ORAL
MAOLATE

@ PHARMACIA AND UPJOHN	400MG	N14217 002			JUN	DISC

CHLORPROMAZINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
THORAZINE

@ GLAXOSMITHKLINE	30MG	N11120 016			JUN	DISC
@	75MG	N11120 017			JUN	DISC
@	150MG	N11120 018			JUN	DISC

CHLORPROPAMIDE
TABLET; ORAL
CHLORPROPAMIDE

@ LEDERLE	100MG	N89561 001	SEP 04, 1987		MAY	DISC
@	250MG	N89562 001	SEP 04, 1987		MAY	DISC

CHLORTETRACYCLINE HYDROCHLORIDE
OINTMENT; OPHTHALMIC
AUREOMYCIN

@ LEDERLE	1%	N50404 001			JUN	DISC

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET; ORAL
CLONIDINE HCL AND CHLORTHALIDONE

@ PAR PHARM	15MG;0.3MG	N71142 001	DEC 16, 1987		OCT	DISC
@	15MG;0.2MG	N71178 001	DEC 16, 1987		OCT	DISC
@	15MG;0.1MG	N71179 001	DEC 16, 1987		OCT	DISC

CLORPRES

+ MYLAN	15MG;0.3MG	N71325 001	FEB 09, 1987		OCT	CRLD

COMBIPRES

@ BOEHRINGER INGELHEIM	15MG;0.1MG	N17503 001			OCT	DISC
@	15MG;0.2MG	N17503 002			OCT	DISC
@	15MG;0.3MG	N17503 003	APR 10, 1984		OCT	DISC

CHLORTHALIDONE; RESERPINE
TABLET; ORAL
DEMI-REGROTON
@ AVENTIS PHARMS 25MG;0.125MG N15103 002 JUL DISC
REGROTON
@ AVENTIS PHARMS 50MG;0.25MG N15103 001 JUL DISC

CHOLESTYRAMINE
TABLET; ORAL
QUESTRAN
@ APOTHECON EQ 800MG RESIN N73403 002 DEC 27, 1999 JUN DISC

CHORIOGONADOTROPIN ALFA
INJECTABLE; INJECTION
OVIDREL
+ SERONO INC 0.25MG/VIAL N21149 001 SEP 20, 2000 FEB CAHN

CHYMOPAPAIN
INJECTABLE; INJECTION
CHYMODIACTIN
@ ABBOTT 4,000 UNITS/VIAL N18663 002 AUG 21, 1984 JUN DISC

CHYMOTRYPSIN
FOR SOLUTION; OPHTHALMIC
ZOLYSE
@ ALCON 750 UNITS/VIAL N11903 001 JUN DISC

CICLOPIROX
SOLUTION; TOPICAL
PENLAC
+ DERMIK LABS 8% N21022 001 DEC 17, 1999 JUN CAHN

CIMETIDINE
TABLET; ORAL
CIMETIDINE
AB LEK LJUBLJANA 300MG N74250 002 JUN 29, 1995 FEB CMFD
AB 400MG N74250 003 JUN 29, 1995 FEB CMFD
AB 800MG N74250 004 JUN 29, 1995 FEB CMFD

CINOXACIN
CAPSULE; ORAL
CINOBAC
@ LILLY 250MG N18067 001 JUN DISC
@ 500MG N18067 002 JUN DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE
>A> TABLET, EXTENDED RELEASE; ORAL
>A> CIPRO XR
>A> + BAYER PHARMS 212.6MG;EQ 287.5MG BASE N21473 001 DEC 13, 2002 DEC NEWA

>A>	CITRIC ACID; UREA, C-13						
>A>	FOR SOLUTION; TABLET, FOR SOLUTION; ORAL						
>A>	IDKIT:HP						
>A>	+ ORIDION	4GM;75MG	N21314 001	DEC 17, 2002	DEC	NEWA	
	CLADRIBINE						
	INJECTABLE; INJECTION						
	LEUSTATIN						
	+ ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993	MAR	CAHN	
	CLARITHROMYCIN						
	FOR SUSPENSION; ORAL						
	BIAXIN						
	@ ABBOTT	187MG/5ML	N50698 003	SEP 30, 1998	JUN	DISC	
	CLINDAMYCIN PHOSPHATE						
	GEL; TOPICAL						
	CLINDAGEL						
BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	OCT	CTNA	
	LOTION; TOPICAL						
	CLEOCIN T						
AB	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001	MAY 31, 1989	JAN	CFTG	
	CLINDAMYCIN PHOSPHATE						
AB	ALTANA	EQ 1% BASE	N65067 001	JAN 31, 2002	JAN	NEWA	
	SWAB; TOPICAL						
AT	CLAY PARK	EQ 1% BASE	N65049 001	MAY 25, 2000	FEB	CDFR	
	CLOBETASOL PROPIONATE						
	GEL; TOPICAL						
	EMBELINE						
AB	HEALTHPOINT	0.05%	N76141 001	APR 12, 2002	APR	NEWA	
	CLOFAZIMINE						
	CAPSULE; ORAL						
	LAMPRENE						
	@ NOVARTIS	100MG	N19500 001	DEC 15, 1986	JUN	DISC	
	CLONAZEPAM						
	TABLET; ORAL						
	KLONOPIN						
	@ ROCHE	0.125MG	N17533 005	APR 09, 1997	JUN	DISC	
	@	0.25MG	N17533 006	APR 09, 1997	JUN	DISC	
	TABLET, ORALLY DISINTEGRATING; ORAL						
	KLONOPIN RAPIDLY DISINTEGRATING						
	@ ROCHE	0.125MG	N20813 001	DEC 23, 1997	JUN	DISC	
	@	0.25MG	N20813 002	DEC 23, 1997	JUN	DISC	
	@	0.5MG	N20813 003	DEC 23, 1997	JUN	DISC	
	@	1MG	N20813 004	DEC 23, 1997	JUN	DISC	
	@	2MG	N20813 005	DEC 23, 1997	JUN	DISC	

		CLONIDINE						
		FILM, EXTENDED RELEASE; TRANSDERMAL						
		CATAPRES-TTS-1						
>D>	+	BOEHRINGER INGELHEIM	0.1MG/24HR	N18891	001	OCT 10, 1984	DEC	CRLD
>A>			0.1MG/24HR	N18891	001	OCT 10, 1984	DEC	CRLD
		CATAPRES-TTS-2						
>D>	+	BOEHRINGER INGELHEIM	0.2MG/24HR	N18891	002	OCT 10, 1984	DEC	CRLD
>A>			0.2MG/24HR	N18891	002	OCT 10, 1984	DEC	CRLD
		CLORAZEPATE DIPOTASSIUM						
		CAPSULE; ORAL						
		TRANXENE						
		@ OVATION PHARMS	3.75MG	N17105	001		SEP	CAHN
		@	7.5MG	N17105	002		SEP	CAHN
		@	15MG	N17105	003		SEP	CAHN
		TABLET; ORAL						
AB		OVATION PHARMS	3.75MG	N17105	006		SEP	CAHN
AB			7.5MG	N17105	007		SEP	CAHN
AB	+		15MG	N17105	008		SEP	CAHN
		TRANXENE SD						
		OVATION PHARMS	11.25MG	N17105	005		SEP	CAHN
	+		22.5MG	N17105	004		SEP	CAHN
		CLOZAPINE						
		TABLET; ORAL						
		CLOZAPINE						
AB		CARACO	25MG	N75713	001	NOV 15, 2002	NOV	NEWA
AB			100MG	N75713	002	NOV 15, 2002	NOV	NEWA
		CLOZARIL						
AB		NOVARTIS	25MG	N19758	001	SEP 26, 1989	MAY	CRLD
AB	+		100MG	N19758	002	SEP 26, 1989	MAY	CRLD
		COLCHICINE; PROBENECID						
		TABLET; ORAL						
		COL-PROBENECID						
BP	+	WATSON LABS	0.5MG;500MG	N84279	001		JUN	CRLD
		COLBENEMID						
		@ MERCK	0.5MG;500MG	N12383	001		JUN	DISC
		COLESEVELAM HYDROCHLORIDE						
		CAPSULE; ORAL						
		WELCHOL						
		@ SANKYO	375MG	N21141	001	MAY 26, 2000	JUN	DISC
		CORTICOTROPIN						
		INJECTABLE; INJECTION						
		CORTICOTROPIN						
	+	ORGANICS LAGRANGE	40 UNITS/ML	N10831	001		AUG	CRLD
		H.P. ACTHAR GEL						
		@ QUESTCOR PHARMS	40 UNITS/ML	N08372	006		JUL	DISC

CORTISONE ACETATE
INJECTABLE; INJECTION
CORTONE

@ MERCK	25MG/ML	N07110 002			JUN	DISC
@	50MG/ML	N07110 003			JUN	DISC

CROMOLYN SODIUM
SOLUTION; INHALATION
CROMOLYN SODIUM

AN	NOVEX	10MG/ML	N75333 001	APR 30, 2002	APR	NEWA

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58
N/A; N/A
DICOPAC KIT

@ AMERSHAM HLTH	N/A;N/A;N/A	N17406 001			FEB	DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR
N/A; N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

@ MALLINCKRODT	0.1MG;0.5uCi;60MG	N16635 001			JUN	DISC

CYCLOBENZAPRINE HYDROCHLORIDE
TABLET; ORAL
FLEXERIL

@ MCNEIL CONS SPECLT	5MG	N17821 001			JUN	CAHN
AB +	10MG	N17821 002			JUN	CAHN

CYCLOPHOSPHAMIDE
INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

AP	BAXTER HLTHCARE	100MG/VIAL	N88371 001	JUL 03, 1986	JUN	CAHN
AP		200MG/VIAL	N88372 001	JUL 03, 1986	JUN	CAHN
AP		500MG/VIAL	N88373 001	JUL 03, 1986	JUN	CAHN
AP		1GM/VIAL	N88374 001	SEP 24, 1986	JUN	CAHN

CYCLOSPORINE
CAPSULE; ORAL
CYCLOSPORINE

AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000	MAY	CTEC
BX		50MG	N65003 002	MAY 12, 2000	MAY	CTEC
AB1		100MG	N65003 003	MAY 12, 2000	MAY	CTEC
AB1	EON	25MG	N65017 002	JAN 13, 2000	MAY	CTEC
AB1		100MG	N65017 001	JAN 13, 2000	MAY	CTEC
AB1	SIDMAK LABS	25MG	N65044 002	DEC 20, 2000	MAY	CTEC
AB1		100MG	N65044 001	DEC 20, 2000	MAY	CTEC
AB2	TORPHARM	25MG	N65040 001	MAY 09, 2002	MAY	CTEC
AB2		100MG	N65040 002	MAY 09, 2002	MAY	NEWA

NEORAL

AB1	NOVARTIS	25MG	N50715 001	JUL 14, 1995	MAY	CTEC
AB1 +		100MG	N50715 002	JUL 14, 1995	MAY	CTEC

SANDIMMUNE

AB2	NOVARTIS	25MG	N50625 001	MAR 02, 1990	MAY	CTEC

AB2 +		100MG	N50625 002	MAR 02, 1990	MAY	CTEC
>A>	EMULSION; OPHTHALMIC					
>A>	RESTASIS					
>A>	+ ALLERGAN	0.05%	N21023 001	DEC 23, 2002	DEC	NEWA
	SOLUTION; ORAL					
	CYCLOSPORINE					
AB	ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD
	CYPROHEPTADINE HYDROCHLORIDE					
	TABLET; ORAL					
	CYPROHEPTADINE HCL					
AA +	IVAX PHARMS	4MG	N87056 001		NOV	CRLD
	PERIACTIN					
	@ MERCK	4MG	N12649 001		NOV	DISC
	CYTARABINE					
	INJECTABLE; INJECTION					
	CYTARABINE					
	+ FAULDING	100MG/ML	N75383 001	NOV 22, 1999	AUG	CPOT
	DACARBAZINE					
	INJECTABLE; INJECTION					
	DACARBAZINE					
AP	BEDFORD	500MG/VIAL	N75812 002	OCT 31, 2002	NOV	NEWA
AP +	GENSIA SICOR PHARMS	500MG/VIAL	N75259 001	SEP 22, 2000	OCT	CRLD
	DALFOPRISTIN; QUINUPRISTIN					
	INJECTABLE; IV (INFUSION)					
	SYNERCID					
	+ AVENTIS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	JUN	CRLD
	@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	JUN	DISC
	DANAPAROID SODIUM					
	INJECTABLE; INJECTION					
	ORGARAN					
	@ ORGANON	750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN	DISC
	DEFEROXAMINE MESYLATE					
	INJECTABLE; INJECTION					
	DESFERAL					
	+ NOVARTIS	2GM/VIAL	N16267 002	MAY 25, 2000	FEB	CPOT
	DEMECARIUM BROMIDE					
	SOLUTION/DROPS; OPHTHALMIC					
	HUMORSOL					
	@ MERCK	0.125%	N11860 002		JUN	DISC
	@	0.25%	N11860 001		JUN	DISC
	DEMECLOCYCLINE HYDROCHLORIDE					
	TABLET; ORAL					
	DECLOMYCIN					
	@ LEDERLE	75MG	N50261 001		JUN	DISC

DESLORATADINE							
TABLET, ORALLY DISINTEGRATING; ORAL							
CLARINEX							
+ SCHERING	5MG		N21312 001	JUN 26, 2002	JUN	NEWA	
DESMOPRESSIN ACETATE							
SOLUTION; NASAL							
CONCENTRAID							
@ FERRING	0.01%		N19776 001	DEC 26, 1990	JUN	DISC	
DDAVP							
+ AVENTIS	0.01%		N17922 001		SEP	CTEC	
SPRAY; NASAL							
DESMOPRESSIN ACETATE							
+ FERRING	0.1MG/SPRAY		N21333 001	SEP 16, 2002	SEP	NEWA	
SPRAY, METERED; NASAL							
DDAVP							
@ AVENTIS	0.01MG/SPRAY		N17922 002	FEB 06, 1989	MAY	DISC	
DESMOPRESSIN ACETATE							
AB + BAUSCH AND LOMB	0.01MG/SPRAY		N74830 001	JAN 25, 1999	MAY	CRLD	
DESOGESTREL; ETHINYL ESTRADIOL							
TABLET; ORAL-28							
KARIVA							
AB BARR	0.15MG;0.02MG;0.01MG		N75863 001	APR 05, 2002	APR	NEWA	
MIRCETTE							
AB + ORGANON	0.15MG;0.02MG;0.01MG		N20713 001	APR 22, 1998	APR	CFTG	
DESONIDE							
LOTION; TOPICAL							
DESONIDE							
AB ALTANA	0.05%		N75860 001	MAR 19, 2002	MAR	NEWA	
DESOWEN							
AB + GALDERMA LABS LP	0.05%		N72354 001	JAN 24, 1992	MAR	CFTG	
DESOXIMETASONE							
OINTMENT; TOPICAL							
DESOXIMETASONE							
@ ALTANA	0.25%		N73440 001	APR 01, 1998	MAY	DISC	
DEXAMETHASONE							
AEROSOL; TOPICAL							
DECASPRAY							
@ MERCK	0.04%		N12731 002		JUN	DISC	
TABLET; ORAL							
DEXAMETHASONE							
@ WATSON LABS	0.25MG		N85455 001		AUG	DISC	
@	0.5MG		N85458 001		AUG	DISC	
@	1.5MG		N85456 001		AUG	DISC	

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

@ MERCK	EQ 8MG BASE/ML	N16675	001		APR	DISC

DEXAMETHASONE ACETATE

@ STERIS	EQ 8MG BASE/ML	N84315	001		APR	DISC
@	EQ 16MG BASE/ML	N87711	001	MAY 24, 1982	APR	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DECADRON

@ MERCK	EQ 4MG PHOSPHATE/ML	N12071	002		OCT	DISC
@	EQ 24MG PHOSPHATE/ML	N12071	004		OCT	DISC

DEXAMETHASONE

@ AM PHARM PARTNERS	EQ 10MG PHOSPHATE/ML	N88469	001	JAN 25, 1984	OCT	DISC

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126	001	AUG 31, 1990	OCT CRLD
AP	+	LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440	001	JUL 21, 1982	OCT CRLD
		@ STERIS	EQ 4MG PHOSPHATE/ML	N89169	001	APR 09, 1986	OCT DISC
		@	EQ 10MG PHOSPHATE/ML	N87668	001	JUL 01, 1982	OCT DISC

HEXADROL

@ ORGANON	EQ 4MG PHOSPHATE/ML	N14694	002		OCT	DISC
@	EQ 10MG PHOSPHATE/ML	N14694	003		OCT	DISC

OINTMENT; OPHTHALMIC

MAXIDEX

@ ALCON	EQ 0.05% PHOSPHATE	N83342	001		JUN	DISC

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

@ MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334	002		JUN	DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	+	GLAXOSMITHKLINE	5MG	N17078	001		JAN CFTG
AB	+		10MG	N17078	002		JAN CFTG
AB	+		15MG	N17078	003		JAN CFTG

DEXTROAMPHETAMINE SULFATE

AB	BARR	5MG	N76137	001	JAN 18, 2002	JAN NEWA
AB		10MG	N76137	002	JAN 18, 2002	JAN NEWA
AB		15MG	N76137	003	JAN 18, 2002	JAN NEWA

TABLET; ORAL

AA	KV PHARM	5MG	N40365	001	OCT 31, 2002	OCT NEWA
AA		10MG	N40367	001	OCT 31, 2002	OCT NEWA
AA	MALLINCKRODT	5MG	N40436	001	JAN 29, 2002	JAN NEWA
AA		10MG	N40436	002	JAN 29, 2002	JAN NEWA

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

@ BRACCO	76%	N10040	017		JUN	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM							
INJECTABLE; INJECTION							
RENOVIST							
@ BRACCO		34.3%;35%	N10040	020		JUN	DISC
RENOVIST II							
@ BRACCO		28.5%;29.1%	N10040	019		JUN	DISC
DIATRIZOATE SODIUM							
INJECTABLE; INJECTION							
HYPAQUE							
@ AMERSHAM HLTH		25%	N09561	003		JUN	DISC
SOLUTION; ORAL, RECTAL							
@ AMERSHAM HLTH		40%	N11386	003		JUL	DISC
SOLUTION; URETERAL							
HYPAQUE SODIUM 20%							
@ AMERSHAM HLTH		20%	N09561	002		JUN	DISC
DIAZEPAM							
INJECTABLE; INJECTION							
DIAZEPAM							
AP + ABBOTT		5MG/ML	N71583	001	OCT 13, 1987	OCT	CRLD
VALIUM							
@ ROCHE		5MG/ML	N16087	001		OCT	DISC
DIAZOXIDE							
CAPSULE; ORAL							
PROGLYCEM							
@ BAKER NORTON		50MG	N17425	001		JUN	DISC
DICLOFENAC POTASSIUM							
TABLET; ORAL							
DICLOFENAC POTASSIUM							
AB MUTUAL PHARM		50MG	N75470	001	FEB 21, 2002	FEB	NEWA
DICLOFENAC SODIUM							
GEL; TOPICAL							
SOLARAZE							
+ BIOGLAN PHARMA		3%	N21005	001	OCT 16, 2000	JUL	CAHN
TABLET, DELAYED RELEASE; ORAL							
DICLOFENAC SODIUM							
AB ALPHAPHARM		50MG	N75281	002	FEB 12, 2002	FEB	NEWA
AB		75MG	N75281	003	FEB 12, 2002	FEB	NEWA
TABLET, EXTENDED RELEASE; ORAL							
AB DEXCEL LTD		100MG	N76201	001	NOV 06, 2002	NOV	NEWA
AB PUREPAC PHARM		100MG	N75910	001	JAN 07, 2002	JAN	NEWA
DICUMAROL							
TABLET; ORAL							
DICUMAROL							
@ ABBOTT		25MG	N05545	003		JUN	DISC

DIENESTROL
CREAM; VAGINAL
DIENESTROL
\+ ORTHO MCNEIL 0.01% N06110 005 JUN CAHN

DIFLORASONE DIACETATE
CREAM; TOPICAL
DIFLORASONE DIACETATE
>D> AB ALTANA 0.05% N75187 001 MAR 30, 2098 DEC CTEC
>A> AB1 0.05% N75187 001 MAR 30, 2098 DEC CTEC
>A> AB2 0.05% N76263 001 DEC 20, 2002 DEC NEWA
>D> AB TARO 0.05% N75508 001 APR 24, 2000 DEC CTEC
>A> AB1 0.05% N75508 001 APR 24, 2000 DEC CTEC
FLORONE E
>D> BX + PHARMACIA AND UPJOHN 0.05% N19259 001 AUG 28, 2085 DEC CTEC
>A> AB2 + 0.05% N19259 001 AUG 28, 2085 DEC CTEC
PSORCON
>D> AB + DERMIK LABS 0.05% N20205 001 NOV 20, 2092 DEC CTEC
>A> AB1 + 0.05% N20205 001 NOV 20, 2092 DEC CTEC

DIGOXIN
TABLET; ORAL
DIGOXIN
AB STEVENS J 0.125MG N76268 001 JUL 26, 2002 JUL NEWA
AB 0.25MG N76268 002 JUL 26, 2002 JUL NEWA

DIHYDROERGOTAMINE MESYLATE
INJECTABLE; INJECTION
D.H.E. 45
XCEL PHARMS 1MG/ML N05929 001 JUN CAHN
SPRAY, METERED; NASAL
MIGRANAL
\+ XCEL PHARM 0.5MG/INH N20148 001 DEC 08, 1997 JUL CAHN

DILTIAZEM HYDROCHLORIDE
INJECTABLE; INJECTION
CARDIZEM
AP + BIOVAIL 5MG/ML N20027 001 OCT 24, 1991 JUN CAHN
\+ 25MG/VIAL N20027 003 AUG 18, 1995 JUN CAHN
DILTIAZEM HCL
>A> AP ABBOTT 100MG/VIAL N75853 001 DEC 17, 2002 DEC NEWA
\+ GENSIA SICOR PHARMS 10MG/ML N74894 002 APR 19, 2002 APR NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE
TABLET, EXTENDED RELEASE; ORAL
TECZEM
\+ BIOVAIL EQ 180MG HCL;5MG N20507 001 OCT 04, 1996 JUN CAHN

DIMETHYL SULFOXIDE
SOLUTION; INTRAVESICAL
DIMETHYL SULFOXIDE
AT BIONICHE (CANADA) 50% N76185 001 NOV 29, 2002 NOV NEWA

		DIMETHYL SULFOXIDE						
		SOLUTION; INTRAVESICAL						
		RIMSO-50						
AT	+	RES INDS	50%	N17788 001		NOV	CFTG	
		DIMYRISTOYL LECITHIN; PERFLEXANE						
		INJECTABLE; INTRAVENOUS						
		IMAGENT						
	+	ALLIANCE PHARM	0.92MG/VIAL;0.092MG/VIAL	N21191 001	MAY 31, 2002	MAY	NEWA	
		DIPHENHYDRAMINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DIPHENHYDRAMINE HCL						
AP		AM PHARM PARTNERS	50MG/ML	N40466 001	MAY 28, 2002	MAY	NEWA	
		DIPHENIDOL HYDROCHLORIDE						
		TABLET; ORAL						
		VONTROL						
	@	GLAXOSMITHKLINE	EQ 25MG BASE	N16033 001		JUN	DISC	
		DIPYRIDAMOLE						
		INJECTABLE; INJECTION						
		DIPYRIDAMOLE						
AP		APOTEX	5MG/ML	N75769 001	NOV 27, 2002	NOV	NEWA	
		DISULFIRAM						
		TABLET; ORAL						
		ANTABUSE						
>D>		ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	DEC	CRLD	
>A>	+		250MG	N88482 001	DEC 08, 1983	DEC	CRLD	
>D>	+		500MG	N88483 001	DEC 08, 1983	DEC	DISC	
>A>	@		500MG	N88483 001	DEC 08, 1983	DEC	DISC	
		DIVALPROEX SODIUM						
		TABLET, EXTENDED RELEASE; ORAL						
		DEPAKOTE ER						
		ABBOTT	EQ 250MG VALPROIC ACID	N21168 002	MAY 31, 2002	JUL	NEWA	
		DONEPEZIL HYDROCHLORIDE						
		TABLET; ORAL						
		ARICEPT						
		EISAI MEDCL RES	5MG	N20690 002	NOV 25, 1996	MAY	CAHN	
	+		10MG	N20690 001	NOV 25, 1996	MAY	CAHN	
		DOXEPIN HYDROCHLORIDE						
		CAPSULE; ORAL						
		DOXEPIN HCL						
	@	LEDERLE	EQ 10MG BASE	N71685 001	JAN 05, 1988	MAY	DISC	
	@		EQ 25MG BASE	N71686 001	JAN 05, 1988	MAY	DISC	
	@		EQ 50MG BASE	N71673 001	JAN 05, 1988	MAY	DISC	
	@		EQ 75MG BASE	N71674 001	JAN 05, 1988	MAY	DISC	

		@	EQ 100MG BASE	N71675 001	JAN 05, 1988	MAY	DISC
		@	EQ 150MG BASE	N71676 001	JAN 05, 1988	MAY	DISC
		CREAM; TOPICAL					
		ZONALON					
	+	BIOGLAN PHARMS	5%	N20126 001	APR 01, 1994	JUN	CAHN
		DOXYCYCLINE					
		TABLET; ORAL					
		DOXYCYCLINE					
>A>		PAR PHARM	EQ 75MG BASE	N65070 003	DEC 30, 2002	DEC	NEWA
		DOXYCYCLINE HYCLATE					
		CAPSULE; ORAL					
		PERIOSTAT					
	@	COLLAGENEX	EQ 20MG BASE	N50744 001	SEP 30, 1998	JUN	DISC
		DROPERIDOL; FENTANYL CITRATE					
		INJECTABLE; INJECTION					
		FENTANYL CITRATE AND DROPERIDOL					
	+	ABBOTT	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	MAY 04, 1988	JUN	CTEC
	@	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72026 001	APR 13, 1989	JUN	DISC
		DUTASTERIDE					
		CAPSULE; ORAL					
		AVODART					
	+	GLAXOSMITHKLINE	0.5MG	N21319 001	NOV 20, 2001	OCT	CTNA
		ECHOTHIOPHATE IODIDE					
		FOR SOLUTION; OPHTHALMIC					
		PHOSPHOLINE IODIDE					
	@	AYERST	0.03%	N11963 002		JUN	DISC
	@		0.06%	N11963 004		JUN	DISC
	@		0.25%	N11963 003		JUN	DISC
		ECONAZOLE NITRATE					
		CREAM; TOPICAL					
		ECONAZOLE NITRATE					
AB		ALTANA	1%	N76075 001	NOV 26, 2002	NOV	NEWA
AB		TARO	1%	N76005 001	NOV 26, 2002	NOV	NEWA
		SPECTAZOLE					
AB	+	JOHNSON AND JOHNSON	1%	N18751 001	DEC 23, 1982	NOV	CFTG
		EDETATE DISODIUM					
		INJECTABLE; INJECTION					
		EDETATE DISODIUM					
AP		APOTEX	150MG/ML	N40376 001	NOV 04, 2002	NOV	NEWA
>A> AP		BIONICHE (CANADA)	150MG/ML	N40437 001	JUL 09, 2002	DEC	CAHN
>D> AP		PHARMAFORCE	150MG/ML	N40437 001	JUL 09, 2002	DEC	CAHN
AP			150MG/ML	N40437 001	JUL 09, 2002	JUL	NEWA

EFAVIRENZ
TABLET; ORAL
SUSTIVA

	BRISTOL MYERS SQUIBB	300MG	N21360	001	FEB 01, 2002	FEB	NEWA
+		600MG	N21360	002	FEB 01, 2002	FEB	NEWA

EFLORNITHINE HYDROCHLORIDE
CREAM; TOPICAL
VANIQA

+	WOMEN FIRST HLTHCARE	13.9%	N21145	001	JUL 27, 2000	JUL	CAHN

ELETRIPTAN HYDROBROMIDE
TABLET; ORAL
RELPAX

>A>	PFIZER	EQ 20MG BASE	N21016	001	DEC 26, 2002	DEC	NEWA
>A> +	PFIZER IRELAND	EQ 40MG BASE	N21016	002	DEC 26, 2002	DEC	NEWA

ENALAPRIL MALEATE
TABLET; ORAL
VASOTEC

AB	BIOVAIL	2.5MG	N18998	005	JUL 26, 1988	MAY	CAHN
AB		5MG	N18998	001	DEC 24, 1985	MAY	CAHN
AB		10MG	N18998	002	DEC 24, 1985	MAY	CAHN
AB +		20MG	N18998	003	DEC 24, 1985	MAY	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
VASERETIC

AB	BIOVAIL	5MG;12.5MG	N19221	003	JUL 12, 1995	MAY	CAHN
AB +		10MG;25MG	N19221	001	OCT 31, 1986	MAY	CAHN

ENALAPRILAT
INJECTABLE; INJECTION
VASOTEC

AP +	BIOVAIL	1.25MG/ML	N19309	001	FEB 09, 1988	MAY	CAHN

ENOXACIN
TABLET; ORAL
PENETREX

	@ AVENTIS	200MG	N19616	004	DEC 31, 1991	JUN	DISC
	@	400MG	N19616	005	DEC 31, 1991	JUN	DISC

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

	@ AVENTIS	90MG/0.6ML	N20164	006	JUN 02, 2000	JUN	DISC

EPINEPHRINE
INJECTABLE; INJECTION
SUS-PHRINE SULFITE-FREE

	@ FORREST LABS	1.5MG/AMP	N07942	003	FEB 05, 1999	JUN	DISC
	@	5MG/ML	N07942	001		JUN	DISC

EPINEPHRINE							
INJECTABLE; INTRAMUSCULAR							
EPI E Z PEN JR							
@ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430	004	AUG 03, 1995	JUN	DISC	
EPIPEN E Z PEN							
@ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430	003	AUG 03, 1995	JUN	DISC	
EPLERENONE							
TABLET; ORAL							
INSPRA							
GD SEARLE LLC	25MG	N21437	001	SEP 27, 2002	SEP	NEWA	
	50MG	N21437	002	SEP 27, 2002	SEP	NEWA	
+	100MG	N21437	003	SEP 27, 2002	SEP	NEWA	
EPROSARTAN MESYLATE							
TABLET; ORAL							
TEVETEN							
BIOVAIL PHARMS	EQ 300MG BASE	N20738	004	DEC 22, 1997	JUN	CAHN	
	EQ 400MG BASE	N20738	005	DEC 22, 1997	JUN	CAHN	
+	EQ 600MG BASE	N20738	006	MAY 27, 1999	JUN	CAHN	
EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE							
TABLET; ORAL							
TEVETEN HCT							
BIOVAIL PHARMS	600MG;12.5MG	N21268	001	NOV 01, 2001	JUN	CAHN	
+	600MG;25MG	N21268	002	NOV 01, 2001	JUN	CAHN	
EPTIFIBATIDE							
INJECTABLE; INJECTION							
INTEGRILIN							
+ MILLENNIUM PHARMS	2MG/ML	N20718	001	MAY 18, 1998	FEB	CAHN	
+	75MG/100ML	N20718	002	MAY 18, 1998	FEB	CAHN	
ERGOLOID MESYLATES							
CAPSULE; ORAL							
HYDERGINE LC							
@ NOVARTIS	1MG	N18706	001	JAN 18, 1983	JUN	DISC	
SOLUTION; ORAL							
HYDERGINE							
@ NOVARTIS	1MG/ML	N18418	001		JUN	DISC	
ERYTHROMYCIN							
GEL; TOPICAL							
E-GLADES							
AT GLADES PHARMS	2%	N65009	001	MAR 18, 2002	MAR	NEWA	

		ESCITALOPRAM OXALATE						
		SOLUTION; ORAL						
		LEXAPRO						
		+ FOREST LABS	EQ 5MG BASE/5ML	N21365	001	NOV 27, 2002	NOV	NEWA
		TABLET; ORAL						
		FOREST LABS	5MG	N21323	001	AUG 14, 2002	AUG	NEWA
			10MG	N21323	002	AUG 14, 2002	AUG	NEWA
		+	20MG	N21323	003	AUG 14, 2002	AUG	NEWA
		ESTRADIOL						
		FILM, EXTENDED RELEASE; TRANSDERMAL						
		ALORA						
	BX	WATSON LABS	0.025MG/24HR	N20655	004	APR 05, 2002	MAY	CMS1
	BX		0.025MG/24HR	N20655	004	APR 16, 2002	APR	NEWA
		FEMPATCH						
		@ PARKE DAVIS	0.025MG/24HR	N20417	001	DEC 03, 1996	NOV	WDGB
		TABLET; ORAL						
		ESTRADIOL						
	AB	USL PHARMA	0.5MG	N40297	001	APR 17, 2002	APR	NEWA
	AB		1MG	N40297	002	APR 17, 2002	APR	NEWA
	AB		2MG	N40297	003	APR 17, 2002	APR	NEWA
		ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE						
		INJECTABLE; INJECTION						
		DEPO-TESTADIOL						
>D>	AO	+ PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N17968	001		DEC	CTEC
>A>		+	2MG/ML;50MG/ML	N17968	001		DEC	CTEC
>D>		TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE						
>D>	AO	STERIS	2MG/ML;50MG/ML	N85603	001	MAR 13, 1986	DEC	DISC
>A>		@	2MG/ML;50MG/ML	N85603	001	MAR 13, 1986	DEC	DISC
>D>		ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE						
>D>		INJECTABLE; INJECTION						
>D>		DITATE-DS						
>D>		+ SAVAGE LABS	8MG/ML;180MG/ML	N86423	001		DEC	DISC
>A>		@	8MG/ML;180MG/ML	N86423	001		DEC	DISC
>D>		TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE						
>D>		+ STERIS	4MG/ML;90MG/ML	N85865	001		DEC	DISC
>A>		@	4MG/ML;90MG/ML	N85865	001		DEC	DISC
		ESTRADIOL; NORETHINDRONE ACETATE						
		TABLET; ORAL						
		ACTIVELLA						
		+ NOVO NORDISK	1MG;0.5MG	N20907	001	NOV 18, 1998	JUN	CTNA
		ESTRADIOL; NORGESTIMATE						
		TABLET; ORAL						
		ORTHO-PREFEST						
		+ KING PHARMS	1MG;1MG;0.09MG	N21040	001	OCT 22, 1999	MAY	CAHN

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN						
DURAMED	0.3MG	N20992	001	JUN 21, 2002	AUG	CAHN
DURAMED PHARM BARR	0.3MG	N20992	001	JUN 21, 2002	JUL	NEWA

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)						
@ WYETH AYERST	0.625MG;0.625MG;5MG	N20303	002	DEC 30, 1994	JUN	DISC
PREMPRO (PREMARIN;CYCRIN)						
@ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303	001	DEC 30, 1994	JUN	DISC

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

PMB 200						
@ WYETH AYERST	0.45MG;200MG	N10971	005		JUN	DISC
PMB 400						
@ WYETH AYERST	0.45MG;400MG	N10971	003		JUN	DISC

ETHCHLORVYNOL

CAPSULE; ORAL

PLACIDYL						
@ ABBOTT	200MG	N10021	007		JUN	DISC
@	500MG	N10021	002		JUN	DISC
@	750MG	N10021	010		JUN	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	ALESSE						
AB +	WYETH AYERST	0.02MG;0.1MG	N20683	001	MAR 27, 1997	MAR	CTEC
AB1 +		0.02MG;0.1MG	N20683	001	MAR 27, 1997	MAY	CTEC
	AVIANE-21						
AB1	DURAMED PHARM BARR	0.02MG;0.1MG	N75796	002	APR 30, 2001	MAR	CTEC
	LESSINA-21						
AB2	BARR	0.02MG;0.1MG	N75803	001	MAR 20, 2002	MAR	NEWA
	LEVLITE						
AB2 +	BERLEX LABS	0.02MG;0.1MG	N20860	001	JUL 13, 1998	MAR	CTEC
	PORTIA-21						
AB	BARR	0.03MG;0.15MG	N75866	001	MAY 23, 2002	MAY	NEWA

TABLET; ORAL-28

	ALESSE						
AB1	WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	MAR	CTEC
	AVIANE-28						
AB1	DURAMED PHARM BARR	0.02MG;0.1MG	N75796	001	APR 30, 2001	MAR	CTEC
	LESSINA-28						
AB	BARR	0.02MG;0.1MG	N75803	002	MAR 20, 2002	MAR	NEWA
	LEVLITE						
AB	BERLEX LABS	0.02MG;0.1MG	N20860	002	JUL 13, 1998	MAR	CTEC
	PORTIA-28						
AB	BARR	0.03MG;0.15MG	N75866	002	MAY 23, 2002	MAY	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORTREL 0.5/35-21

AB	BARR	0.035MG;0.5MG	N72692 001	FEB 28, 1992	AUG	CTNA

NORTREL 1/35-21

AB	BARR	0.035MG;1MG	N72693 001	FEB 28, 1992	AUG	CTNA

NORTREL 7/7/7

AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N75478 001	AUG 30, 2002	AUG	NEWA

ORTHO-NOVUM 7/7/7-21

AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 001	APR 04, 1984	AUG	CFTG

TABLET; ORAL-28

NORTREL 0.5/35-28

AB	BARR	0.035MG;0.5MG	N72695 001	FEB 28, 1992	AUG	CTNA

NORTREL 1/35-28

AB	BARR	0.035MG;1MG	N72696 001	FEB 28, 1992	AUG	CTNA

NORTREL 7/7/7

AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N75478 002	AUG 30, 2002	AUG	NEWA

ORTHO-NOVUM 7/7/7-28

AB	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.75MG	N18985 002	APR 04, 1984	AUG	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

ESTROSTEP 21

@	PARKE DAVIS	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 001	OCT 09, 1996	JUN	DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO CYCLEN-28

AB +	ORTHO MCNEIL PHARM	0.035MG;0.25MG	N19653 002	DEC 29, 1989	SEP	CFTG

ORTHO TRI-CYCLEN

>D> +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	DEC	CFTG
>A> AB +		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	DEC	CFTG
+		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N19697 001	JUL 03, 1992	SEP	CRLD

ORTHO TRI-CYCLEN LO

+	JOHNSON AND JOHNSON	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.215MG	N21241 001	AUG 22, 2002	AUG	NEWA

SPRINTEC

AB	BARR	0.035MG;0.25MG	N75804 001	SEP 25, 2002	SEP	NEWA

TRI-SPRINTEC

>A> AB	BARR	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N75808 001	DEC 18, 2002	DEC	NEWA

		ETHOSUXIMIDE						
		CAPSULE; ORAL						
		ETHOSUXIMIDE						
	AB	BANNER PHARMACAPS	250MG	N40430	001	OCT 28, 2002	OCT	NEWA
		ZARONTIN						
	AB +	PARKE DAVIS	250MG	N12380	001		OCT	CFTG
		ETHOTOIN						
		TABLET; ORAL						
		PEGANONE						
	+	ABBOTT	250MG	N10841	001		JUN	CRLD
		@	500MG	N10841	003		JUN	DISC
		ETIDOCAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DURANEST						
		@ ASTRAZENECA	1%	N17751	005		SEP	DISC
		ETODOLAC						
		CAPSULE; ORAL						
		ETODOLAC						
	AB	NEOSAN PHARMS	300MG	N74929	001	JAN 30, 1998	JUL	CAHN
		TABLET; ORAL						
>A>	AB	APOTEX	400MG	N76004	001	DEC 03, 2002	DEC	NEWA
>A>	AB		500MG	N76004	002	DEC 03, 2002	DEC	NEWA
	AB	NEOSAN PHARMS	400MG	N74927	001	OCT 30, 1997	JUL	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
	AB	EON	400MG	N75943	001	JUL 26, 2002	JUL	NEWA
	AB		500MG	N75943	002	JUL 26, 2002	JUL	NEWA
	AB		600MG	N75943	003	JUL 26, 2002	JUL	NEWA
		EZETIMIBE						
		TABLET; ORAL						
		ZETIA						
	+	MSP SINGAPORE	10MG	N21445	001	OCT 25, 2002	OCT	NEWA
		FAMOTIDINE						
		INJECTABLE; INJECTION						
		FAMOTIDINE						
	AP	APOTEX	10MG/ML	N75942	001	AUG 02, 2002	AUG	NEWA
	AP	BAXTER HLTHCARE	10MG/ML	N75799	001	APR 30, 2002	APR	NEWA
		FAMOTIDINE PRESERVATIVE FREE						
	AP	APOTEX	10MG/ML	N76324	001	NOV 27, 2002	NOV	NEWA
		@ APOTHECON	10MG/ML	N75708	001	APR 16, 2001	MAR	WDAG
	AP	BAXTER HLTHCARE	10MG/ML	N75789	001	APR 30, 2002	APR	NEWA
		FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
	AP	APOTEX	10MG/ML	N76322	001	NOV 27, 2002	NOV	NEWA
		FENOFIBRATE						
		CAPSULE; ORAL						
		FENOFIBRATE (MICRONIZED)						
	AB	TEVA	67MG	N75753	001	SEP 03, 2002	SEP	NEWA

AB		134MG	N75753 002	APR 09, 2002	APR	NEWA
AB		200MG	N75753 003	APR 09, 2002	APR	NEWA
	TRICOR (MICRONIZED)					
AB	ABBOTT	67MG	N19304 002	FEB 09, 1998	SEP	CFTG
AB		134MG	N19304 003	JUN 30, 1999	APR	CFTG
AB +		200MG	N19304 004	JUN 30, 1999	APR	CFTG
	FENOPROFEN CALCIUM					
	CAPSULE; ORAL					
	NALFON					
AB +	RANBAXY	EQ 300MG BASE	N17604 002		JUN	CAHN
	NALFON 200					
AB	RANBAXY	EQ 200MG BASE	N17604 003		JUN	CAHN
	TABLET; ORAL					
	FENOPROFEN CALCIUM					
AB +	MYLAN	EQ 600MG BASE	N72267 001	AUG 17, 1988	NOV	CRLD
	NALFON					
	@ DISTA	EQ 600MG BASE	N17710 001		NOV	DISC
	FENTANYL CITRATE					
	TROCHE/LOZENGE; ORAL					
	FENTANYL					
	@ ANESTA	EQ 0.1MG BASE	N20195 007	OCT 30, 1995	JUN	DISC
	@	EQ 0.2MG BASE	N20195 001	OCT 04, 1993	JUN	DISC
	@	EQ 0.3MG BASE	N20195 002	OCT 04, 1993	JUN	DISC
	@	EQ 0.4MG BASE	N20195 003	OCT 04, 1993	JUN	DISC
	FERRIC AMMONIUM CITRATE					
	FOR SOLUTION; ORAL					
	FERRISELTZ					
	@ AMERSHAM HLTH	600MG/PACKET	N20292 001	OCT 14, 1997	JUL	DISC
	FLECAINIDE ACETATE					
	TABLET; ORAL					
	FLECAINIDE ACETATE					
AB	BARR	50MG	N75882 001	OCT 28, 2002	OCT	NEWA
AB		100MG	N75882 002	OCT 28, 2002	OCT	NEWA
AB		150MG	N75882 003	OCT 28, 2002	OCT	NEWA
AB	GENEVA PHARMS TECH	50MG	N76030 001	OCT 28, 2002	OCT	NEWA
AB		100MG	N76030 002	OCT 28, 2002	OCT	NEWA
AB		150MG	N76030 003	OCT 28, 2002	OCT	NEWA
	FLOXURIDINE					
	INJECTABLE; INJECTION					
	FUDR					
AP +	FAULDING	500MG/VIAL	N16929 001		APR	CAHN
	FLUDEOXYGLUCOSE, F-18					
	INJECTABLE; INJECTION					
	FLUDEOXYGLUCOSE F 18					
	@ DOWNSTATE CLINCL	4-40mCi/ML	N20306 001	AUG 19, 1994	JUL	DISC

FLUDROCORTISONE ACETATE								
TABLET; ORAL								
FLORINEF								
AB	+	KING PHARMS	0.1MG	N10060	001		MAR	CFTG
FLUDROCORTISONE ACETATE								
AB		IMPAX LABS	0.1MG	N40431	001	MAR 18, 2002	MAR	NEWA
FLUNISOLIDE								
SPRAY, METERED; NASAL								
FLUNISOLIDE								
AB		BAUSCH AND LOMB	0.025MG/SPRAY	N74805	001	FEB 20, 2002	FEB	NEWA
NASALIDE								
AB	+	IVAX RES	0.025MG/SPRAY	N18148	001		FEB	CTEC
FLUOCINOLONE ACETONIDE								
CREAM; TOPICAL								
SYNALAR-HP								
	@	MEDICIS	0.2%	N16161	002		JUN	DISC
SOLUTION; TOPICAL								
FLUONID								
	@	ALLERGAN HERBERT	0.01%	N87158	001	MAR 17, 1983	MAY	DISC
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN								
CREAM; TOPICAL								
TRI-LUMA								
	+	HILL DERMAC	0.01%;4%;0.05%	N21112	001	JAN 18, 2002	JAN	NEWA
FLUOCINONIDE								
CREAM; TOPICAL								
FLUOCINONIDE EMULSIFIED BASE								
AB		TEVA	0.05%	N72490	001	FEB 07, 1989	AUG	CTNA
FLUOXETINE HYDROCHLORIDE								
CAPSULE; ORAL								
FLUOXETINE								
AB		ALPHAPHARM	EQ 10MG BASE	N75577	001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75577	002	JAN 29, 2002	JAN	NEWA
AB		BARR	EQ 10MG BASE	N74803	002	JAN 30, 2002	JAN	NEWA
AB		CARLSBAD	EQ 10MG BASE	N76022	001	JAN 30, 2002	JAN	NEWA
AB			EQ 20MG BASE	N76022	002	JAN 30, 2002	JAN	NEWA
AB		DR REDDYS LABS INC	EQ 10MG BASE	N75465	001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75465	002	JAN 29, 2002	JAN	NEWA
AB		EON	EQ 10MG BASE	N75807	001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75807	002	JAN 29, 2002	JAN	NEWA
AB		IVAX PHARMS	EQ 10MG BASE	N75245	002	JAN 31, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75245	001	JAN 31, 2002	JAN	NEWA
AB		MALLINCKRODT	EQ 10MG BASE	N75658	001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75658	002	JAN 29, 2002	JAN	NEWA
AB		MUTUAL PHARMA	EQ 10MG BASE	N75787	001	JAN 29, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75787	002	JAN 29, 2002	JAN	NEWA
AB		MYLAN	EQ 10MG BASE	N75207	001	JAN 30, 2002	JAN	NEWA
AB			EQ 20MG BASE	N75207	002	JAN 30, 2002	JAN	NEWA

AB	RANBAXY	EQ 10MG BASE	N76165	001	FEB 01, 2002	FEB	NEWA
AB		EQ 20MG BASE	N76165	002	FEB 01, 2002	FEB	NEWA
AB	SIDMAK LABS	EQ 10MG BASE	N76001	001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N76001	002	JAN 29, 2002	JAN	NEWA
AB	SIEGFRIED	EQ 10MG BASE	N75464	001	JAN 30, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75464	002	JAN 30, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75452	001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75452	002	JAN 29, 2002	JAN	NEWA
AB		EQ 40MG BASE	N75452	003	JAN 29, 2002	JAN	NEWA
AB	WATSON LABS	EQ 10MG BASE	N75662	001	JAN 29, 2002	JAN	NEWA
AB		EQ 20MG BASE	N75662	002	JAN 29, 2002	JAN	NEWA
	FLUOXETINE HCL						
AB	GENEVA PHARMS	EQ 20MG BASE	N75049	002	JAN 29, 2002	JAN	NEWA
AB		EQ 40MG BASE	N75049	003	JAN 29, 2002	JAN	NEWA
	SOLUTION; ORAL						
	FLUOXETINE						
AA	ALPHARMA	EQ 20MG BASE/5ML	N75690	001	JAN 31, 2002	JAN	NEWA
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920	001	JAN 29, 2002	JAN	NEWA
AA	NOVEX	EQ 20MG BASE/5ML	N75292	001	FEB 07, 2002	FEB	NEWA
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015	001	JAN 30, 2002	JAN	NEWA
	FLUOXETINE HCL						
AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525	001	JUN 27, 2002	JUN	NEWA
AA	MORTON GROVE	EQ 20MG BASE/5ML	N75514	001	AUG 29, 2002	AUG	NEWA
	TABLET; ORAL						
AB	BARR	EQ 10MG BASE	N75810	001	FEB 01, 2002	FEB	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006	001	JAN 30, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N76024	001	JAN 29, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75872	001	JAN 29, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865	001	FEB 28, 2002	FEB	NEWA

FLUPHENAZINE ENANTHATE

	INJECTABLE; INJECTION						
	PROLIXIN ENANTHATE						
	@ APOTHECON	25MG/ML	N16110	001		JUN	DISC

FLUPHENAZINE HYDROCHLORIDE

	TABLET; ORAL						
	PERMITIL						
	@ SCHERING	2.5MG	N12034	004		NOV	WDGB
	@	5MG	N12034	005		NOV	WDGB

FLUVOXAMINE MALEATE

	TABLET; ORAL						
	FLUVOXAMINE MALEATE						
AB +	EON	100MG	N75888	003	NOV 29, 2000	MAY	CRLD
AB	MUTUAL PHARM	25MG	N76125	001	APR 29, 2002	APR	NEWA
AB		50MG	N76125	002	APR 29, 2002	APR	NEWA
AB		100MG	N76125	003	APR 29, 2002	APR	NEWA
AB	TEVA	25MG	N75893	001	SEP 10, 2002	SEP	NEWA
AB		50MG	N75893	002	SEP 10, 2002	SEP	NEWA
AB		100MG	N75893	003	SEP 10, 2002	SEP	NEWA
	LUVOX						
	@ SOLVAY	25MG	N20243	001	DEC 05, 1994	MAY	DISC

	@	50MG	N20243 002	DEC 05, 1994	MAY	DISC
	@	100MG	N20243 003	DEC 05, 1994	MAY	DISC
	FOLIC ACID					
	TABLET; ORAL					
	FOLIC ACID					
AA	+ WATSON LABS	1MG	N80680 001		FEB	CAHN
	FOLLITROPIN ALFA/BETA					
	INJECTABLE; INJECTION					
	GONAL-F					
	@ SERONO	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
	FULVESTRANT					
	INJECTABLE; INTRAMUSCULAR					
	FASLODEX					
	+ ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002	APR	NEWA
	FURAZOLIDONE					
	SUSPENSION; ORAL					
	FUROXONE					
	@ SHIRE LABS	50MG/15ML	N11323 002		JUL	DISC
	TABLET; ORAL					
	@ SHIRE LABS	100MG	N11270 002		JUL	DISC
	GALLIUM CITRATE, GA-67					
	INJECTABLE; INJECTION					
	NEOSCAN					
	@ AMERSHAM HLTH	2mCi/ML	N17655 001		JUN	DISC
	GALLIUM NITRATE					
	INJECTABLE; INJECTION					
	GANITE					
>D>	@ GENTA	25MG/ML	N19961 002	JAN 17, 1991	DEC	CMFD
>A>	+	25MG/ML	N19961 002	JAN 17, 1991	DEC	CMFD
	@	25MG/ML	N19961 002	JAN 17, 1991	JUL	CAHN
	GATIFLOXACIN					
	INJECTABLE; INJECTION					
	TEQUIN					
>A>	BRISTOL MYERS SQUIBB	2MG /ML (200MG/100ML)	N21062 001	DEC 17, 1999	DEC	CPOT
>A>		2MG /ML (400MG/200ML)	N21062 002	DEC 17, 1999	DEC	CPOT
>A>		10MG /ML (200MG)	N21062 003	DEC 17, 1999	DEC	NEWA
>A>	+	10MG /ML (400MG)	N21062 004	DEC 17, 1999	DEC	NEWA
>D>	+	200MG/VIAL	N21062 001	DEC 17, 1999	DEC	CPOT
>D>	+	400MG/VIAL	N21062 002	DEC 17, 1999	DEC	CPOT
	GLATIRAMER ACETATE					
	FOR SOLUTION; SUBCUTANEOUS					
	COPAXONE					
	+ TEVA	20MG/VIAL	N20622 001	DEC 20, 1996	JUN	CDFR
	INJECTABLE; SUBCUTANEOUS					
	+ TEVA	20MG/ML	N20622 002	FEB 12, 2002	JUN	NEWA

GLIPIZIDE							
TABLET, EXTENDED RELEASE; ORAL							
GLUCOTROL XL							
PFIZER	2.5MG		N20329 003	AUG 10, 1999	FEB	CRLD	
	5MG		N20329 001	APR 26, 1994	FEB	CRLD	
GLIPIZIDE; METFORMIN HYDROCHLORIDE							
TABLET; ORAL							
METAGLIP							
BRISTOL MYERS SQUIBB	2.5MG;250MG		N21460 001	OCT 21, 2002	OCT	NEWA	
	2.5MG;500MG		N21460 002	OCT 21, 2002	OCT	NEWA	
+	5MG;500MG		N21460 003	OCT 21, 2002	OCT	NEWA	
GLUCAGON HYDROCHLORIDE							
INJECTABLE; INJECTION							
GLUCAGON							
@ LILLY	EQ 1MG BASE/VIAL		N12122 001		JUN	DISC	
GLYBURIDE							
TABLET; ORAL							
GLYBURIDE							
AB AMIDE PHARM	1.5MG		N75947 001	NOV 14, 2002	NOV	NEWA	
AB	3MG		N75947 002	NOV 14, 2002	NOV	NEWA	
AB	6MG		N75947 003	NOV 14, 2002	NOV	NEWA	
AB COREPHARMA	1.25MG		N76257 001	JUN 27, 2002	JUN	NEWA	
AB	2.5MG		N76257 002	JUN 27, 2002	JUN	NEWA	
AB	5MG		N76257 003	JUN 27, 2002	JUN	NEWA	
GONADORELIN ACETATE							
INJECTABLE; INJECTION							
LUTREPULSE KIT							
@ FERRING	0.8MG/VIAL		N19687 001	OCT 10, 1989	JUL	DISC	
@	3.2MG/VIAL		N19687 002	OCT 10, 1989	JUN	DISC	
GONADORELIN HYDROCHLORIDE							
INJECTABLE; INJECTION							
FACTREL							
@ WYETH AYERST	EQ 0.5MG BASE/VIAL		N18123 003	SEP 30, 1982	JUN	DISC	
GONADOTROPIN, CHORIONIC							
INJECTABLE; INJECTION							
A.P.L.							
@ WYETH AYERST	20,000 UNITS/VIAL		N17055 003		JUN	DISC	
CHORIONIC GONADOTROPIN							
@ STERIS	2,000 UNITS/VIAL		N17016 011	FEB 16, 1990	JUN	DISC	
GRANISETRON HYDROCHLORIDE							
SOLUTION; ORAL							
KYTRIL							
@ ROCHE	EQ 2MG BASE/10ML		N21238 001	JUN 27, 2001	JUN	DISC	

GRISEOFULVIN, MICROCRYSTALLINE
TABLET; ORAL
GRISACTIN
@ WYETH AYERST 500MG N60212 001 MAY DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA
@ WYETH AYERST 165MG N62438 001 NOV 17, 1983 MAY DISC
@ 330MG N62438 002 NOV 17, 1983 MAY DISC

GUANADREL SULFATE
TABLET; ORAL
HYLOREL
@ PHARMACIA AND UPJOHN 10MG N18104 001 DEC 29, 1982 JUN DISC
@ 25MG N18104 002 DEC 29, 1982 JUN DISC

GUANETHIDINE MONOSULFATE
TABLET; ORAL
ISMELIN
@ NOVARTIS EQ 10MG SULFATE N12329 001 JUN DISC
@ EQ 25MG SULFATE N12329 002 JUN DISC

GUANFACINE HYDROCHLORIDE
TABLET; ORAL
TENEX
AB ESP PHARMA EQ 1MG BASE N19032 001 OCT 27, 1986 APR CAHN
AB + EQ 2MG BASE N19032 002 NOV 07, 1988 APR CAHN
@ EQ 3MG BASE N19032 003 NOV 07, 1988 APR CAHN

HALOPERIDOL
TABLET; ORAL
HALDOL
@ ORTHO MCNEIL 0.5MG N15921 001 AUG DISC
@ 1MG N15921 002 AUG DISC
@ 2MG N15921 003 AUG DISC
@ 5MG N15921 004 AUG DISC
@ 10MG N15921 005 AUG DISC
@ 20MG N15921 006 FEB 02, 1982 AUG DISC
HALOPERIDOL
+ GENEVA PHARMS 20MG N71211 001 MAR 11, 1988 AUG CRLD

HALOPERIDOL LACTATE
CONCENTRATE; ORAL
HALDOL
@ ORTHO MCNEIL EQ 2MG BASE/ML N15922 001 AUG DISC
HALOPERIDOL
@ ALPHARMA EQ 2MG BASE/ML N70318 001 APR 11, 1986 MAY DISC
AA + TEVA EQ 2MG BASE/ML N71015 001 AUG 25, 1987 AUG CRLD

HALOTHANE							
LIQUID; INHALATION							
FLUOTHANE							
@ WYETH AYERST		99.99%	N11338 001		APR	DISC
HALOTHANE							
AN + ABBOTT		99.99%	N83254 001		APR	CTEC
HEPARIN SODIUM							
INJECTABLE; INJECTION							
HEP-LOCK							
AP + ELKINS SINN		10 UNITS/ML	N17037 007		JUN	CRLD
AP +		100 UNITS/ML	N17037 006		JUN	CRLD
HEPARIN LOCK FLUSH							
@ WYETH AYERST		10 UNITS/ML	N17007 008		JUN	DISC
@		100 UNITS/ML	N17007 009		JUN	DISC
HEPARIN SODIUM							
AP + ABBOTT		2,500 UNITS/ML	N88099 001	APR 28, 1983	JUN	CRLD
AP + AM PHARM PARTNERS		20,000 UNITS/ML	N17029 004		JUN	CRLD
@ WYETH AYERST		1,000 UNITS/ML	N17007 001		JUN	DISC
@		2,500 UNITS/ML	N17007 007		JUN	DISC
@		5,000 UNITS/ML	N17007 002		JUN	DISC
@		5,000 UNITS/0.5ML	N17007 010		JUN	DISC
@		7,500 UNITS/ML	N17007 003		JUN	DISC
@		10,000 UNITS/ML	N17007 004		JUN	DISC
@		20,000 UNITS/ML	N17007 006		JUN	DISC
HEXACHLOROPHENE							
SOAP; TOPICAL							
GAMOPHEN							
@ ARBROOK		2%	N06270 003		JUN	DISC
SPONGE; TOPICAL							
E-Z SCRUB							
@ BECTON DICKINSON		450MG	N17452 001		JUN	DISC
HISTRELIN ACETATE							
INJECTABLE; INJECTION							
SUPPRELIN							
@ SHIRE LABS		EQ 0.2MG BASE/ML	N19836 001	DEC 24, 1991	JUL	DISC
@		EQ 0.5MG BASE/ML	N19836 002	DEC 24, 1991	JUL	DISC
@		EQ 1MG BASE/ML	N19836 003	DEC 24, 1991	JUL	DISC
HYDROCHLOROTHIAZIDE							
CAPSULE; ORAL							
HYDROCHLOROTHIAZIDE							
AB VINTAGE PHARMS		12.5MG	N75907 001	SEP 17, 2002	SEP	NEWA
TABLET; ORAL							
ESIDRIX							
AB + NOVARTIS		100MG	N11793 009		MAR	CRLD
@		100MG	N11793 009		SEP	DISC
HYDROCHLOROTHIAZIDE							
AB + IVAX PHARMS		100MG	N85022 001		SEP	CRLD
@ LEDERLE		100MG	N87060 001		SEP	DISC

AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
AB		50MG	N40412 002	MAR 29, 2002	MAR	NEWA
	@ WATSON LABS	100MG	N81190 001	JAN 24, 1992	SEP	DISC
	HYDRODIURIL					
	@ MERCK	25MG	N11835 003		MAR	DISC
	@	50MG	N11835 006		MAR	DISC
	@	100MG	N11835 007		MAR	DISC
	ORETIC					
	@ ABBOTT	25MG	N11971 001		SEP	DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	EON	12.5MG;10MG	N76262 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76262 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76262 003	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	12.5MG;10MG	N75926 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75926 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75926 003	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	12.5MG;10MG	N75776 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75776 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75776 003	JUL 01, 2002	JUL	NEWA
AB	MYLAN	12.5MG;10MG	N76113 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76113 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76113 003	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76230 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76230 003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N76007 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76007 003	JUL 01, 2002	JUL	NEWA
AB	TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;20MG	N75869 002	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N75869 003	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	12.5MG;20MG	N76194 001	JUL 01, 2002	JUL	NEWA
AB		12.5MG;10MG	N76194 003	JUL 01, 2002	JUL	NEWA
AB		25MG;20MG	N76194 002	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002	JUL	NEWA
AB		12.5MG;20MG	N76265 002	JUL 08, 2002	JUL	NEWA
AB		25MG;20MG	N76265 003	JUL 08, 2002	JUL	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

	SCHWARZ PHARMA	12.5MG;15MG	N20729 003	FEB 14, 2002	JUN	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	INDERIDE LA 120/50					
	@ WYETH AYERST	50MG;120MG	N19059 002	JUL 03, 1985	JUN	DISC
	INDERIDE LA 160/50					
	@ WYETH AYERST	50MG;160MG	N19059 003	JUL 03, 1985	JUN	DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
INDERIDE LA 80/50

@	WYETH AYERST	50MG;80MG	N19059 001	JUL 03, 1985	JUN	DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDROPRES 25

@	MERCK	25MG;0.125MG	N11958 002		JUN	DISC

HYDROPRES 50

@	MERCK	50MG;0.125MG	N11958 003		JUN	DISC

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
SYRUP; ORAL
CODAMINE

@	ALPHARMA	5MG/5ML;25MG/5ML	N75103 001	SEP 29, 2000	SEP	DISC

HYCOMINE

@	ENDO PHARMS	5MG/5ML;25MG/5ML	N19410 001	AUG 17, 1990	SEP	DISC

HYCOMINE PEDIATRIC

@	ENDO PHARMS	2.5MG/5ML;12.5MG/5ML	N19411 001	AUG 17, 1990	SEP	DISC

HYDROCORTISONE
TABLET; ORAL
CORTEF

+	PHARMACIA AND UPJOHN	5MG	N08697 003		MAY	CRLD
		5MG	N08697 003		OCT	CRLD
BP +		10MG	N08697 001		MAY	CRLD
BP		10MG	N08697 001		OCT	CRLD
BP +		20MG	N08697 002		MAY	CRLD

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC

+	FERNDALE LABS	2%	N40398 001	MAR 29, 2002	MAR	NEWA

INJECTABLE; INJECTION
HYDROCORTISONE ACETATE

+	STERIS	25MG/ML	N83128 001		JUN	CRLD
@		25MG/ML	N83128 001		OCT	DISC

HYDROCORTONE

@	MERCK	25MG/ML	N08228 001		JUN	DISC
@		50MG/ML	N08228 004		JUN	DISC

HYDROCORTISONE BUTYRATE
CREAM; TOPICAL
LOCOID

+	FERNDALE LABS	0.1%	N18514 001	MAR 31, 1982	MAR	CAHN

LOCOID LIPOCREAM

+	FERNDALE LABS	0.1%	N20769 001	SEP 08, 1997	MAR	CAHN

OINTMENT; TOPICAL
LOCOID

+	FERNDALE LABS	0.1%	N18652 001	OCT 29, 1982	MAR	CAHN

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE
OINTMENT; OPHTHALMIC
ACHROMYCIN
@ LEDERLE 1.5%;1% N50272 001 JUN DISC

HYDROFLUMETHIAZIDE
TABLET; ORAL
SALURON
>D> AB + SHIRE 50MG N11949 001 DEC CAHN
>A> AB + SHIRE LABS 50MG N11949 001 DEC CAHN

HYDROFLUMETHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE AND HYDROFLUMETHIAZIDE
@ PAR PHARM 50MG;0.125MG N88907 001 SEP 20, 1985 AUG DISC
SALUTENSIN
>D> + SHIRE 50MG;0.125MG N12359 003 DEC CAHN
>A> + SHIRE LABS 50MG;0.125MG N12359 003 DEC CAHN
SALUTENSIN-DEMI
>D> @ SHIRE 25MG;0.125MG N12359 004 DEC CAHN
>A> @ SHIRE LABS 25MG;0.125MG N12359 004 DEC CAHN
@ 25MG;0.125MG N12359 004 JUL DISC

HYDROXYAMPHETAMINE HYDROBROMIDE
SOLUTION/DROPS; OPHTHALMIC
PAREDRINE
@ AKORN 1% N00004 004 JUN DISC

HYDROXYPROGESTERONE CAPROATE
INJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE
@ STERIS 250MG/ML N17439 002 JUN DISC

HYDROXYZINE HYDROCHLORIDE
SYRUP; ORAL
HYDROXYZINE HCL
AA VINTAGE PHARMS 10MG/5ML N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN
SUSPENSION/DROPS; ORAL
MOTRIN
@ MCNEIL 40MG/ML N20476 001 MAY 25, 1995 JUN DISC
TABLET; ORAL
@ MCNEIL CONS SPECLT 100MG N20418 001 NOV 16, 1994 JUN DISC
TABLET, CHEWABLE; ORAL
@ MCNEIL CONS SPECLT 50MG N20135 001 NOV 16, 1994 JUN DISC
@ 100MG N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE
INJECTABLE; INJECTION
IDAMYCIN
AP + PHARMACIA AND UPJOHN 5MG/VIAL N50661 002 SEP 27, 1990 MAY CFTG

	@	5MG/VIAL	N50661 002	SEP 27, 1990	JUN	DISC	
AP	+	10MG/VIAL	N50661 001	SEP 27, 1990	MAY	CFTG	
	@	10MG/VIAL	N50661 001	SEP 27, 1990	JUN	DISC	
AP	+	20MG/VIAL	N50661 003	APR 25, 1995	MAY	CFTG	
	@	20MG/VIAL	N50661 003	APR 25, 1995	JUN	DISC	
	IDAMYCIN PFS						
AP	+ PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997	MAY	CFTG	
	IDARUBICIN HCL						
AP	GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002	MAY	NEWA	
	+	10MG/VIAL	N65037 002	MAY 01, 2002	JUN	CRLD	
AP		10MG/VIAL	N65037 002	MAY 01, 2002	MAY	NEWA	
	+	20MG/VIAL	N65037 001	MAY 01, 2002	JUN	CRLD	
AP		20MG/VIAL	N65037 001	MAY 01, 2002	MAY	NEWA	
	IDARUBICIN HCL PFS						
AP	GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002	MAY	NEWA	
IFOSFAMIDE							
	INJECTABLE; INJECTION						
	IFSOFAMIDE						
	+ AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	AUG	CRLD	
		1GM/VIAL	N76078 001	MAY 28, 2002	MAY	NEWA	
	+	3GM/VIAL	N76078 002	MAY 28, 2002	MAY	NEWA	
IFOSFAMIDE; MESNA							
	INJECTABLE; INTRAVENOUS						
	IFOSFAMIDE/MESNA KIT						
	+ GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB	NEWA	
	+	3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB	NEWA	
INAMRINONE LACTATE							
	INJECTABLE; INJECTION						
	AMRINONE						
AP	+ ABBOTT	EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN	CRLD	
	INOCOR						
	@ SANOFI SYNTHELABO	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN	DISC	
INDOCYANINE GREEN							
	INJECTABLE; INJECTION						
	CARDIO-GREEN						
	@ AKORN	50MG/VIAL	N11525 002		JUN	DISC	
INDOMETHACIN							
	CAPSULE; ORAL						
	INDOMETHACIN						
AB	PAR PHARM	25MG	N18829 002	AUG 06, 1984	JUL	CAHN	
AB		50MG	N18829 001	AUG 06, 1984	JUL	CAHN	
	CAPSULE, EXTENDED RELEASE; ORAL						
AB	ABLE	75MG	N76114 001	FEB 06, 2002	FEB	NEWA	
	SUPPOSITORY; RECTAL						
	INDOCIN						
	@ MERCK	50MG	N17814 001	AUG 13, 1984	MAY	DISC	

INDOMETHACIN						
SUPPOSITORY; RECTAL						
INDOMETHEGAN						
+ G AND W LABS	50MG	N73314	001	AUG 31, 1992	MAY	CRLD
INSULIN PORK						
INJECTABLE; INJECTION						
ILETIN I						
@ LILLY	500 UNITS/ML	N17931	001		JUN	DISC
IODIPAMIDE MEGLUMINE						
INJECTABLE; INJECTION						
CHOLOGRAFIN MEGLUMINE						
@ BRACCO	10.3%	N09321	007		JUN	DISC
IODIXANOL						
INJECTABLE; INJECTION						
VISIPAQUE 270						
@ AMERSHAM HLTH	55%	N20808	001	AUG 29, 1997	JUN	DISC
VISIPAQUE 320						
@ AMERSHAM HLTH	65.2%	N20808	002	AUG 29, 1997	JUN	DISC
IODOHIPPURATE SODIUM, I-131						
INJECTABLE; INJECTION						
HIPPURAN I 131						
@ MALLINCKRODT	0.25mCi/ML	N16666	001		JUN	DISC
IOFETAMINE HYDROCHLORIDE I-123						
INJECTABLE; INJECTION						
SPECTAMINE						
@ IMP	1mCi/ML	N19432	001	DEC 24, 1987	JUN	DISC
IOHEXOL						
INJECTABLE; INJECTION						
OMNIPAQUE 210						
@ AMERSHAM HLTH	45.3%	N18956	006	JUN 30, 1989	JUN	DISC
SOLUTION; URETHRAL						
OMNIPAQUE 70						
@ AMERSHAM HLTH	15.1%	N18956	007	JUN 01, 1994	JUN	DISC
IOPAMIDOL						
INJECTABLE; INJECTION						
IOPAMIDOL						
@ FAULDING	61%	N74734	001	DEC 10, 1996	JUL	DISC
@	76%	N74734	002	DEC 10, 1996	JUL	DISC
ISOVUE-128						
@ BRACCO	26%	N18735	005	OCT 21, 1986	JUN	DISC

IOPROMIDE
INJECTABLE; INJECTION
ULTRAVIST (PHARMACY BULK)

+	BERLEX LABS	300MG/ML	N21425 001	SEP 20, 2002	SEP	NEWA
+		370MG/ML	N21425 002	SEP 20, 2002	SEP	NEWA

IOTHALAMATE SODIUM
INJECTABLE; INJECTION
CONRAY 325

@	MALLINCKRODT	54.3%	N17685 001		JUN	DISC

IOXILAN
INJECTABLE; INJECTION
OXILAN-300

	GUERBET	62%	N20316 001	DEC 21, 1995	JUN	CAHN

OXILAN-350

	GUERBET	73%	N20316 002	DEC 21, 1995	JUN	CAHN

IPODATE SODIUM
CAPSULE; ORAL
ORAGRAFIN SODIUM

@	BRACCO	500MG	N12967 001		JUN	DISC

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPATROPIUM BROMIDE

AN	ROXANE	0.02%	N75867 001	JUL 22, 2002	JUL	NEWA

ISOPROTERENOL HYDROCHLORIDE
AEROSOL, METERED; INHALATION
ISOPROTERENOL HCL

@	3M	0.12MG/INH	N10375 004		JUN	DISC

ISOPROTERENOL SULFATE
AEROSOL, METERED; INHALATION
MEDIHALER-ISO

@	3M	0.08MG/INH	N10375 003		JUN	DISC

ISOSORBIDE
SOLUTION; ORAL
ISMOTIC

@	ALCON	100GM/220ML	N17063 001		JUN	DISC

ISOSORBIDE DINITRATE
TABLET; ORAL
SORBITRATE

@	ASTRAZENECA	5MG	N16192 001	APR 01, 1996	SEP	DISC
@		10MG	N16192 002	APR 01, 1996	SEP	DISC

TABLET, CHEWABLE; ORAL

@	ASTRAZENECA	5MG	N16776 002	APR 01, 1996	SEP	DISC

		ISOSORBIDE MONONITRATE						
		TABLET; ORAL						
		ISMO						
	AB	ESP PHARMA	20MG	N19091	001	DEC 30, 1991	JUL	CAHN
		ISOTRETINOIN						
		CAPSULE; ORAL						
		ACCUTANE						
	AB	HLR	10MG	N18662	002	MAY 07, 1982	NOV	CFTG
	AB +		20MG	N18662	004	MAR 28, 1983	NOV	CFTG
	AB +		40MG	N18662	003	MAY 07, 1982	NOV	CFTG
		AMNESTEEM						
	AB	GENPHARM	10MG	N75945	001	NOV 08, 2002	NOV	NEWA
	AB		20MG	N75945	002	NOV 08, 2002	NOV	NEWA
	AB		40MG	N75945	003	NOV 08, 2002	NOV	NEWA
		ISOTRETINOIN						
>A>	AB	RANBAXY	10MG	N76041	001	DEC 24, 2002	DEC	NEWA
>A>	AB		20MG	N76041	002	DEC 24, 2002	DEC	NEWA
>A>	AB		40MG	N76041	003	DEC 24, 2002	DEC	NEWA
		KANAMYCIN SULFATE						
		INJECTABLE; INJECTION						
>A>		KANAMYCIN						
>A>	AP	AM PHARM PARTNERS	EQ 500MG BASE/2ML	N65111	001	DEC 17, 2002	DEC	NEWA
>A>	AP		EQ 1GM BASE/3ML	N65111	002	DEC 17, 2002	DEC	NEWA
		KANTREX						
>D>	+	APOTHECON	EQ 500MG BASE/2ML	N61901	001		DEC	CFTG
>A>	AP +		EQ 500MG BASE/2ML	N61901	001		DEC	CFTG
>D>	+		EQ 1GM BASE/3ML	N61901	002		DEC	CFTG
>A>	AP +		EQ 1GM BASE/3ML	N61901	002		DEC	CFTG
		KETAMINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		KETAMINE HCL						
	AP	BIONICHE (CANADA)	EQ 100MG BASE/ML	N76092	003	OCT 25, 2002	OCT	NEWA
		KETOCONAZOLE						
		CREAM; TOPICAL						
		KETOZOLE						
>A>	AB	TARO	2%	N75638	001	DEC 18, 2002	DEC	NEWA
		TABLET; ORAL						
		KETOCONAZOLE						
	AB	NEOSAN PHARMS	200MG	N75341	001	JUL 27, 1999	JUL	CAHN
	AB	TORPHARM	200MG	N75912	001	JAN 10, 2002	JAN	NEWA
		KETOPROFEN						
		CAPSULE, EXTENDED RELEASE; ORAL						
		KETOPROFEN						
	AB	MYLAN	100MG	N75679	003	FEB 20, 2002	FEB	NEWA
	AB		150MG	N75679	002	FEB 20, 2002	FEB	NEWA
	AB		200MG	N75679	001	FEB 20, 2002	FEB	NEWA

		KETOROLAC TROMETHAMINE						
		INJECTABLE; INJECTION						
		KETOROLAC TROMETHAMINE						
	AP	AM PHARM PARTNERS	15MG/ML	N75784	001	JAN 11, 2002	JAN	NEWA
	AP		30MG/ML	N75784	002	JAN 11, 2002	JAN	NEWA
		KRYPTON, KR-81M						
		GAS; INHALATION						
		MPI KRYPTON 81M GAS GENERATOR						
		@ AMERSHAM HLTH	N/A	N18088	001		JUL	DISC
		LABETALOL HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		LABETALOL HCL						
	AP	APOTEX	5MG/ML	N76051	001	JUL 05, 2002	JUL	NEWA
		LACTULOSE						
		SOLUTION; ORAL						
		LACTULOSE						
	AA	NOVEX	10GM/15ML	N75911	001	FEB 21, 2002	FEB	NEWA
		SOLUTION; ORAL, RECTAL						
		CEPHULAC						
		@ AVENTIS PHARMS	10GM/15ML	N17657	001		JUL	DISC
		ENULOSE						
	AA +	ALPHARMA	10GM/15ML	N71548	001	AUG 15, 1988	JUL	CRLD
		LAMOTRIGINE						
		TABLET, CHEWABLE; ORAL						
		LAMICTAL CD						
	+	GLAXOSMITHKLINE	25MG	N20764	002	AUG 24, 1998	MAR	CRLD
		@	100MG	N20764	003	AUG 24, 1998	MAR	DISC
		LANSOPRAZOLE						
		TABLET, ORALLY DISINTEGRATING; ORAL						
		PREVACID						
		TAP PHARM	15MG	N21428	001	AUG 30, 2002	AUG	NEWA
	+		30MG	N21428	002	AUG 30, 2002	AUG	NEWA
		LEUCOVORIN CALCIUM						
		FOR SOLUTION; ORAL						
		LEUCOVORIN CALCIUM						
>D>		@ IMMUNEX	EQ 60MG BASE/VIAL	N08107	003	JAN 30, 1987	DEC	CAHN
>A>		@ XANODYNE PHARM	EQ 60MG BASE/VIAL	N08107	003	JAN 30, 1987	DEC	CAHN
		INJECTABLE; INJECTION						
>D>		@ IMMUNEX	EQ 3MG BASE/ML	N08107	001		DEC	CAHN
>D>	AP +		EQ 50MG BASE/VIAL	N08107	002		DEC	CAHN
>D>	AP +		EQ 100MG BASE/VIAL	N08107	004	MAY 23, 1988	DEC	CAHN
>D>	AP +		EQ 350MG BASE/VIAL	N08107	005	APR 05, 1989	DEC	CAHN
>A>		@ XANODYNE PHARM	EQ 3MG BASE/ML	N08107	001		DEC	CAHN
>A>	AP +		EQ 50MG BASE/VIAL	N08107	002		DEC	CAHN
>A>	AP +		EQ 100MG BASE/VIAL	N08107	004	MAY 23, 1988	DEC	CAHN
>A>	AP +		EQ 350MG BASE/VIAL	N08107	005	APR 05, 1989	DEC	CAHN

LEUCOVORIN CALCIUM							
TABLET; ORAL							
LEUCOVORIN CALCIUM							
BX	XANODYNE PHARM	EQ 5MG BASE	N18459	001	JAN 30, 1986	AUG	CAHN
AB		EQ 10MG BASE	N71962	001	NOV 19, 1987	AUG	CAHN
AB		EQ 15MG BASE	N71104	001	MAR 04, 1987	JUN	CAHN
LEUPROLIDE ACETATE							
INJECTABLE; SUBCUTANEOUS							
ELIGARD							
+	ATRIX	7.5MG/VIAL	N21343	001	JAN 23, 2002	JAN	NEWA
+		22.5MG/VIAL	N21379	001	JUL 24, 2002	JUL	NEWA
LEVALBUTEROL HYDROCHLORIDE							
SOLUTION; INHALATION							
XOPENEX							
+	SEPRACOR	EQ 0.0105% BASE	N20837	003	JAN 30, 2002	JUN	NEWA
LEVOCARNITINE							
SOLUTION; ORAL							
CARNITOR							
@	SIGMA TAU	1GM/10ML	N18948	002	APR 27, 1988	JUN	DISC
+		1GM/10ML	N19257	001	APR 10, 1986	JUL	CMFD
@		1GM/10ML	N19257	001	APR 10, 1986	JUN	DISC
LEVODOPA							
TABLET; ORAL							
LARODOPA							
@	ROCHE	100MG	N16912	005		JUN	DISC
@		250MG	N16912	003		JUN	DISC
@		500MG	N16912	004		JUN	DISC
LEVOTHYROXINE SODIUM							
TABLET; ORAL							
LEVO-T							
BX	MOVA	0.025MG	N21342	001	MAR 01, 2002	MAR	NEWA
BX		0.05MG	N21342	002	MAR 01, 2002	MAR	NEWA
BX		0.075MG	N21342	003	MAR 01, 2002	MAR	NEWA
BX		0.088MG	N21342	004	MAR 01, 2002	MAR	NEWA
BX		0.1MG	N21342	005	MAR 01, 2002	MAR	NEWA
BX		0.112MG	N21342	006	MAR 01, 2002	MAR	NEWA
BX		0.125MG	N21342	007	MAR 01, 2002	MAR	NEWA
BX		0.15MG	N21342	008	MAR 01, 2002	MAR	NEWA
BX		0.175MG	N21342	009	MAR 01, 2002	MAR	NEWA
BX		0.2MG	N21342	010	MAR 01, 2002	MAR	NEWA
BX +		0.3MG	N21342	011	MAR 01, 2002	MAR	NEWA
LEVOTHYROXINE SODIUM							
AB	MYLAN	0.025MG	N76187	001	JUN 05, 2002	JUN	NEWA
AB		0.05MG	N76187	002	JUN 05, 2002	JUN	NEWA
AB		0.075MG	N76187	003	JUN 05, 2002	JUN	NEWA

AB		0.088MG	N76187 004	JUN 05, 2002	JUN	NEWA
AB		0.1MG	N76187 005	JUN 05, 2002	JUN	NEWA
AB		0.112MG	N76187 006	JUN 05, 2002	JUN	NEWA
AB		0.125MG	N76187 007	JUN 05, 2002	JUN	NEWA
AB		0.15MG	N76187 008	JUN 05, 2002	JUN	NEWA
AB		0.175MG	N76187 009	JUN 05, 2002	JUN	NEWA
AB		0.2MG	N76187 010	JUN 05, 2002	JUN	NEWA
AB		0.3MG	N76187 011	JUN 05, 2002	JUN	NEWA
	NOVOTHYROX					
BX	GENPHARM	0.025MG	N21292 001	MAY 31, 2002	MAY	NEWA
BX		0.05MG	N21292 002	MAY 31, 2002	MAY	NEWA
BX		0.075MG	N21292 003	MAY 31, 2002	MAY	NEWA
BX		0.088MG	N21292 004	MAY 31, 2002	MAY	NEWA
BX		0.1MG	N21292 005	MAY 31, 2002	MAY	NEWA
BX		0.112MG	N21292 006	MAY 31, 2002	MAY	NEWA
BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA
BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA
BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA
BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA
BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA
BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA
	SYNTHROID					
BX	ABBOTT	0.025MG	N21402 001	JUL 24, 2002	JUL	NEWA
BX		0.05MG	N21402 002	JUL 24, 2002	JUL	NEWA
BX		0.075MG	N21402 003	JUL 24, 2002	JUL	NEWA
BX		0.088MG	N21402 004	JUL 24, 2002	JUL	NEWA
BX		0.1MG	N21402 005	JUL 24, 2002	JUL	NEWA
BX		0.112MG	N21402 006	JUL 24, 2002	JUL	NEWA
BX		0.125MG	N21402 007	JUL 24, 2002	JUL	NEWA
BX		0.137MG	N21402 008	JUL 24, 2002	JUL	NEWA
BX		0.15MG	N21402 009	JUL 24, 2002	JUL	NEWA
BX		0.175MG	N21402 010	JUL 24, 2002	JUL	NEWA
BX		0.2MG	N21402 012	JUL 24, 2002	AUG	NEWA
BX +		0.3MG	N21402 011	JUL 24, 2002	JUL	NEWA
	THYRO-TABS					
BX	LLOYD	0.025MG	N21116 001	OCT 24, 2002	OCT	NEWA
BX		0.05MG	N21116 002	OCT 24, 2002	OCT	NEWA
BX		0.075MG	N21116 003	OCT 24, 2002	OCT	NEWA
BX		0.088MG	N21116 010	OCT 24, 2002	OCT	NEWA
BX		0.1MG	N21116 004	OCT 24, 2002	OCT	NEWA
BX		0.112MG	N21116 011	OCT 24, 2002	OCT	NEWA
BX		0.125MG	N21116 005	OCT 24, 2002	OCT	NEWA
BX		0.15MG	N21116 006	OCT 24, 2002	OCT	NEWA
BX		0.175MG	N21116 007	OCT 24, 2002	OCT	NEWA
BX		0.2MG	N21116 008	OCT 24, 2002	OCT	NEWA
BX +		0.3MG	N21116 009	OCT 24, 2002	OCT	NEWA
	UNITHROID					
AB	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD
AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD
AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD
AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD
AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD
AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD

AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD
AB		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD
AB		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD
AB	+	0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD
	LIDOCAINE					
	AEROSOL; ORAL					
	XYLOCAINE					
	@ ASTRAZENECA	10%	N14394 001		JUN	DISC
	FILM, EXTENDED RELEASE; BUCCAL					
	LIDOCAINE					
	@ NOVEN	23MG/PATCH	N20575 001	MAY 21, 1996	JUN	DISC
	OINTMENT; TOPICAL					
AT	+ FOUGERA	5%	N80198 001		SEP	CRLD
	XYLOCAINE					
	@ ASTRAZENECA	5%	N08048 001		SEP	DISC
	LIDOCAINE HYDROCHLORIDE					
	INJECTABLE; SPINAL					
	LIDOCAINE HCL 5% AND DEXTROSE 7.5%					
	+ ABBOTT	5%	N83914 001		SEP	CRLD
	XYLOCAINE 5% W/ GLUCOSE 7.5%					
	@ ASTRAZENECA	5%	N10496 002	JUL 07, 1982	SEP	DISC
	LINCOMYCIN HYDROCHLORIDE					
	CAPSULE; ORAL					
	LINCOCIN					
	@ PHARMACIA AND UPJOHN	EQ 250MG BASE	N50316 001		JUN	DISC
	@	EQ 500MG BASE	N50316 002		JUN	DISC
	LINEZOLID					
	TABLET; ORAL					
	ZYVOX					
	@ PHARMACIA AND UPJOHN	400MG	N21130 001	APR 18, 2000	JUN	DISC
	LISINOPRIL					
	TABLET; ORAL					
	LISINOPRIL					
AB	APOTEX	2.5MG	N76102 001	SEP 30, 2002	SEP	NEWA
AB		5MG	N76102 002	SEP 30, 2002	SEP	NEWA
AB		10MG	N76102 003	SEP 30, 2002	SEP	NEWA
AB		20MG	N76102 004	SEP 30, 2002	SEP	NEWA
AB		30MG	N76102 005	SEP 30, 2002	SEP	NEWA
AB		40MG	N76102 006	SEP 30, 2002	SEP	NEWA
AB	EON	2.5MG	N75994 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75994 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75994 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75994 004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75994 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75994 006	JUL 01, 2002	JUL	NEWA
AB	GENEVA PHARMS TECH	2.5MG	N75903 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75903 002	JUL 01, 2002	JUL	NEWA

AB		10MG	N75903	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75903	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75903	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75903	006	JUL 01, 2002	JUL	NEWA
AB	IVAX PHARMS	2.5MG	N75752	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75752	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75752	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75752	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75752	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75752	006	JUL 01, 2002	JUL	NEWA
AB	LEK PHARM	2.5MG	N75999	001	JUL 01, 2002	AUG	NEWA
AB		5MG	N75999	002	JUL 01, 2002	AUG	NEWA
AB		10MG	N75999	003	JUL 01, 2002	AUG	NEWA
AB		20MG	N75999	004	JUL 01, 2002	AUG	NEWA
AB		30MG	N75999	005	JUL 01, 2002	AUG	NEWA
AB		40MG	N75999	006	JUL 01, 2002	AUG	NEWA
AB	MYLAN	2.5MG	N76071	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76071	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76071	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76071	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76071	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76071	006	JUL 01, 2002	JUL	NEWA
AB	PAR PHARM	2.5MG	N75743	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75743	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75743	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75743	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75743	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75743	006	JUL 01, 2002	JUL	NEWA
AB	PUREPAC PHARM	2.5MG	N76180	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76180	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76180	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76164	001	JUL 01, 2002	JUL	NEWA
AB		30MG	N76164	002	JUL 01, 2002	JUL	NEWA
AB		40MG	N76164	003	JUL 01, 2002	JUL	NEWA
AB	RANBAXY	2.5MG	N75944	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75944	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75944	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75944	004	JUL 01, 2002	JUL	NEWA
AB		40MG	N75944	005	JUL 01, 2002	JUL	NEWA
AB	TEVA	2.5MG	N75783	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N75783	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N75783	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N75783	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N75783	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N75783	006	JUL 01, 2002	JUL	NEWA
AB	WATSON LABS	2.5MG	N76059	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76059	002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76059	003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76059	004	JUL 01, 2002	JUL	NEWA
AB		30MG	N76059	005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76059	006	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	2.5MG	N76063	001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76063	002	JUL 01, 2002	JUL	NEWA

AB		10MG	N76063 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76063 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N76063 005	JUL 01, 2002	JUL	NEWA
	ZESTRIL					
AB	+ ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	JUL	CFTG
	LITHIUM CARBONATE					
	CAPSULE; ORAL					
	LITHIUM CARBONATE					
AB	WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
AB	BARR	300MG	N76170 001	JUN 10, 2002	JUN	NEWA
	LITHOBID					
AB	+ SOLVAY	300MG	N18027 001		JUN	CFTG
	LOMEFLOXACIN HYDROCHLORIDE					
	TABLET; ORAL					
	MAXAQUIN					
	+ PHARMACIA	EQ 400MG BASE	N20013 001	FEB 21, 1992	JUL	CAHN
	LORATADINE					
	TABLET; ORAL					
	CLARITIN					
	+ SCHERING	10MG	N19658 001	APR 12, 1993	JUL	CTEC
	LOVASTATIN					
	TABLET; ORAL					
	LOVASTATIN					
AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN	NEWA
AB		20MG	N75991 002	JUN 05, 2002	JUN	NEWA
AB		40MG	N75991 003	JUN 05, 2002	JUN	NEWA
	TABLET, EXTENDED RELEASE; ORAL					
	ALTOCOR					
	ANDRX	10MG	N21316 001	JUN 26, 2002	JUL	CAHN
		20MG	N21316 002	JUN 26, 2002	JUL	CAHN
		40MG	N21316 003	JUN 26, 2002	JUL	CAHN
	+	60MG	N21316 004	JUN 26, 2002	JUL	CAHN
	AURA LABS	10MG	N21316 001	JUN 26, 2002	JUN	NEWA
		20MG	N21316 002	JUN 26, 2002	JUN	NEWA
		40MG	N21316 003	JUN 26, 2002	JUN	NEWA
	+	60MG	N21316 004	JUN 26, 2002	JUN	NEWA
	LOXAPINE HYDROCHLORIDE					
	CONCENTRATE; ORAL					
	LOXITANE C					
	@ WATSON LABS	EQ 25MG BASE/ML	N17658 001		JUL	DISC
	INJECTABLE; INJECTION					
	LOXITANE IM					
	@ WATSON LABS	EQ 50MG BASE/ML	N18039 001		JUL	DISC

MANGANESE CHLORIDE TETRAHYDRATE
FOR SOLUTION; ORAL
LUMENHANCE
@ BRACCO 3.49MG/GM N20686 001 DEC 19, 1997 JUN DISC

MANNITOL
INJECTABLE; INJECTION
MANNITOL 25%
@ ASTRAZENECA 12.5GM/50ML N89239 001 MAY 06, 1987 NOV WDGA

MASOPROCOL
CREAM; TOPICAL
ACTINEX
@ UNIV AZ CANCER CTR 10% N19940 001 SEP 04, 1992 JUN DISC

MAZINDOL
TABLET; ORAL
MAZANOR
@ WYETH AYERST 1MG N17980 002 APR DISC
SANOREX
NOVARTIS 1MG N17247 001 APR CTEC
@ 1MG N17247 001 JUN DISC
@ 2MG N17247 002 JUN DISC

MEDROXYPROGESTERONE ACETATE
TABLET; ORAL
AMEN
@ AMARIN PHARMS 10MG N83242 001 SEP DISC

MEFLOQUINE HYDROCHLORIDE
TABLET; ORAL
LARIAM
AB + ROCHE 250MG N19591 001 MAY 02, 1989 FEB CFTG
MEFLOQUINE HCL
AB GENEVA PHARMS TECH 250MG N76175 001 FEB 20, 2002 FEB NEWA

MEGESTROL ACETATE
SUSPENSION; ORAL
MEGESTROL ACETATE
AB ROXANE 40MG/ML N75997 001 FEB 15, 2002 FEB NEWA

MENOTROPINS (FSH;LH)
INJECTABLE; INJECTION
PERGONAL
BX + SERONO 75 IU/AMP;75 IU/AMP N17646 001 AUG CMFD
75 IU/AMP;75 IU/AMP N17646 001 JUN DISC
@ 150 IU/AMP;150 IU/AMP N17646 002 MAY 20, 1985 JUN DISC
REPRONEX
+ FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 AUG 27, 1999 JUN CRLD
BX 75 IU/VIAL;75 IU/VIAL N21047 001 AUG 27, 1999 AUG CRLD
+ 150 IU/VIAL;150 IU/VIAL N21047 002 AUG 27, 1999 JUN CRLD

MEPERIDINE HYDROCHLORIDE
TABLET; ORAL
MEPERIDINE HCL

AA	CARACO	50MG	N40446 001	AUG 08, 2002	AUG	NEWA
AA		100MG	N40446 002	AUG 08, 2002	AUG	NEWA

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPERGAN

	@ WYETH AYERST	25MG/ML;25MG/ML	N11730 001		JUN	DISC

MEPHENTERMINE SULFATE
INJECTABLE; INJECTION
WYAMINE SULFATE

	@ WYETH AYERST	EQ 15MG BASE/ML	N08248 002		JUN	DISC

MEPHENYTOIN
TABLET; ORAL
MESANTOIN

	@ NOVARTIS	100MG	N06008 001		JUN	DISC

MEQUINOL; TRETINOIN
SOLUTION; TOPICAL
SOLAGE

+	GALDERMA LABS	2%;0.01%	N20922 001	DEC 10, 1999	APR	CAHN

MESNA
INJECTABLE; INTRAVENOUS
MESNEX

AP +	BAXTER HLTHCARE	100MG/ML	N19884 001	DEC 30, 1988	MAR	CAHN

TABLET; ORAL

+	BAXTER HLTHCARE	400MG	N20855 001	MAR 21, 2002	JUN	CAHN
+	BRISTOL MYERS SQUIBB	400MG	N20855 001	MAR 21, 2002	MAR	NEWA

MESORIDAZINE BESYLATE
INJECTABLE; INJECTION
SERENTIL

	@ NOVARTIS	EQ 25MG BASE/ML	N16775 001		JUN	DISC

MESTRANOL; NORETHINDRONE
TABLET; ORAL-28
NORINYL 1+50 28-DAY

AB	WATSON LABS	0.05MG;1MG	N16659 001		JAN	CAHN

METAPROTERENOL SULFATE
SOLUTION; INHALATION
ALUPENT

	@ BOEHRINGER INGELHEIM	5%	N17659 001		JUN	DISC

METAPROTERENOL SULFATE

AN	MORTON GROVE	0.4%	N75586 001	MAY 30, 2002	MAY	NEWA
AN		0.6%	N75586 002	MAY 30, 2002	MAY	NEWA

METAPROTERENOL SULFATE							
TABLET; ORAL							
ALUPENT							
@ BOEHRINGER INGELHEIM	10MG	N15874	002		NOV	WDGB
@	20MG	N15874	001		NOV	WDGB
AB + PAR PHARM	20MG	N72025	001	JUN 28, 1988	NOV	CRLD
METAXALONE							
TABLET; ORAL							
SKELAXIN							
+ ELAN PHARMS	400MG	N13217	001		JUN	CAHN
	400MG	N13217	001		AUG	CRLD
+	800MG	N13217	003	AUG 30, 2002	AUG	NEWA
METFORMIN HYDROCHLORIDE							
TABLET; ORAL							
GLUCOPHAGE							
AB BRISTOL MYERS SQUIBB	500MG	N20357	001	MAR 03, 1995	JAN	CFTG
AB	850MG	N20357	002	MAR 03, 1995	JAN	CFTG
AB +	1GM	N20357	005	NOV 05, 1998	JAN	CFTG
METFORMIN HCL							
AB ALPHAPHARM	500MG	N75969	001	JAN 29, 2002	JAN	NEWA
AB	850MG	N75969	002	JAN 29, 2002	JAN	NEWA
AB	1GM	N75969	003	JAN 29, 2002	JAN	NEWA
AB ANDRX PHARMS	500MG	N75961	001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75961	002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75961	003	JAN 25, 2002	JAN	NEWA
AB BARR	500MG	N75971	001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75971	002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75971	003	JAN 25, 2002	JAN	NEWA
AB CARACO	500MG	N75967	001	JAN 29, 2002	JAN	NEWA
AB	850MG	N75967	002	JAN 29, 2002	JAN	NEWA
AB	1GM	N75967	003	JAN 29, 2002	JAN	NEWA
AB EON	500MG	N75965	001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75965	002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75965	003	JAN 25, 2002	JAN	NEWA
AB GENEVA PHARMS	500MG	N75985	001	JAN 25, 2002	MAY	CAHN
AB	850MG	N75985	002	JAN 25, 2002	MAY	CAHN
AB	1GM	N75985	003	JAN 25, 2002	MAY	CAHN
AB GENEVA PHARMS TECH	500MG	N75985	001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75985	002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75985	003	JAN 25, 2002	JAN	NEWA
AB GENPHARM	500MG	N75973	001	JAN 25, 2002	JAN	NEWA
AB	850MG	N75973	002	JAN 25, 2002	JAN	NEWA
AB	1GM	N75973	003	JAN 25, 2002	JAN	NEWA
AB GOLDLINE	500MG	N75972	001	JAN 24, 2002	JAN	NEWA
AB	625MG	N75972	005	JAN 24, 2002	JAN	NEWA
AB	750MG	N75972	004	JAN 24, 2002	JAN	NEWA
AB	850MG	N75972	002	JAN 24, 2002	JAN	NEWA
AB	1GM	N75972	003	JAN 24, 2002	JAN	NEWA
AB MUTUAL PHARMA	500MG	N76038	001	FEB 21, 2002	FEB	NEWA

	AB		850MG	N76038 002	FEB 21, 2002	FEB	NEWA
	AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA
	AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA
	AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA
	AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA
>A>	AB		500MG	N76328 001	DEC 16, 2002	DEC	NEWA
	AB		850MG	N75978 002	JAN 25, 2002	JAN	NEWA
>A>	AB		850MG	N76328 002	DEC 16, 2002	DEC	NEWA
	AB		1GM	N75978 003	NOV 05, 2002	NOV	NEWA
>A>	AB		1GM	N76328 003	DEC 16, 2002	DEC	NEWA
	AB	TORPHARM	500MG	N75984 001	APR 23, 2002	APR	NEWA
	AB		850MG	N75984 002	APR 23, 2002	APR	NEWA
	AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
	AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75979 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75979 003	JAN 24, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002	JAN	NEWA
	AB		625MG	N75975 004	JAN 24, 2002	JAN	NEWA
	AB		750MG	N75975 005	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75975 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL							
AVANDAMET							
	GLAXOSMITHKLINE	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002	OCT	NEWA
		500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002	OCT	NEWA
+		500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002	OCT	NEWA

METHADONE HYDROCHLORIDE

SYRUP; ORAL							
DOLOPHINE HCL							
@	ROXANE	10MG/30ML	N06134 004			JUL	DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL							
DESOXYN							
+	OVATION PHARMS	5MG	N05378 002			SEP	CAHN
TABLET, EXTENDED RELEASE; ORAL							
@	ABBOTT	5MG	N05378 004			JUN	DISC
@		10MG	N05378 003			JUN	DISC
@		15MG	N05378 005			JUN	DISC
@	OVATION PHARMS	5MG	N05378 004			SEP	CAHN
@		10MG	N05378 003			SEP	CAHN
@		15MG	N05378 005			SEP	CAHN

		METHANTHELINE BROMIDE					
		TABLET; ORAL					
		BANTHINE					
		@ SHIRE LABS	50MG	N07390 001		JUL	DISC
		METHOHEXITAL SODIUM					
		INJECTABLE; INJECTION					
		BREVITAL SODIUM					
	+	KING PHARMS	500MG/VIAL	N11559 001		FEB	CAHN
	+		2.5GM/VIAL	N11559 002		FEB	CAHN
	+		5GM/VIAL	N11559 003		FEB	CAHN
		METHOTREXATE SODIUM					
		INJECTABLE; INJECTION					
		FOLEX					
	+	PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN	CRLD
	+		EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN	CRLD
		METHOTREXATE SODIUM					
		@ LEDERLE	EQ 2.5MG BASE/ML	N11719 004		JUN	DISC
		@	EQ 50MG BASE/VIAL	N11719 003		JUN	DISC
		@	EQ 100MG BASE/VIAL	N11719 006		JUN	DISC
		TABLET; ORAL					
AB	+	CLONMEL HLTHCARE	EQ 2.5MG BASE	N08085 002		JUL	CAHN
		METHYCLOTHIAZIDE; RESERPINE					
		TABLET; ORAL					
		DIUTENSEN-R					
		@ WALLACE LABS	2.5MG;0.1MG	N12708 005		OCT	DISC
		METHYLDOPA					
		SUSPENSION; ORAL					
		ALDOMET					
		@ MERCK	250MG/5ML	N18389 001		JUN	DISC
		METHYLPHENIDATE HYDROCHLORIDE					
		CAPSULE, EXTENDED RELEASE; ORAL					
		METADATE CD					
BX	+	CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	JUN	CTEC
		RITALIN LA					
BX		NOVARTIS	20MG	N21284 001	JUN 05, 2002	JUN	NEWA
			30MG	N21284 002	JUN 05, 2002	JUN	NEWA
	+		40MG	N21284 003	JUN 05, 2002	JUN	NEWA
>A>		SOLUTION; ORAL					
>A>		METHYLIN					
>A>	+	MALLINCKRODT BAKER	5MG/5ML	N21419 001	DEC 19, 2002	DEC	NEWA
>A>	+		10MG/5ML	N21419 002	DEC 19, 2002	DEC	NEWA
		TABLET; ORAL					
		METHYLPHENIDATE HCL					
AB		PUREPAC PHARM	5MG	N40321 001	FEB 05, 2002	FEB	NEWA
AB			10MG	N40321 002	FEB 05, 2002	FEB	NEWA
AB			20MG	N40321 003	FEB 05, 2002	FEB	NEWA

METHYLPHENIDATE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
CONCERTA

+	ALZA	27MG	N21121	004	APR 01, 2002	JUN	NEWA

METHYLPREDNISOLONE
TABLET; ORAL
METHYLPREDNISOLONE

AB	GENEVA PHARMS	4MG	N40194	001	OCT 31, 1997	MAY	CAHN

METHYLPREDNISOLONE ACETATE
INJECTABLE; INJECTION
DEPO-MEDROL

+	PHARMACIA AND UPJOHN	80MG/ML	N11757	004		SEP	CTEC

METHYLPREDNISOLONE ACETATE

@	STERIS	20MG/ML	N85597	001		SEP	DISC
@		80MG/ML	N85595	001		SEP	DISC

METHYLTESTOSTERONE
TABLET; ORAL
METHYLTESTOSTERONE

@	LANNETT	10MG	N87092	001	NOV 05, 1982	SEP	DISC
@		25MG	N87111	001	JAN 27, 1983	SEP	DISC

METOCLOPRAMIDE HYDROCHLORIDE
SOLUTION; ORAL
METOCLOPRAMIDE HCL

AA	+ TEVA	EQ 5MG BASE/5ML	N70819	001	JUL 10, 1987	NOV	CRLD

REGLAN

@	ROBINS AH	EQ 5MG BASE/5ML	N18821	001	MAR 25, 1983	NOV	WDGB

METRONIDAZOLE
INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ GD SEARLE LLC	500MG/100ML	N18353	002		JUL	CAHN

METRONIDAZOLE HYDROCHLORIDE
INJECTABLE; INJECTION
FLAGYL I.V.

+	GD SEARLE LLC	EQ 500MG BASE/VIAL	N18353	001		JUL	CAHN

MICONAZOLE NITRATE
CREAM, INSERT; TOPICAL, VAGINAL
MONISTAT DUAL- PAK

@	PERSONAL PRODS	1.2GM;2%	N20968	001	JUN 30, 1999	JUN	DISC

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	+ ABBOTT	EQ 1MG BASE/ML	N75293	001	JUN 20, 2000	OCT	CRLD
AP		EQ 1MG BASE/ML	N75857	001	JUL 22, 2002	JUL	NEWA

AP	+		EQ 5MG BASE/ML	N75293 002	JUN 20, 2000	OCT	CRLD
AP			EQ 5MG BASE/ML	N75857 002	JUL 22, 2002	JUL	NEWA
AP		ROSS LABS	EQ 1MG BASE/ML	N75856 001	JUN 13, 2002	JUN	NEWA
AP			EQ 5MG BASE/ML	N75856 002	JUN 13, 2002	JUN	NEWA
		VERSED					
		@ HLR	EQ 1MG BASE/ML	N18654 002	MAY 26, 1987	OCT	DISC
		@	EQ 5MG BASE/ML	N18654 001	DEC 20, 1985	OCT	DISC
		SYRUP; ORAL					
		MIDAZOLAM HCL					
AA		RANBAXY	EQ 2MG BASE/ML	N76058 001	MAR 15, 2002	MAR	NEWA
AA	+	ROXANE	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	SEP	CRLD
AA			EQ 2MG BASE/ML	N75873 001	APR 30, 2002	APR	NEWA
		VERSED					
AA	+	ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	MAR	CFTG
		@	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	AUG	DISC
		MIDODRINE HYDROCHLORIDE					
		TABLET; ORAL					
		PROAMATINE					
		SHIRE LABS	10MG	N19815 003	MAR 20, 2002	JUL	CRLD
	+		10MG	N19815 003	MAR 20, 2002	JUN	NEWA
		SHIRE PHARM	2.5MG	N19815 001	SEP 06, 1996	SEP	CMFD
			5MG	N19815 002	SEP 06, 1996	JUN	CRLD
	+		5MG	N19815 002	SEP 06, 1996	OCT	CRLD
			10MG	N19815 003	MAR 20, 2002	OCT	CRLD
		MIFEPRISTONE					
		TABLET; ORAL					
		MIFEPREX					
	+	DANCO LABS LLC	200MG	N20687 001	SEP 28, 2000	OCT	CAHN
		MILRINONE LACTATE					
		INJECTABLE; INJECTION					
		MILRINONE LACTATE					
AP		ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEWA
AP		AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEWA
AP		BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA
AP		BEDFORD	EQ 10MG /10ML BASE (10MG/ML)	N75660 001	MAY 28, 2002	NOV	CPOT
AP			EQ 10MG 10/ML (10MG/ML)	N75660 001	MAY 28, 2002	MAY	NEWA
AP			EQ 20MG /20ML BASE (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA
AP			EQ 50MG /50ML BASE (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA
AP		ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA
AP		FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA
AP		INTL MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002	AUG	NEWA
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA
AP	+		EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA
AP		BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA
AP			EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA
AP			EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEWA
AP		ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA
		MILRINONE LACTOSE IN 5% DEXTROSE					
AP		ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	NEWA

MILRINONE LACTATE
INJECTABLE; INJECTION
PRIMACOR

AP	+ SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
AP	+	EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
AP	+	EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG

MINOCYCLINE HYDROCHLORIDE
SUSPENSION; ORAL
MINOCIN

@ LEDERLE	EQ 50MG BASE/5ML	N50445 001		JUN	DISC

MISOPROSTOL
TABLET; ORAL
CYTOTEC

AB	GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990	JUL	CFTG
AB	+	0.2MG	N19268 001	DEC 27, 1988	JUL	CFTG

MISOPROSTOL

AB	IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002	JUL	NEWA
AB		0.2MG	N76095 002	JUL 10, 2002	JUL	NEWA

MITOMYCIN
INJECTABLE; INJECTION
MYTOZYTREX

+	SUPERGEN	5MG/VIAL	N50763 001	NOV 14, 2002	NOV	NEWA

MITOXANTRONE HYDROCHLORIDE
INJECTABLE; INJECTION
NOVANTRONE

>D>	+	IMMUNEX	EQ 2MG BASE/ML	N19297 001	DEC 23, 1987	DEC	CAHN
>A>	+	SERONO INC	EQ 2MG BASE/ML	N19297 001	DEC 23, 1987	DEC	CAHN

MIVACURIUM CHLORIDE
INJECTABLE; INJECTION
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT	EQ 0.5MG BASE/ML	N20098 002	JAN 22, 1992	JUN	DISC

MOMETASONE FUROATE
OINTMENT; TOPICAL
ELOCON

AB	+ SCHERING	0.1%	N19543 001	APR 30, 1987	MAR	CFTG

MOMETASONE FUROATE

AB	CLAY PARK	0.1%	N76067 001	MAR 18, 2002	MAR	NEWA

MONOCTANOIN
LIQUID; PERFUSION, BILIARY
MOCTANIN

@ ETHITEK	100%	N19368 001	OCT 29, 1985	JUN	DISC

MONTELUKAST SODIUM
GRANULE; ORAL
SINGULAIR

+	MERCK	EQ 4MG BASE/PACKET	N21409 001	JUL 26, 2002	JUL	NEWA

MORICIZINE HYDROCHLORIDE
TABLET; ORAL
ETHMOZINE

>D>		SHIRE	200MG	N19753 001	JUN 19, 1990	DEC	CAHN
>A>		SHIRE LABS	200MG	N19753 001	JUN 19, 1990	DEC	CAHN
>D>		SHIRE	250MG	N19753 002	JUN 19, 1990	DEC	CAHN
>A>		SHIRE LABS	250MG	N19753 002	JUN 19, 1990	DEC	CAHN
>D>	+	SHIRE	300MG	N19753 003	JUN 19, 1990	DEC	CAHN
>A>	+	SHIRE LABS	300MG	N19753 003	JUN 19, 1990	DEC	CAHN

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

BX	+	ELAN PHARM	30MG	N21260 001	MAR 20, 2002	SEP	CTEC
			30MG	N21260 001	MAR 20, 2002	MAR	NEWA
BX	+		60MG	N21260 002	MAR 20, 2002	SEP	CTEC
			60MG	N21260 002	MAR 20, 2002	MAR	NEWA
	+		90MG	N21260 003	MAR 20, 2002	SEP	CRLD
			90MG	N21260 003	MAR 20, 2002	MAR	NEWA
	+		120MG	N21260 004	MAR 20, 2002	MAR	NEWA

KADIAN

BX	+	FAULDING PHARMS	30MG	N20616 004	MAR 09, 2001	SEP	CTEC
BX	+		60MG	N20616 005	MAR 09, 2001	SEP	CTEC

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN

AB		PURDUE FREDERICK	15MG	N19516 003	SEP 12, 1989	OCT	CRLD
AB			30MG	N19516 001	MAY 29, 1987	OCT	CRLD
AB			100MG	N19516 004	JAN 16, 1990	OCT	CRLD
AB			200MG	N19516 005	NOV 08, 1993	OCT	CRLD

MUPIROCIN
OINTMENT; TOPICAL
MUPIROCIN

>A>		CLAY PARK LABS	2%	N50788 001	DEC 04, 2002	DEC	NEWA

NABUMETONE
TABLET; ORAL
NABUMETONE

AB		EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
AB			750MG	N75280 002	FEB 25, 2002	FEB	NEWA
AB		INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
AB			750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUM
CAPSULE; ORAL
UNIPEN

	@	WYETH AYERST	EQ 250MG BASE	N50111 001		JUN	DISC

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL
@ ABBOTT 1.5MG/ML N20200 001 MAR 12, 1993 JUL DISC

NALIDIXIC ACID
SUSPENSION; ORAL
NEGGRAM
@ SANOFI SYNTHELABO 250MG/5ML N17430 001 JUN DISC

NALTREXONE HYDROCHLORIDE
TABLET; ORAL
NALTREXONE HCL
MALLINCKRODT 25MG N76264 001 MAR 22, 2002 MAR NEWA
AB 50MG N76264 002 MAR 22, 2002 MAR NEWA
\+ 100MG N76264 003 MAR 22, 2002 MAR NEWA
REVIA
AB + BARR PHARMS 50MG N18932 001 NOV 20, 1984 NOV CAHN

NAPROXEN SODIUM
TABLET, EXTENDED RELEASE; ORAL
NAPRELAN
@ ELAN PHARM EQ 750MG BASE N20353 003 JAN 05, 1996 JUN DISC

NEOMYCIN SULFATE
SOLUTION; ORAL
MYCIFRADIN
AA + PHARMACIA AND UPJOHN EQ 87.5MG BASE/5ML N50285 001 MAY CFTG
@ EQ 87.5MG BASE/5ML N50285 001 JUN DISC
NEO-FRADIN
\+ PHARMATEK EQ 87.5MG BASE/5ML N65010 001 MAY 23, 2002 JUN CRLD
AA EQ 87.5MG BASE/5ML N65010 001 MAY 23, 2002 MAY NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
STATROL
@ ALCON EQ 3.5MG BASE/GM;10,000 UNITS/GM N50344 002 JUN DISC
SOLUTION/DROPS; OPHTHALMIC
@ ALCON EQ 3.5MG BASE/ML;16,250 UNITS/ML N50456 001 JUN DISC

NIACIN
TABLET, EXTENDED RELEASE; ORAL
NIASPAN
@ KOS 375MG N20381 001 JUL 28, 1997 AUG DISC
\+ 500MG N20381 002 JUL 28, 1997 AUG CMFD
@ 500MG N20381 002 JUL 28, 1997 JUN DISC
NIASPAN TITRATION STARTER PACK
@ KOS 375MG;500MG;750MG N20381 005 JUL 28, 1997 JUN DISC

NICOTINE								
INHALANT; INHALATION								
NICOTROL								
@ PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N20714	001	MAY 02, 1997	NOV	WDGB
NIFEDIPINE								
TABLET, EXTENDED RELEASE; ORAL								
ADALAT CC								
AB1 + BAYER	90MG	N20198	003	APR 21, 1993	AUG	CTEC
NIFEDIPINE								
AB1 BIOVAIL	90MG	N76070	001	AUG 16, 2002	AUG	NEWA
NILUTAMIDE								
TABLET; ORAL								
NILANDRON								
@ AVENTIS PHARMS	50MG	N20169	001	SEP 19, 1996	JUN	DISC
+	150MG	N20169	002	APR 30, 1999	JUL	CMFD
NISOLDIPINE								
TABLET, EXTENDED RELEASE; ORAL								
SULAR								
+ FIRST HORIZON	10MG	N20356	001	FEB 02, 1995	MAR	CAHN
	20MG	N20356	002	FEB 02, 1995	MAR	CAHN
+	30MG	N20356	003	FEB 02, 1995	MAR	CAHN
+	40MG	N20356	004	FEB 02, 1995	MAR	CAHN
+ WHITEHALL ROBINS	10MG	N20356	001	FEB 02, 1995	FEB	CAHN
	20MG	N20356	002	FEB 02, 1995	FEB	CAHN
+	40MG	N20356	004	FEB 02, 1995	FEB	CAHN
NITAZOXANIDE								
FOR SUSPENSION; ORAL								
ALINIA								
+ ROMARK	100MG/5ML	N21498	001	NOV 22, 2002	NOV	NEWA
NITISINONE								
CAPSULE; ORAL								
ORFADIN								
R R REGISTRATIONS	2MG	N21232	001	JAN 18, 2002	JAN	NEWA
	5MG	N21232	002	JAN 18, 2002	JAN	NEWA
+	10MG	N21232	003	JAN 18, 2002	JAN	NEWA
SWEDISH ORPHAN	2MG	N21232	001	JAN 18, 2002	MAY	CAHN
	5MG	N21232	002	JAN 18, 2002	MAY	CAHN
+	10MG	N21232	003	JAN 18, 2002	MAY	CAHN
NITROFURANTOIN								
SUSPENSION; ORAL								
FURADANTIN								
+ FIRST HORIZON	25MG/5ML	N09175	001		JAN	CAHN

NITROFURAZONE							
CREAM; TOPICAL							
FURACIN							
@ SHIRE LABS	0.2%	N83789 001			JUL	DISC
OINTMENT; TOPICAL							
@ SHIRE LABS	0.2%	N05795 001			JUL	DISC
+ SHIRE PHARM	0.2%	N05795 001			SEP	CMFD
NITROGLYCERIN							
AEROSOL; SUBLINGUAL							
NITROLINGUAL							
@ FIRST HORIZON	0.4MG/SPRAY	N18705 001	OCT 31, 1985		APR	CAHN
@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985		JUN	CAHN
SPRAY, METERED; SUBLINGUAL							
NITROLINGUAL PUMPSPRAY							
+ FIRST HORIZON	0.4MG/SPRAY	N18705 002	JAN 10, 1997		APR	CAHN
+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997		JUN	CAHN
TABLET; SUBLINGUAL							
NITROSTAT							
PFIZER PHARMS	0.4MG	N21134 002	MAY 01, 2000		JUN	CAHN
NIZATIDINE							
CAPSULE; ORAL							
AXID							
AB LILLY	150MG	N19508 001	APR 12, 1988		JUL	CFTG
AB +	300MG	N19508 002	APR 12, 1988		JUL	CFTG
AB RELIANT PHARMS	150MG	N19508 001	APR 12, 1988		AUG	CAHN
AB +	300MG	N19508 002	APR 12, 1988		AUG	CAHN
NIZATIDINE							
AB EON	150MG	N76178 001	JUL 05, 2002		JUL	NEWA
AB	300MG	N76178 002	JUL 05, 2002		JUL	NEWA
AB GENPHARM	150MG	N75934 001	JUL 09, 2002		JUL	NEWA
AB	300MG	N75934 002	JUL 09, 2002		JUL	NEWA
AB MYLAN	150MG	N75806 001	JUL 05, 2002		JUL	NEWA
AB	300MG	N75806 002	JUL 05, 2002		JUL	NEWA
AB TEVA	150MG	N75668 001	SEP 12, 2002		SEP	NEWA
AB	300MG	N75668 002	SEP 12, 2002		SEP	NEWA
AB WATSON LABS	150MG	N75616 001	JUL 09, 2002		JUL	NEWA
AB	300MG	N75616 002	JUL 09, 2002		JUL	NEWA
AB ZENITH GOLDLINE	150MG	N75461 001	JUL 08, 2002		JUL	NEWA
AB	300MG	N75461 002	JUL 08, 2002		JUL	NEWA
NORETHINDRONE							
TABLET; ORAL							
NOR-QD							
+ WATSON LABS (UTAH)	0.35MG	N17060 001			MAY	CAHN
TABLET; ORAL-28							
CAMILA							
AB1 BARR	0.35MG	N76177 001	OCT 21, 2002		OCT	NEWA
ERRIN							
AB2 BARR	0.35MG	N76225 001	OCT 21, 2002		OCT	NEWA
MICRONOR							

NORETHINDRONE							
TABLET; ORAL-28							
MICRONOR							
AB2 + ORTHO MCNEIL PHARM	0.35MG	N16954 001			OCT	CFTG
NOR-QD							
AB1 + WATSON LABS (UTAH)	0.35MG	N17060 001			OCT	CFTG
NORTRIPTYLINE HYDROCHLORIDE							
SOLUTION; ORAL							
AVENTYL HCL							
AA + RANBAXY	EQ 10MG BASE/5ML	N14685 001			JUN	CAHN
NOVOBIOCIN SODIUM							
CAPSULE; ORAL							
ALBAMYCIN							
@ PHARMACIA AND UPJOHN	EQ 250MG BASE	N50339 001			JUN	DISC
NYSTATIN							
TABLET; ORAL							
NILSTAT							
@ LEDERLE	500,000 UNITS	N61151 001			JUN	DISC
TABLET; VAGINAL							
@ LEDERLE	100,000 UNITS	N61325 001			JUL	DISC
OCTREOTIDE ACETATE							
INJECTABLE; INJECTION							
SANDOSTATIN LAR							
NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998		NOV	CRLD
	EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998		NOV	CRLD
OFLOXACIN							
INJECTABLE; INJECTION							
FLOXIN							
AP + JOHNSON RW	40MG/ML	N20087 003	MAR 31, 1992		JAN	CFTG
@ ORTHO MCNEIL PHARM	20MG/ML	N20087 002	MAR 31, 1992		JUL	DISC
OFLOXACIN							
AP BEDFORD	40MG/ML	N75762 001	JAN 16, 2002		JAN	NEWA
OLANZAPINE							
TABLET; ORAL							
ZYPREXA							
LILLY	2.5MG	N20592 001	SEP 30, 1996		OCT	CRLD
OLMESARTAN MEDOXOMIL							
TABLET; ORAL							
BENICAR							
SANKYO	5MG	N21286 001	APR 25, 2002		APR	NEWA
	20MG	N21286 003	APR 25, 2002		APR	NEWA
+	40MG	N21286 004	APR 25, 2002		APR	NEWA

OMEPRAZOLE
CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

>A>	AB	EON	10MG	N75791	001	DEC 23, 2002	DEC	NEWA
>A>	AB		20MG	N75791	002	DEC 23, 2002	DEC	NEWA
	AB	IMPAX LABS	10MG	N75785	001	NOV 08, 2002	NOV	NEWA
	AB		20MG	N75785	002	NOV 08, 2002	NOV	NEWA
	AB	KREMERS URBAN DEV	10MG	N75410	001	NOV 01, 2002	NOV	NEWA
	AB		20MG	N75410	002	NOV 01, 2002	NOV	NEWA

OXALIPLATIN
INJECTABLE; IV (INFUSION)
ELOXATIN

		SANOFI	50MG/VIAL	N21492	001	AUG 09, 2002	AUG	NEWA
	+		100MG/VIAL	N21492	002	AUG 09, 2002	AUG	NEWA

OXANDROLONE
TABLET; ORAL
OXANDRIN

		BIO TECH GEN	2.5MG	N13718	001		JUN	CRLD
	+		10MG	N13718	002	NOV 05, 2001	JUN	NEWA

OXAPROZIN
TABLET; ORAL
OXAPROZIN

AB		CARACO	600MG	N75844	001	JAN 03, 2002	JAN	NEWA
AB		IVAX PHARMS	600MG	N75846	001	MAY 13, 2002	MAY	NEWA
AB		TEVA	600MG	N75849	001	JUL 03, 2002	JUL	NEWA

OXAPROZIN POTASSIUM
TABLET; ORAL
DAYPRO ALTA

	+	PHARMACIA	600MG	N20776	001	OCT 17, 2002	OCT	NEWA

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL

AP		ABBOTT	6MG/ML	N76131	001	MAY 08, 2002	MAY	NEWA
AP		NAPRO	6MG/ML	N76233	001	AUG 01, 2002	AUG	NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP		AESGEN	30MG/VIAL	N75594	001	MAY 06, 2002	MAY	NEWA
AP			90MG/VIAL	N75594	002	MAY 06, 2002	MAY	NEWA
AP		AM PHARM PARTNERS	30MG/VIAL	N75773	001	MAY 06, 2002	MAY	NEWA
AP			30MG /10ML(3MG/ML)	N76207	001	MAY 17, 2002	MAY	NEWA
AP			90MG/VIAL	N75773	002	MAY 06, 2002	MAY	NEWA
AP			90MG /10ML(9MG/ML)	N76207	002	MAY 17, 2002	MAY	NEWA
AP		BEDFORD	30MG /10ML(3MG/ML)	N21113	001	MAR 04, 2002	MAY	CDFR
AP	+		90MG /10ML(9MG/ML)	N21113	002	MAR 04, 2002	MAY	CDFR
AP		FAULDING	30MG /10ML(3MG/ML)	N75841	001	JUN 27, 2002	JUN	NEWA

AP		60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002	JUN	NEWA
AP		90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002	JUN	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDFR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR
	INJECTABLE; IV (INFUSION)					
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA
AP +		90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)						
	CAPSULE; ORAL					
	COTAZYM					
	@ ORGANON	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N20580 001	DEC 09, 1996	JUN	DISC
PARAMETHADIONE						
	CAPSULE; ORAL					
	PARADIONE					
	@ ABBOTT	150MG	N06800 003		JUN	DISC
	@	300MG	N06800 001		JUN	DISC
PAROXETINE HYDROCHLORIDE						
	TABLET, EXTENDED RELEASE; ORAL					
	PAXIL CR					
	GLAXOSMITHKLINE	EQ 12.5MG BASE	N20936 001	FEB 16, 1999	OCT	CRLD
		EQ 25MG BASE	N20936 002	FEB 16, 1999	OCT	CRLD
PENICILLIN G POTASSIUM						
	INJECTABLE; INJECTION					
	PENICILLIN G POTASSIUM					
AP	GENEVA PHARMS	1,000,000 UNITS/VIAL	N65079 001	AUG 30, 2002	AUG	NEWA
AP		5,000,000 UNITS/VIAL	N65079 002	AUG 30, 2002	AUG	NEWA
AP		20,000,000 UNITS/VIAL	N65079 003	AUG 30, 2002	AUG	NEWA
PENICILLIN V POTASSIUM						
	FOR SOLUTION; ORAL					
	PEN-VEE K					
	@ WYETH AYERST	EQ 125MG BASE/5ML	N60007 001		MAY	DISC
	@	EQ 250MG BASE/5ML	N60007 002		MAY	DISC
PENTAGASTRIN						
	INJECTABLE; INJECTION					
	PEPTAVLON					
	@ WYETH AYERST	0.25MG/ML	N17048 001		APR	DISC
PENTOSAN POLYSULFATE SODIUM						
	CAPSULE; ORAL					
	ELMIRON					
+	JOHNSON AND JOHNSON	100MG	N20193 001	SEP 26, 1996	JUL	CAHN

PERGOLIDE MESYLATE
TABLET; ORAL
PERGOLIDE MESYLATE

AB	TEVA	EQ 0.05MG BASE	N76061	001	NOV 27, 2002	NOV	NEWA
AB		EQ 0.25MG BASE	N76061	002	NOV 27, 2002	NOV	NEWA
AB		EQ 1MG BASE	N76061	003	NOV 27, 2002	NOV	NEWA

PERMAX

AB	+ LILLY	EQ 0.05MG BASE	N19385	001	DEC 30, 1988	NOV	CFTG
AB		EQ 0.25MG BASE	N19385	002	DEC 30, 1988	NOV	CFTG
AB		EQ 1MG BASE	N19385	003	DEC 30, 1988	NOV	CFTG

PHENACEMIDE
TABLET; ORAL
PHENURONE

	@ ABBOTT	500MG	N07707	001		JUN	DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

	@ ABLE	200MG;800MG;160MG	N21105	001	JUN 26, 2001	JUN	DISC

PHENDIMETRAZINE TARTRATE
TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	MIKART	35MG	N89452	001	OCT 30, 1991	MAR	CMFD

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
PHENTERMINE HCL

AA	VINTAGE PHARMS	37.5MG	N40377	001	JAN 04, 2002	JAN	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
SOLUTION/DROPS; OPHTHALMIC
PREFRIN-A

	@ ALLERGAN	0.12%;0.1%	N07953	001		JUN	DISC

PHENYTOIN
SUSPENSION; ORAL
PHENTYTOIN

AB	MORTON GROVE	125MG/5ML	N40420	001	APR 19, 2002	APR	NEWA

PILOCARPINE
DRUG DELIVERY SYSTEM; OPHTHALMIC
OCUSERT PILO-40

	@ AKORN	11MG	N17548	001		JUN	DISC

INSERT, EXTENDED RELEASE; OPHTHALMIC
OCUSERT PILO-20

	@ AKORN	5MG	N17431	001		JUN	DISC

PIPECURONIUM BROMIDE							
INJECTABLE; INJECTION							
ARDUAN							
@ ORGANON	10MG/VIAL		N19638	001	JUN 26, 1990	JUN	DISC
PODOFILOX							
SOLUTION; TOPICAL							
CONDYLOX							
AT + PADDOCK	0.5%		N19795	001	DEC 13, 1990	JAN	CFTG
PODOFILOX							
AT PADDOCK	0.5%		N75600	001	JAN 29, 2002	JAN	NEWA
POTASSIUM CHLORIDE							
TABLET, EXTENDED RELEASE; ORAL							
POTASSIUM CHLORIDE							
AB ANDRX PHARMS	10MEQ		N75604	001	APR 10, 2002	APR	NEWA
AB	20MEQ		N75604	002	APR 10, 2002	APR	NEWA
AB KV PHARM	20MEQ		N76044	001	APR 05, 2002	APR	NEWA
PRAVASTATIN SODIUM							
TABLET; ORAL							
PRAVACHOL							
BRISTOL MYERS SQUIBB	40MG		N19898	004	MAR 22, 1993	MAR	CRLD
+	80MG		N19898	008	DEC 18, 2001	MAR	NEWA
PREDNICARBATE							
CREAM; TOPICAL							
DERMATOP							
+ DERMIK LABS	0.1%		N20279	001	OCT 29, 1993	JUN	CAHN
OINTMENT; TOPICAL							
+ DERMIK LABS	0.1%		N19568	001	SEP 23, 1991	JUN	CAHN
PREDNISOLONE							
SYRUP; ORAL							
PREDNISOLONE							
AA KV PHARM	15MG/5ML		N40364	001	APR 10, 2002	APR	NEWA
PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM							
OINTMENT; OPHTHALMIC							
METIMYD							
@ SCHERING	0.5%;10%		N10210	002	SEP 09, 1984	JUL	DISC
VASOCIDIN							
+ NOVARTIS	0.5%;10%		N88791	001	OCT 05, 1984	AUG	CRLD
SUSPENSION; OPHTHALMIC							
ISOPTO CETAPRED							
@ ALCON	0.25%;10%		N87547	001		JUN	DISC
SUSPENSION/DROPS; OPHTHALMIC							
METIMYD							
@ SCHERING	0.5%;10%		N10210	001		JUL	DISC

		PREDNISOLONE SODIUM PHOSPHATE						
		SOLUTION; ORAL						
		ORAPRED						
	AA +	ASCENT PEDS	EQ 15MG BASE/5ML	N75117 001	DEC 14, 2000	JUL	CFTG	
		PEDIAPRED						
	AA +	CELLTECH PHARMS	EQ 5MG BASE/5ML	N19157 001	MAY 28, 1986	JUN	CFTG	
		PREDNISOLONE SODIUM PHOSPHATE						
	AA	MORTON GROVE	EQ 5MG BASE/5ML	N75099 001	JUN 28, 2002	JUN	NEWA	
>A>	AA	PHARM ASSOC	EQ 5MG BASE/5ML	N76123 001	DEC 23, 2002	DEC	NEWA	
>A>	AA	WE PHARMS	EQ 5MG BASE/5ML	N75181 001	DEC 23, 2002	DEC	NEWA	
	AA		EQ 15MG BASE/5ML	N75250 001	JUL 12, 2002	JUL	NEWA	
		PREDNISOLONE TEBUTATE						
		INJECTABLE; INJECTION						
		HYDELTRA-TBA						
		@ MERCK	20MG/ML	N10562 001		JUN	DISC	
		PREDNISONE						
		TABLET; ORAL						
		PREDNISONE						
		@ LANNETT	5MG	N80514 001		SEP	DISC	
	AB	VINTAGE PHARMS	5MG	N40256 001	JUL 12, 2002	JUL	NEWA	
	AB		10MG	N40256 002	JUL 12, 2002	JUL	NEWA	
		PRIMIDONE						
		SUSPENSION; ORAL						
		MYSOLINE						
		@ XCEL PHARMS	250MG/5ML	N10401 001		JUL	DISC	
		PROCHLORPERAZINE MALEATE						
		CAPSULE, EXTENDED RELEASE; ORAL						
		COMPAZINE						
		@ GLAXOSMITHKLINE	EQ 10MG BASE	N11000 001		JUN	DISC	
	+		EQ 10MG BASE	N21019 001	OCT 06, 1999	JUN	CRLD	
		@	EQ 15MG BASE	N11000 002		JUN	DISC	
	+		EQ 15MG BASE	N21019 002	OCT 06, 1999	JUN	CRLD	
		@	EQ 30MG BASE	N11000 003		JUN	DISC	
		PROGESTERONE						
		GEL; VAGINAL						
		CRINONE						
>D>	+	COLUMBIA RES LABS	8%	N20756 001	MAY 13, 1997	DEC	CMS2	
>A>			8%	N20756 001	MAY 13, 1997	DEC	CMS2	
		INSERT, EXTENDED RELEASE; INTRAUTERINE						
		PROGESTASERT						
		@ ALZA	38MG	N17553 001		JUN	DISC	
		PROMAZINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		SPARINE						
		@ WYETH AYERST	50MG/ML	N10349 006		JUN	DISC	

PROMAZINE HYDROCHLORIDE							
TABLET; ORAL							
SPARINE							
@ WYETH AYERST		25MG	N10348	001		JUN	DISC
@		50MG	N10348	002		JUN	DISC
PROMETHAZINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
PROMETHAZINE HCL							
AP	GENSIA SICOR PHARMS	25MG/ML	N40454	001	AUG 22, 2002	AUG	NEWA
AP		50MG/ML	N40454	002	AUG 22, 2002	AUG	NEWA
AP	PHARMAFORCE	25MG/ML	N40471	001	NOV 21, 2002	NOV	NEWA
SUPPOSITORY; RECTAL							
PHENERGAN							
AB +	WYETH AYERST	25MG	N10926	001		FEB	CTEC
PROMETHAZINE HCL							
AB	G AND W LABS	25MG	N40428	001	FEB 05, 2002	FEB	NEWA
SYRUP; ORAL							
PHENERGAN FORTIS							
@ WYETH AYERST		25MG/5ML	N08381	003		JUN	DISC
PROPAFENONE HYDROCHLORIDE							
TABLET; ORAL							
PROPAFENONE HCL							
AB	KV PHARM	150MG	N76193	001	FEB 07, 2002	FEB	NEWA
AB		225MG	N76193	002	FEB 07, 2002	FEB	NEWA
AB		300MG	N76193	003	FEB 07, 2002	FEB	NEWA
AB	VINTAGE PHARMS	150MG	N75938	001	OCT 17, 2002	OCT	NEWA
AB		225MG	N75938	002	OCT 17, 2002	OCT	NEWA
AB		300MG	N75938	003	OCT 17, 2002	OCT	NEWA
PROPOXYPHENE HYDROCHLORIDE							
CAPSULE; ORAL							
DARVON							
AA +	AAI PHARMA	32MG	N10997	001		JUN	CAHN
AA +		65MG	N10997	003		JUN	CAHN
PROPOXYPHENE NAPSYLATE							
SUSPENSION; ORAL							
DARVON-N							
+	NEOSAN PHARMS	50MG/5ML	N16861	001		JUN	CAHN
TABLET; ORAL							
+	AAIPHARMA LLC	100MG	N16862	002		JUN	CAHN
PROPRANOLOL HYDROCHLORIDE							
TABLET; ORAL							
PROPRANOLOL HCL							
@ LEDERLE		60MG	N71495	001	DEC 31, 1987	FEB	DISC
@		80MG	N70128	001	JUL 30, 1985	MAY	CAHN
@		90MG	N71496	001	DEC 31, 1987	FEB	DISC
@ PUREPAC PHARM		10MG	N70814	001	NOV 03, 1986	MAY	DISC

			@	20MG	N70815 001	NOV 03, 1986	MAY	DISC
			@	40MG	N70816 001	NOV 03, 1986	MAY	DISC
			@	60MG	N70817 001	NOV 03, 1986	MAY	DISC
			@	80MG	N70757 001	NOV 03, 1986	MAY	DISC
		PYRAZINAMIDE						
		TABLET; ORAL						
		PYRAZINAMIDE						
	AB	+	CLONMEL	500MG	N80157 001		JUL	CAHN
		PYRIDOSTIGMINE BROMIDE						
		TABLET; ORAL						
		MESTINON						
>D>		+	ICN	60MG	N09829 002		DEC	CFTG
>A>	AB	+		60MG	N09829 002		DEC	CFTG
>A>		PYRIDOSTIGMINE BROMIDE						
>A>	AB		COREPHARMA	60MG	N40457 001	DEC 26, 2002	DEC	NEWA
		QUINETHAZONE						
		TABLET; ORAL						
		HYDROMOX						
		@	LEDERLE	50MG	N13264 001		APR	DISC
		RABEPRAZOLE SODIUM						
		TABLET, DELAYED RELEASE; ORAL						
		ACIPHEX						
		@	EISAI MEDCL RES	10MG	N20973 001	MAY 29, 2002	JUL	DISC
		+		20MG	N20973 002	AUG 19, 1999	MAY	CAHN
		+		20MG	N20973 002	AUG 19, 1999	JUL	CMFD
		@		20MG	N20973 002	AUG 19, 1999	JUN	DISC
		RANITIDINE HYDROCHLORIDE						
		CAPSULE; ORAL						
		RANITIDINE HCL						
	AB	+	GENEVA PHARMS	EQ 300MG BASE	N74655 002	OCT 22, 1997	AUG	CRLD
		ZANTAC 300						
		@	GLAXOSMITHKLINE	EQ 300MG BASE	N20095 002	MAR 08, 1994	AUG	DISC
		RAPACURONIUM BROMIDE						
		INJECTABLE; INJECTION						
		RAPLON						
		@	ORGANON	100MG/VIAL	N20984 001	AUG 18, 1999	JUN	DISC
		@		200MG/VIAL	N20984 002	AUG 18, 1999	JUN	DISC
		RIBAVIRIN						
>A>		TABLET; ORAL						
>A>		COPEGUS						
>A>		+	ROCHE	200MG	N21511 001	DEC 03, 2002	DEC	NEWA
		RIMANTADINE HYDROCHLORIDE						
		TABLET; ORAL						
		RIMANTADINE HCL						
	AB		IMPAX LABS	100MG	N76132 001	AUG 30, 2002	AUG	NEWA

	RISEDRONATE SODIUM							
	TABLET; ORAL							
	ACTONEL							
	PROCTER AND GAMBLE	30MG	N20835	001	MAR 27, 1998	JUL	CRLD	
	+	35MG	N20835	003	MAY 25, 2002	JUL	NEWA	
	RITONAVIR							
	CAPSULE; ORAL							
	NORVIR							
	@ ABBOTT	100MG	N20680	001	MAR 01, 1996	JUN	DISC	
	+	100MG	N20945	001	JUN 29, 1999	JUN	CRLD	
	ROCURONIUM BROMIDE							
	INJECTABLE; INJECTION							
	ZEMURON							
	@ ORGANON	10MG/ML	N20214	002	MAR 17, 1994	JUN	DISC	
	SECOBARBITAL SODIUM							
	CAPSULE; ORAL							
	SECONAL SODIUM							
	+ RANBAXY	50MG	N86101	001	OCT 03, 1983	JUN	CAHN	
AA	+	100MG	N86101	002	OCT 03, 1983	JUN	CAHN	
	SECRETIN							
	FOR SOLUTION; INTRAVENOUS							
	SECREFLO							
	+ CHIRHOCLIN	16UGM/VIAL	N21209	001	APR 04, 2002	APR	NEWA	
	SELEGILINE HYDROCHLORIDE							
	CAPSULE; ORAL							
	SELEGILINE HCL							
AB	CLONMEL HLTHCARE	5MG	N75352	001	NOV 30, 1998	JUN	CAHN	
	TABLET; ORAL							
AB	CLONMEL HLTHCARE	5MG	N74641	001	AUG 02, 1996	APR	CAHN	
AB	SIEGFRIED	5MG	N74672	001	APR 01, 1997	AUG	CAHN	
	SELENIUM SULFIDE							
	LOTION/SHAMPOO; TOPICAL							
	SELSUN							
AT	+ CHATTEM	2.5%	N07936	001		AUG	CAHN	
	SELENOMETHIONINE, SE-75							
	INJECTABLE; INJECTION							
	SELENOMETHIONINE SE 75							
	@ CIS	500uCi/ML	N17322	001		JUN	DISC	
	SEVOFLURANE							
	LIQUID; INHALATION							
	SEVOFLURANE							
AN	BAXTER HLTHCARE	100%	N75895	001	JUL 02, 2002	SEP	NEWA	
	ULTANE							
AN	+ ABBOTT	100%	N20478	001	JUN 07, 1995	SEP	CFTG	

SIMETHICONE-CELLULOSE							
SUSPENSION; ORAL							
SONORX							
@ BRACCO	7.5MG/ML	N20773	001	OCT 29, 1998	JUN	DISC	
SIROLIMUS							
TABLET; ORAL							
RAPAMUNE							
+ WYETH AYERST	1MG	N21110	001	AUG 25, 2000	JUN	NEWA	
SODIUM BENZOATE; SODIUM PHENYLACETATE							
SOLUTION; ORAL							
UCEPHAN							
@ B BRAUN	100MG/ML;100MG/ML	N19530	001	DEC 23, 1987	JUN	DISC	
SODIUM IODIDE, I-131							
CAPSULE; ORAL							
IODOTOPE							
@ BRACCO	1-150mCi	N10929	003		JUN	DISC	
SOLUTION; ORAL							
@ BRACCO	7-106mCi/BOT	N10929	002		JUN	DISC	
SODIUM OXYBATE							
SOLUTION; ORAL							
XYREM							
+ ORPHAN MEDCL	500MG/ML	N21196	001	JUL 17, 2002	JUL	NEWA	
SOMATROPIN RECOMBINANT							
INJECTABLE; INJECTION							
NORDITROPIN							
@ NOVO NORDISK	4MG/VIAL	N19721	001	MAY 08, 1995	JUN	DISC	
@	8MG/VIAL	N19721	002	MAY 08, 1995	JUN	DISC	
NUTROPIN AQ PEN							
BX + GENENTECH	5MG/ML	N20522	002	APR 22, 2002	JUN	NEWA	
SAIZEN							
BX + SERONO	8.8MG/VIAL	N19764	003	AUG 29, 2000	SEP	CDFR	
+	8.8MG/VIAL	N19764	003	AUG 29, 2000	NOV	CTEC	
SEROSTIM							
BX + SERONO	4MG/VIAL	N20604	003	JUL 25, 1997	JUN	CRLD	
BX	6MG/VIAL	N20604	001	AUG 23, 1996	JUN	CRLD	
+	8.8MG/VIAL	N20604	004	SEP 06, 2001	NOV	CTEC	
BX +	8.8MG/VIAL	N20604	004	SEP 06, 2001	SEP	CTNA	
SEROSTIM IN PLASTIC CONTAINER							
BX + SERONO	8.8MG/VIAL	N20604	004	SEP 06, 2001	JUN	NEWA	
TEV-TROVIN							
BX + BIO TECH GEN	5MG/ML	N19774	002	JAN 04, 2002	JUN	NEWA	
SOTALOL HYDROCHLORIDE							
TABLET; ORAL							
SOTALOL HCL							
AB APOTEX	80MG	N76140	001	SEP 26, 2002	SEP	NEWA	
AB	120MG	N76140	002	SEP 26, 2002	SEP	NEWA	

AB		160MG	N76140 003	SEP 26, 2002	SEP	NEWA
AB		240MG	N76140 004	SEP 26, 2002	SEP	NEWA
	SPECTINOMYCIN HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	TROBICIN					
	@ PHARMACIA AND UPJOHN	EQ 4GM BASE/VIAL	N50347 002		JUN	DISC
	STAVUDINE					
>A>	CAPSULE, EXTENDED RELEASE; ORAL					
>A>	ZERIT XR					
>A>	BRISTOL MYERS SQUIBB	37.5MG	N21453 001	DEC 31, 2002	DEC	NEWA
>A>		50MG	N21453 002	DEC 31, 2002	DEC	NEWA
>A>		75MG	N21453 003	DEC 31, 2002	DEC	NEWA
>A>	+	100MG	N21453 004	DEC 31, 2002	DEC	NEWA
	SUCCINYLCHOLINE CHLORIDE					
	INJECTABLE; INJECTION					
	QUELICIN PRESERVATIVE FREE					
	@ ABBOTT	50MG/ML	N08845 002		JUN	DISC
	SULFAMETHIZOLE					
	TABLET; ORAL					
	THIOSULFIL					
	@ WYETH AYERST	500MG	N08565 004		JUN	DISC
	SULFAMETHOXAZOLE					
	TABLET; ORAL					
	GANTANOL					
	@ ROCHE	500MG	N12715 002		MAY	CTEC
	SULFAMETHOXAZOLE; TRIMETHOPRIM					
	SUSPENSION; ORAL					
	BACTRIM PEDIATRIC					
	@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 002		APR	DISC
	SEPTRA					
AB +	MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001		APR	CRLD
	SULFAPYRIDINE					
	TABLET; ORAL					
	SULFAPYRIDINE					
	@ LILLY	500MG	N00159 001		JUN	DISC
	SULFASALAZINE					
	TABLET; ORAL					
	SULFASALAZINE					
AB	VINTAGE PHARMS	500MG	N40349 001	JAN 11, 2002	JAN	NEWA
	TABLET, DELAYED RELEASE; ORAL					
	AZULFIDINE EN-TABS					
AB +	PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983	JAN	CFTG
	SULFASALAZINE					
AB	VINTAGE PHARMS	500MG	N75339 001	JAN 11, 2002	JAN	NEWA

SULFISOXAZOLE ACETYL					
SYRUP; ORAL					
GANTRISIN					
@ ROCHE	EQ 500MG BASE/5ML	N09182 002		JUN	DISC
SUMATRIPTAN SUCCINATE					
TABLET; ORAL					
IMITREX					
GLAXOSMITHKLINE	EQ 50MG BASE	N20132 003	JUN 01, 1995	JUN	CRLD
+	EQ 100MG BASE	N20132 001	JUN 01, 1995	JUN	CMFD
SUPROFEN					
SOLUTION/DROPS; OPHTHALMIC					
PROFENAL					
@ ALCON	1%	N19387 001	DEC 23, 1988	JUN	DISC
TAMOXIFEN CITRATE					
TABLET; ORAL					
NOLVADEX					
+ ASTRAZENECA	EQ 20MG BASE	N17970 002	MAR 21, 1994	AUG	CTEC
TAZAROTENE					
CREAM; TOPICAL					
AVAGE					
+ ALLERGAN	0.1%	N21184 003	SEP 30, 2002	OCT	NEWA
TECHNETIUM TC-99M ALBUMIN COLLOID KIT					
INJECTABLE; INJECTION					
MICROLITE					
@ CIS	N/A	N18263 001	MAR 25, 1983	JUN	DISC
TECHNETIUM TC-99M ALBUMIN KIT					
INJECTABLE; INJECTION					
TECHNETIUM TC 99M HSA					
@ AMERSHAM HLTH	N/A	N17775 001		JUL	DISC
TECHNETIUM TC-99M RED BLOOD CELL KIT					
INJECTABLE; INJECTION					
RBC-SCAN					
@ CADEMA	N/A	N20063 001	JUN 11, 1992	JUN	DISC
TECHNETIUM TC-99M SODIUM PERTECHNETATE					
SOLUTION; INJECTION, ORAL					
SODIUM PERTECHNETATE TC 99M					
@ MALLINCKRODT	10-60mCi/ML	N17725 001		JUN	DISC
TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR					
SOLUTION; INJECTION, ORAL					
TECHNETIUM TC 99M GENERATOR					
@ AMERSHAM HLTH	830-16600mCi/GENERATOR	N17693 001		JUN	DISC

		TEGASEROD MALEATE						
		TABLET; ORAL						
		ZELNORM						
		NOVARTIS	EQ 2MG BASE	N21200 001	JUL 24, 2002	AUG	CPOT
			2MG	N21200 001	JUL 24, 2002	JUL	NEWA
	+		EQ 6MG BASE	N21200 002	JUL 24, 2002	AUG	CPOT
	+		6MG	N21200 002	JUL 24, 2002	JUL	NEWA
		TERAZOSIN HYDROCHLORIDE						
		CAPSULE; ORAL						
		TERAZOSIN HCL						
	AB	RANBAXY	EQ 1MG BASE	N76021 001	AUG 22, 2002	AUG	NEWA
	AB		EQ 2MG BASE	N76021 002	AUG 22, 2002	AUG	NEWA
	AB		EQ 5MG BASE	N76021 003	AUG 22, 2002	AUG	NEWA
	AB		EQ 10MG BASE	N76021 004	AUG 22, 2002	AUG	NEWA
		TERBINAFINE						
		GEL; TOPICAL						
		LAMISIL						
>D>		@ NOVARTIS	1%	N20846 001	APR 29, 1998	DEC	CAHN
>A>		@ NOVARTIS CONS	1%	N20846 001	APR 29, 1998	DEC	CAHN
		@	1%	N20846 001	APR 29, 1998	JUN	DISC
		TERBINAFINE HYDROCHLORIDE						
		SOLUTION; TOPICAL						
>D>	+	NOVARTIS	1%	N20749 001	OCT 17, 1997	DEC	CAHN
>A>	+	NOVARTIS CONS	1%	N20749 001	OCT 17, 1997	DEC	CAHN
		TERBUTALINE SULFATE						
		INJECTABLE; INJECTION						
		BRETHINE						
	+	AAIPHARMA	1MG/ML	N18571 001		JUL	CAHN
	+	NEOSAN PHARMS	1MG/ML	N18571 001		FEB	CAHN
		TABLET; ORAL						
	AB	AAIPHARMA	2.5MG	N17849 001		JUL	CAHN
	AB +		5MG	N17849 002		JUL	CAHN
	AB	NEOSAN PHARMS	2.5MG	N17849 001		FEB	CAHN
	AB +		5MG	N17849 002		FEB	CAHN
		TERIPARATIDE ACETATE						
		INJECTABLE; SUBCUTANEOUS						
>D>		FORTEO						
>D>	+	LILLY	EQ 0.75MG 3ML(0.25MG/ML)	N21318 001	NOV 26, 2002	DEC	CTNA
>A>		FORTEO						
>A>	+	LILLY	EQ 0.75MG 3ML(0.25MG/ML)	N21318 001	NOV 26, 2002	DEC	CTNA
	+	LILLY	EQ 0.75MG 3ML(0.25MG/ML)	N21318 001	NOV 26, 2002	NOV	NEWA
		TESTOSTERONE						
		FILM, EXTENDED RELEASE; TRANSDERMAL						
		TESTODERM TTS						
	BX +	ALZA	5MG/24HR	N20791 001	DEC 18, 1997	JAN	CTNA

TESTOSTERONE							
GEL; TOPICAL							
TESTIM							
+ AUXILIUM A2	1%	N21454	001	OCT 31, 2002	OCT	NEWA
TETRACYCLINE HYDROCHLORIDE							
FIBER, EXTENDED RELEASE; PERIODONTAL							
ACTISITE							
+ ALZA	12.7MG/FIBER	N50653	001	MAR 25, 1994	FEB	CAHN
FOR SOLUTION; TOPICAL							
TOPICYCLINE							
@ SHIRE LABS	2.2MG/ML	N50493	001		JUL	DISC
INJECTABLE; INJECTION							
ACHROMYCIN							
@ LEDERLE	250MG/VIAL	N50273	002		JUN	DISC
+	500MG/VIAL	N50273	003		JUN	CRLD
@	500MG/VIAL	N50273	003		JUL	DISC
SUSPENSION; ORAL							
ACHROMYCIN V							
@ LEDERLE	125MG/5ML	N50263	002		APR	DISC
SUMYCIN							
+ APOTHECON	125MG/5ML	N60400	001		APR	CTEC
TABLET; ORAL							
@ PAR PHARM	50MG	N61147	003		MAY	CAHN
@	100MG	N61147	002		MAY	CAHN
	250MG	N61147	001		MAY	CAHN
+	500MG	N61147	004		MAY	CAHN
THEOPHYLLINE							
TABLET, EXTENDED RELEASE; ORAL							
THEO-DUR							
AB SCHERING	100MG	N85328	001		OCT	CRLD
AB	200MG	N86998	001		OCT	CRLD
AB	300MG	N85328	002		OCT	CRLD
AB	450MG	N89131	001	JUN 25, 1986	OCT	CRLD
THEOPHYLLINE							
AB + SIDMAK LABS NJ	100MG	N89807	001	APR 30, 1990	OCT	CRLD
AB +	200MG	N89808	001	APR 30, 1990	OCT	CRLD
AB +	300MG	N89763	001	APR 30, 1990	OCT	CRLD
AB +	450MG	N81236	001	NOV 09, 1992	OCT	CRLD
UNI-DUR							
BC SCHERING	400MG	N89822	001	JAN 04, 1995	OCT	CRLD
BC	600MG	N89823	001	JAN 04, 1995	OCT	CRLD
UNIPHYL							
BC + PURDUE FREDERICK	400MG	N87571	001	SEP 01, 1982	OCT	CRLD
BC +	600MG	N40086	001	APR 15, 1996	OCT	CRLD
THIETHYLPERAZINE MALATE							
INJECTABLE; INJECTION							
TORECAN							
@ NOVARTIS	5MG/ML	N12754	002		JUN	DISC

THIORIDAZINE							
SUSPENSION; ORAL							
MELLARIL-S							
@ NOVARTIS	EQ 25MG HCL/5ML	N17923	001		JUN	DISC
@	EQ 100MG HCL/5ML	N17923	002		JUN	DISC
THIORIDAZINE HYDROCHLORIDE							
CONCENTRATE; ORAL							
MELLARIL							
@ NOVARTIS	30MG/ML	N11808	012		AUG	DISC
@	100MG/ML	N11808	018		AUG	DISC
THIORIDAZINE HCL							
AA + COPLEY PHARM	30MG/ML	N89602	001	NOV 09, 1987	AUG	CRLD
AA +	100MG/ML	N89603	001	NOV 09, 1987	AUG	CRLD
TABLET; ORAL							
MELLARIL							
@ NOVARTIS	10MG	N11808	003		AUG	DISC
@	15MG	N11808	016		AUG	DISC
@	25MG	N11808	006		AUG	DISC
@	50MG	N11808	011		AUG	DISC
@	100MG	N11808	009		AUG	DISC
@	150MG	N11808	017		AUG	DISC
@	200MG	N11808	015		AUG	DISC
THIORIDAZINE HCL							
AB + GENEVA PHARMS	25MG	N88133	001	AUG 30, 1983	AUG	CRLD
AB +	100MG	N88135	001	NOV 20, 1984	AUG	CRLD
AB +	200MG	N88137	001	SEP 17, 1986	AUG	CRLD
THIOTEPA							
INJECTABLE; INJECTION							
THIOTEPA							
AP AM PHARM PARTNERS	15MG/VIAL	N75698	001	SEP 20, 2001	FEB	CAHN
THIOTHIXENE HYDROCHLORIDE							
CONCENTRATE; ORAL							
THIOTHIXENE HCL INTENSOL							
@ ROXANE	EQ 5MG BASE/ML	N73494	001	JUN 30, 1992	JAN	DISC
TIAGABINE HYDROCHLORIDE							
TABLET; ORAL							
GABITRIL							
+ CEPHALON	16MG	N20646	003	SEP 30, 1997	JUN	CRLD
@	20MG	N20646	004	SEP 30, 1997	JUN	DISC
TICLOPIDINE HYDROCHLORIDE							
TABLET; ORAL							
TICLOPIDINE HCL							
AB CARACO	250MG	N75526	001	SEP 26, 2002	SEP	NEWA

TIMOLOL MALEATE							
SOLUTION; OPHTHALMIC							
TIMOLOL MALEATE							
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	SEP 10, 2002	SEP	NEWA	
TINZAPARIN SODIUM							
INJECTABLE; INJECTION							
INNOHEP							
+	LEO PHARM	20,000 IU/ML	N20484 001	JUL 14, 2000	APR	CAHN	
+	PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000	JUL	CAHN	
TIZANIDINE HYDROCHLORIDE							
CAPSULE; ORAL							
ZANAFLEX							
	ELAN PHARMS	EQ 2MG BASE	N21447 001	AUG 29, 2002	AUG	NEWA	
		EQ 4MG BASE	N21447 002	AUG 29, 2002	AUG	NEWA	
+		EQ 6MG BASE	N21447 003	AUG 29, 2002	AUG	NEWA	
TABLET; ORAL							
TIZANIDINE HCL							
AB	COREPHARMA	EQ 2MG BASE	N76347 001	OCT 11, 2002	OCT	NEWA	
AB		EQ 4MG BASE	N76347 002	OCT 11, 2002	OCT	NEWA	
AB	DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	JUL 03, 2002	JUL	NEWA	
AB		EQ 4MG BASE	N76286 002	JUL 03, 2002	JUL	NEWA	
AB	EON	EQ 2MG BASE	N76399 001	NOV 26, 2002	NOV	NEWA	
AB		EQ 4MG BASE	N76280 002	JUN 27, 2002	JUN	NEWA	
AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	JUL 12, 2002	JUL	NEWA	
AB		EQ 4MG BASE	N76283 002	JUL 12, 2002	JUL	NEWA	
AB	TEVA	EQ 2MG BASE	N76284 001	JUL 03, 2002	JUL	NEWA	
AB		EQ 4MG BASE	N76284 002	JUL 03, 2002	JUL	NEWA	
ZANAFLEX							
AB	ELAN PHARMS	EQ 2MG BASE	N20397 002	FEB 04, 2000	AUG	CFTG	
AB +		EQ 4MG BASE	N20397 001	NOV 27, 1996	JUN	CFTG	
TOBRAMYCIN							
SOLUTION/DROPS; OPHTHALMIC							
TOBRAMYCIN							
AT	NOVEX	0.3%	N65087 001	FEB 25, 2002	FEB	NEWA	
TOBRAMYCIN SULFATE							
INJECTABLE; INJECTION							
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N65122 001	NOV 29, 2002	NOV	NEWA	
AP		EQ 40MG BASE/ML	N65122 002	NOV 29, 2002	NOV	NEWA	
TOBRAMYCIN (PHARMACY BULK)							
AP	AM PHARM PARTNERS	EQ 40MG BASE/ML	N65120 001	NOV 29, 2002	NOV	NEWA	
TOBRAMYCIN SULFATE							
	@ ASTRAZENECA	EQ 40MG BASE/ML	N63120 001	OCT 31, 1994	FEB	DISC	
	@	EQ 40MG BASE/ML	N63122 001	OCT 31, 1994	JAN	DISC	
TOLAZOLINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
PRISCOLINE							
	@ NOVARTIS	25MG/ML	N06403 005	FEB 22, 1985	JUN	DISC	

TOPIRAMATE							
TABLET; ORAL							
TOPAMAX							
+	JOHNSON AND JOHNSON	25MG	N20505 004	DEC 24, 1996	JAN	CAHN
@		50MG	N20505 005	DEC 24, 1996	JAN	CAHN
		100MG	N20505 001	DEC 24, 1996	JAN	CAHN
		200MG	N20505 002	DEC 24, 1996	JAN	CAHN
@		300MG	N20505 003	DEC 24, 1996	JAN	CAHN
@		400MG	N20505 006	DEC 24, 1996	JAN	CAHN
TORSEMIDE							
TABLET; ORAL							
DEMADEX							
AB	ROCHE	5MG	N20136 001	AUG 23, 1993	MAY	CFTG
AB		10MG	N20136 002	AUG 23, 1993	MAY	CFTG
AB +		20MG	N20136 003	AUG 23, 1993	MAY	CFTG
AB		100MG	N20136 004	AUG 23, 1993	MAY	CFTG
TORSEMIDE							
AB	TEVA	5MG	N76110 001	MAY 14, 2002	MAY	NEWA
AB		10MG	N76110 002	MAY 14, 2002	MAY	NEWA
AB		20MG	N76110 003	MAY 14, 2002	MAY	NEWA
AB		100MG	N76110 004	MAY 14, 2002	MAY	NEWA
TRAMADOL HYDROCHLORIDE							
TABLET; ORAL							
TRAMADOL HCL							
AB	ABLE	50MG*	N75963 001	JUL 03, 2002	JUL	NEWA
AB	ALPHAPHARM	50MG*	N75980 001	NOV 21, 2002	NOV	NEWA
AB	ASTA	50MG*	N75974 001	JUL 12, 2002	JUL	NEWA
AB	CARACO	50MG*	N75964 001	JUN 19, 2002	JUN	NEWA
AB	COREPHARMA	50MG*	N76003 001	JUN 20, 2002	JUN	NEWA
AB	EON	50MG*	N75968 001	JUN 25, 2002	JUN	NEWA
AB	MALLINCKRODT	50MG*	N75983 001	JUN 25, 2002	JUN	NEWA
AB	MUTUAL PHARM	50MG*	N76100 001	JUN 20, 2002	JUN	NEWA
AB	MYLAN	50MG*	N75986 001	JUN 21, 2002	JUN	NEWA
AB	PUREPAC PHARM	50MG*	N75960 001	JUN 19, 2002	JUN	NEWA
AB	SIDMAK LABS	50MG*	N75982 001	JUL 01, 2002	JUL	NEWA
AB	TEVA	50MG*	N75977 001	JUN 19, 2002	JUN	NEWA
AB	TORPHARM	50MG*	N75981 001	JUL 10, 2002	JUL	NEWA
AB	WATSON LABS	50MG*	N75962 001	JUN 24, 2002	JUN	NEWA
ULTRAM							
+	JOHNSON AND JOHNSON	50MG	N20281 002	MAR 03, 1995	FEB	CAHN
@		100MG	N20281 001	MAR 03, 1995	FEB	CAHN
AB +	ORTHO MCNEIL PHARM	50MG	N20281 002	MAR 03, 1995	JUN	CTEC
TREPROSTINIL SODIUM							
INJECTABLE; SUBCUTANEOUS							
REMODULIN							
	UNITED THERAP	1MG/ML	N21272 001	MAY 21, 2002	MAY	NEWA
		2.5MG/ML	N21272 002	MAY 21, 2002	MAY	NEWA
		5MG/ML	N21272 003	MAY 21, 2002	MAY	NEWA
+		10MG/ML	N21272 004	MAY 21, 2002	MAY	NEWA

* SEE SECTION 1.4 OF INTRODUCTION

TRETINOIN							
GEL; TOPICAL							
RETIN-A							
AB + JOHNSON AND JOHNSON	0.01%	N17955	001		JUN	CFTG
RETIN-A MICRO							
+ JOHNSON AND JOHNSON	0.04%	N20475	002	MAY 10, 2002	SEP	NEWA
TRETINOIN							
AB SPEAR PHARMS	0.01%	N75589	001	JUN 11, 2002	JUN	NEWA
TRIAMCINOLONE							
TABLET; ORAL							
ARISTOCORT							
@ FUJISAWA HLTHCARE	1MG	N11161	009		JUL	DISC
@	2MG	N11161	004		JUL	DISC
@	8MG	N11161	011		JUL	DISC
KENACORT							
+ BRISTOL MYERS SQUIBB	8MG	N11283	010		AUG	CTEC
TRIAMCINOLONE ACETONIDE							
INJECTABLE; INJECTION							
KENALOG-10							
APOTHECON	10MG/ML	N12041	001		JUN	CRLD
KENALOG-40							
BP + APOTHECON	40MG/ML	N14901	001		JUN	CRLD
+	40MG/ML	N14901	001		SEP	CTEC
TRIAMCINOLONE ACETONIDE							
@ PARNELL	3MG/ML	N19503	001	OCT 16, 1987	JUN	DISC
@ STERIS	40MG/ML	N85825	001		SEP	DISC
SPRAY, METERED; NASAL							
TRI-NASAL							
@ MURO	0.05MG/SPRAY	N20120	001	FEB 04, 2000	JUN	DISC
TRIAMCINOLONE DIACETATE							
INJECTABLE; INJECTION							
ARISTOCORT							
+ FUJISAWA HLTHCARE	25MG/ML	N11685	003		OCT	CAHN
+	40MG/ML	N12802	001		OCT	CAHN
+ LEDERLE	40MG/ML	N12802	001		SEP	CTEC
TRIAMCINOLONE DIACETATE							
@ STERIS	40MG/ML	N84072	001		SEP	DISC
SYRUP; ORAL							
ARISTOCORT							
@ FUJISAWA HLTHCARE	2MG/5ML	N11960	004		JUL	DISC
TRIAMCINOLONE HEXACETONIDE							
INJECTABLE; INJECTION							
ARISTOSPAN							
+ FUJISAWA HLTHCARE	5MG/ML	N16466	001		OCT	CAHN
+	20MG/ML	N16466	002		OCT	CAHN

TRIFLUPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
VESPRIN
@ APOTHECON 10MG/ML N11325 004 JUN DISC
@ 20MG/ML N11325 001 JUN DISC

TRILOSTANE
CAPSULE; ORAL
MODRASTANE
@ BIOENVISION 30MG N18719 002 DEC 31, 1984 JUN CAHN
@ 60MG N18719 001 DEC 31, 1984 JUN CAHN

TRIMETHADIONE
CAPSULE; ORAL
TRIDIONE
@ ABBOTT 300MG N05856 005 JUN DISC
SOLUTION; ORAL
@ ABBOTT 200MG/5ML N05856 002 JUN DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE
CAPSULE; ORAL
TIGAN
+ KING PHARMS 300MG N17531 006 DEC 13, 2001 JAN NEWA
INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL
@ STERIS 100MG/ML N87939 001 DEC 28, 1982 FEB DISC

TRIMETHOPRIM
TABLET; ORAL
TRIMPEX
@ ROCHE 100MG N17952 001 AUG DISC

TRIOXSALEN
TABLET; ORAL
TRISORALEN
@ ICN 5MG N12697 001 JUN DISC

TRIPELENNAMINE CITRATE
ELIXIR; ORAL
PBZ
@ NOVARTIS EQ 25MG HCL/5ML N05914 004 JUN DISC

TRIPELENNAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
PBZ-SR
@ NOVARTIS 100MG N10533 001 JUN DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
TABLET; VAGINAL
SULTRIN
@ ORTHO MCNEIL PHARM 184MG;143.75MG;172.5MG N05794 002 JUN DISC

UREA, C-13
FOR SOLUTION; ORAL
PYLORI-CHEK BREATH TEST

@	ALIMENTERICS	100MG/VIAL	N20900	001	FEB 04, 1999	JUL	DISC

UROFOLLITROPIN
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE

BX	+ FERRING	75 IU/VIAL	N21289	001	MAY 06, 2002	MAY	NEWA

INJECTABLE; SUBCUTANEOUS
FERTINEX

BX	+ SERONO	75 IU/AMP	N19415	005	AUG 23, 1996	MAY	CTEC
	@	150 IU/AMP	N19415	004	AUG 23, 1996	JUN	DISC

URSODIOL
CAPSULE; ORAL
ACTIGALL

	@ WATSON PHARMS	150MG	N19594	001	DEC 31, 1987	FEB	CAHN
AB	+	300MG	N19594	002	DEC 31, 1987	FEB	CAHN

VALACYCLOVIR HYDROCHLORIDE
TABLET; ORAL
VALTREX

	@ GLAXOSMITHKLINE	EQ 500MG BASE	N20487	001	JUN 23, 1995	MAR	DISC
	@	EQ 1GM BASE	N20487	002	JUN 23, 1995	MAR	DISC

VALPROATE SODIUM
INJECTABLE; INJECTION
DEPACON

AP	+ ABBOTT	EQ 100MG BASE/ML	N20593	001	DEC 30, 1996	NOV	CFTG

VALPROATE SODIUM

AP	BEDFORD	EQ 100MG BASE/ML	N76295	001	NOV 14, 2002	NOV	NEWA

VALSARTAN
CAPSULE; ORAL
DIOVAN

	@ NOVARTIS	80MG	N20665	001	DEC 23, 1996	JUN	DISC
	@	160MG	N20665	002	DEC 23, 1996	JUN	DISC

VECURONIUM BROMIDE
INJECTABLE; INJECTION
NORCURON

	@ ORGANON	20MG/VIAL	N18776	003	JAN 03, 1992	JUN	DISC

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

	WYETH AYERST	EQ 37.5MG BASE	N20699	001	OCT 20, 1997	MAY	CRLD
		EQ 150MG BASE	N20699	004	OCT 20, 1997	MAY	CRLD

VERAPAMIL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

AB	+	ELAN DRUG	120MG	N19614 001	MAY 29, 1990	APR	CAHN
AB	+		180MG	N19614 003	JAN 09, 1992	APR	CAHN
AB	+		240MG	N19614 002	MAY 29, 1990	APR	CAHN
	+		360MG	N19614 004	MAY 10, 1996	APR	CAHN

VINCRISTINE SULFATE
INJECTABLE; INJECTION
VINCRISTINE SULFATE

>A>	+	AM PHARM PARTNERS	1MG/ML	N76296 001	DEC 20, 2002	DEC	NEWA

VITAMIN A PALMITATE
INJECTABLE; INJECTION
AQUASOL A

	+	AAIPHARMA	EQ 50,000 UNITS BASE/ML	N06823 001		JUL	CAHN

VORICONAZOLE
INJECTABLE; IV (INFUSION)
VFEND

	+	PFIZER	200MG/VIAL	N21267 001	MAY 24, 2002	MAY	NEWA

TABLET; ORAL

		PFIZER	50MG	N21266 001	MAY 24, 2002	MAY	NEWA
	+		200MG	N21266 002	MAY 24, 2002	MAY	NEWA

XENON, XE-127
GAS; INHALATION
XENON XE 127

	@	MALLINCKRODT	5mCi/VIAL	N18536 001	OCT 01, 1982	JUN	DISC
	@		10mCi/VIAL	N18536 002	OCT 01, 1982	JUN	DISC

XYLOSE
POWDER; ORAL
XYLOSE

	@	LYNE	25GM/BOT	N18856 001	MAR 26, 1987	JUL	DISC

ZILEUTON
TABLET; ORAL
ZYFLO

	+	ABBOTT	300MG	N20471 001	DEC 09, 1996	JUN	CRLD
	@		300MG	N20471 001	DEC 09, 1996	JUL	DISC

ZIPRASIDONE MESYLATE
INJECTABLE; INTRAMUSCULAR
GEODON

	+	PFIZER	EQ 20MG BASE/ML	N20919 001	JUN 21, 2002	JUN	NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT

	+	ASTRAZENECA	5MG	N21231 002	SEP 17, 2001	JUN	NEWA

ACETAMINOPHEN
TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN
COREPHARMA 650MG N76200 001 MAR 19, 2002 MAR NEWA

CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL
CHLORAPREP ONE-STEP SEPP
\+ BECKLOFF 2% N21555 001 OCT 07, 2002 OCT NEWA
SPONGE; TOPICAL
E-Z SCRUB
@ BECTON DICKINSON 4% N73416 001 MAR 14, 2000 SEP DISC

>A> CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
>A> TABLET; ORAL
>A> ADVIL ALLERGY SINUS
>A> \+ WYETH CONS 2MG;200MG;30MG N21441 001 DEC 19, 2002 DEC NEWA

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CONTAC 12 HOUR
@ GLAXOSMITHKLINE 8MG;75MG N18099 001 JAN DISC
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE
@ CENT PHARMS 8MG;75MG N18809 001 MAY 07, 1984 FEB DISC

CIMETIDINE
SUSPENSION; ORAL
TAGAMET HB 200
@ GLAXOSMITHKLINE 200MG/20ML N20951 001 JUL 09, 1999 SEP DISC
TABLET; ORAL
CIMETIDINE
TORPHARM 200MG N74948 002 JUL 26, 2002 JUL NEWA

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE
EON 10MG N76101 001 OCT 21, 2002 OCT NEWA
TORPHARM 10MG N75610 001 MAR 12, 2002 MAR NEWA

GUAIFENESIN
TABLET, EXTENDED RELEASE; ORAL
MUCINEX
\+ ADAMS LABS 600MG N21282 001 JUL 12, 2002 NOV CRLD
600MG N21282 001 JUL 12, 2002 JUL NEWA

IBUPROFEN
CAPSULE; ORAL
IBUPROFEN
BANNER PHARMACAPS 200MG N21472 001 OCT 18, 2002 OCT NEWA
TABLET; ORAL
PERRIGO 200MG N75995 001 MAR 14, 2002 MAR NEWA

	IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	ADVIL COLD AND SINUS						
	WYETH CONS	200MG;30MG	N21374 001	MAY 30, 2002	MAY	NEWA
	SUSPENSION; ORAL						
	CHILDREN'S ADVIL COLD						
	WYETH CONS	100MG/5ML;15MG/5ML	N21373 001	APR 18, 2002	APR	NEWA
	TABLET; ORAL						
	IBUPROFEN AND PSEUDOEPHEDRINE HCL						
	PHARM FORM	200MG;30MG	N75588 001	APR 08, 2002	APR	NEWA
	INSULIN PURIFIED PORK						
	INJECTABLE; INJECTION						
	REGULAR PURIFIED PORK INSULIN						
	@ NOVO NORDISK	100 UNITS/ML	N18381 001		FEB	DISC
	INSULIN RECOMBINANT HUMAN						
	INJECTABLE; INJECTION						
	VELOSULIN BR						
+	NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999	JUN	CMS2
	INSULIN SUSP ISOPHANE PURIFIED PORK						
	INJECTABLE; INJECTION						
	NPH PURIFIED PORK ISOPHANE INSULIN						
	@ NOVO NORDISK	100 UNITS/ML	N18623 001		FEB	DISC
	INSULIN ZINC SUSP PURIFIED PORK						
	INJECTABLE; INJECTION						
	LENTE						
	@ NOVO NORDISK	100 UNITS/ML	N18383 001		FEB	DISC
	KETOPROFEN						
	TABLET; ORAL						
	KETOPROFEN						
	PERRIGO	12.5MG	N75364 001	FEB 07, 2002	FEB	NEWA
	LOPERAMIDE HYDROCHLORIDE; SIMETHICONE						
	TABLET, CHEWABLE; ORAL						
	LOPERAMIDE HCL AND SIMETHICONE						
	PERRIGO	2MG;125MG	N76029 001	AUG 30, 2002	AUG	NEWA
>A>	LORATADINE						
>A>	TABLET, ORALLY DISINTEGRATING; ORAL						
>A>	ALAVERT						
>A>	+ WYETH CONS	10MG	N21375 001	DEC 19, 2002	DEC	NEWA
	MINOXIDIL						
	SOLUTION; TOPICAL						
	MINOXIDIL EXTRA STRENGTH (FOR MEN)						
	CLAY PARK	5%	N75737 001	MAR 15, 2002	MAR	NEWA
	NOVEX	5%	N75839 001	OCT 01, 2001	MAR	CTNA

	NAPROXEN SODIUM						
	TABLET; ORAL						
	NAPROXEN SODIUM						
	DR REDDYS LABS INC	EQ 200MG BASE	N75168 001	JUL 28, 1998	AUG	CAHN
	NICOTINE POLACRILEX						
	TROCHE/LOZENGE; ORAL						
	COMMIT						
	GLAXOSMITHKLINE CONS	2MG	N21330 001	OCT 31, 2002	OCT	NEWA
+		4MG	N21330 002	OCT 31, 2002	OCT	NEWA
	POTASSIUM IODIDE						
	TABLET; ORAL						
	THYROSAFE						
>D>	R R REGISTRATIONS	65MG	N76350 001	SEP 10, 2002	DEC	CRLD
>A> +		65MG	N76350 001	SEP 10, 2002	DEC	CRLD
		65MG	N76350 001	SEP 10, 2002	SEP	NEWA
	PSEUDOEPHEDRINE HYDROCHLORIDE						
	TABLET, EXTENDED RELEASE; ORAL						
	SUDAFED 12 HOUR						
+	WARNER LAMBERT	120MG	N73585 001	OCT 31, 1991	MAY	CAHN
	RANITIDINE HYDROCHLORIDE						
	TABLET; ORAL						
	RANITIDINE						
	GENEVA PHARMS	EQ 75MG BASE	N75519 001	SEP 26, 2002	SEP	NEWA
	PERRIGO	EQ 75MG BASE	N76195 001	AUG 30, 2002	AUG	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER '02

NO DECEMBER 2002 APPROVALS

This data is provided to the Office of Generic Drugs from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List

November 2002

(December update not available)

albuterol	DD: 3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
	MA:		
allantoin Alwextin	DD: 11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East Lake Crystal MN 56055
	MA:		
antiangiogenic components extracted from marine cartilage Neovastat (AE-941)	DD: 10/16/2002	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Clinical & Regulatory Affairs 1405 boul. Du Parc - Technologique Quebec G1P 4P5 CANADA
	MA:		
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype Mylovenge	DD: 4/18/2002	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue Seattle WA 98121
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 7/11/2002	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
autologous tumor-derived gp96 heat shock protein-peptide complex Oncophage	DD: 5/10/2002	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
	MA:		
aztreonam	DD: 3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
	MA:		
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
	MA:		

Orphan Products Designations and Approvals List
November 2002

capsaicin	DD: 10/23/2002 MA:	Treatment of erythromelalgia	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester	DD: 1/15/2002 MA:	Management of cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road P.O. Box 368 Ridgefield CT 06877
cells produced using the AastromReplicelle System and SC-I Therapy Kit	DD: 7/10/2002 MA:	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
clofarabine Clofarex	DD: 2/7/2002 MA:	Treatment of acute lymphoblastic leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
clofarabine Clofarex	DD: 3/14/2002 MA:	Treatment of acute myelogenous leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
creatine Creapure	DD: 2/12/2002 MA:	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
D-peptide of the sequence AKRHHGYKRKFH - NH2 PulmaDex	DD: 10/23/2002 MA:	Treatment of cystic fibrosis	Demegen, Inc. 1051 Brinton Road Pittsburgh PA 15221
decitabine	DD: 9/9/2002 MA:	Treatment of sickle cell anemia	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
Deferasirox	DD: 11/21/2002 MA:	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation 59 Route 10 East Hanover NJ 07936-1080
DHA-paclitaxel Taxoprexin	DD: 10/10/2002 MA:	Treatment of metastatic malignant melanoma	Protarga, Inc. 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406

Orphan Products Designations and Approvals List
November 2002

G17DT Immunogen	DD: 7/18/2002 MA:	Treatment of gastric cancer	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
G17DT Immunogen	DD: 7/10/2002 MA:	Treatment of adenocarcinoma of the pancreas	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
genetically engineered herpes simplex virus (G207)	DD: 4/29/2002 MA:	Tretament of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121
heat killed mycobacterium with immunomodulator CADI Mw	DD: 11/21/2002 MA:	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
Hepatitis C virus immune globulin (human)	DD: 11/14/2002 MA:	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
homoharringtonine	DD: 2/8/2002 MA:	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
human anti-transforming growth factor beta 1 monoclonal antibody	DD: 1/11/2002 MA:	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
human gammaglobulin	DD: 9/16/2002 MA:	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Protein Therapeutics, Inc. 9040 S. Rita Road Suite 1100 Tucson AZ 85747
hyaluronic acid	DD: 3/19/2002 MA:	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
I(131)-TM-601 (chlorotoxin)	DD: 2/14/2002 MA:	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
infliximab Remicade	DD: 10/23/2002 MA:	Treatment of juvenile rheumatoid arthritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307

Orphan Products Designations and Approvals List
November 2002

inolimomab Leukotac	DD: 10/23/2002 MA:	Treatment of graft versus host disease	Opi 6, Chemin de l'industrie 69570 DARDILLY - France
interferon gamma-1b Actimmune	DD: 9/12/2002 MA:	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	DD: 1/15/2002 MA:	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	DD: 1/15/2002 MA:	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877
lintuzumab Zamyl	DD: 9/9/2002 MA:	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
lipase, amylase, and protease TheraCLEC-Total	DD: 1/23/2002 MA:	Treatment of pancreatic insufficiency	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139
meloxicam Mobic	DD: 11/22/2002 MA:	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road P. O. Box 368 Ridgefield CT 06877-0368
methylbicyclone	DD: 11/14/2002 MA:	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002 MA:	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup Denmark
N-acetylcysteine	DD: 9/9/2002 MA:	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Dallas TX 75390-9151
Natural human lymphoblastoid interferon-alpha	DD: 11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.

Orphan Products Designations and Approvals List
November 2002

	MA:		800 West 9th Avenue Amarillo TX 79101
nitazoxanide Cryptaz	DD: 2/14/2002 MA:	Treatment of intestinal giardiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A Aerugen	DD: 5/16/2002 MA:	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson" 70 avenue du General de Gaulle, 92046 Paris La Defense France
phenylephrine	DD: 2/14/2002 MA:	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford United Kingdom WD25 7SA
polyinosinic-polycytidilic acid Poly-ICLC	DD: 11/19/2002 MA:	Treatment for orthopox virus infections	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
polyinosinic-polycytidilic acid Poly-ICLC	DD: 8/2/2002 MA:	As an adjuvant to smallpox vaccination	Ribopharm, Inc. 3203 Cleveland Ave., NW Washington DC 20008-3450
recombinant human endostatin protein	DD: 2/21/2002 MA:	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 SomatoKine	DD: 5/17/2002 MA:	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Insmed, Inc. 4851 Lake Brook Drive Glen Allen VA 23060
recombinant human monoclonal antibody to hsp90 Mycograb	DD: 9/16/2002 MA:	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., Manchester M139WL, UK
recombinant human porphobilinogen deaminase	DD: 9/9/2002 MA:	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark
retroviral gamma-c cDNA containing vector	DD: 4/29/2002 MA:	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210

Orphan Products Designations and Approvals List
November 2002

rituximab Rituxan	DD: 3/12/2002 MA:	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
rubitecan	DD: 7/17/2002 MA:	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002 MA:	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
SS1(dsFv)-PE38	DD: 2/11/2002 MA:	Treatment of epithelial ovarian cancer	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
SS1(dsFv)-PE38	DD: 2/11/2002 MA:	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide Oncomun	DD: 6/5/2002 MA:	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensberg Germany
tinidazole	DD: 4/18/2002 MA:	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
tirapazamine	DD: 10/23/2002 MA:	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
toralizumab	DD: 3/14/2002 MA:	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 2002 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6417191	MAR 28, 2016	U-248		
			6417191*PED	SEP 28, 2016	U-248		
>ADD>	021478 001	ACYCLOVIR;ZOVIRAX				NDF	DEC 30, 2005
	021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	U-470	NCE	SEP 20, 2007
			4808716	APR 25, 2006			
			5663159	SEP 02, 2014	U-470		
			4724233	APR 21, 2006	U-470		
>ADD>	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5695743	JUL 06, 2010	U-491		
			6352684	NOV 28, 2009			
	021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013			
	021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013			
	021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
	021212 002	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
	020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003		NS	JUN 20, 2005
			4572909	JUL 31, 2006			
			4879303	MAR 25, 2007			
			6162802	DEC 19, 2017	U-367		
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018			
	021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	NOV 27, 2018		NDF	OCT 11, 2004
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018			
	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	NOV 27, 2018		NDF	OCT 11, 2004
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018			
	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	NOV 27, 2018		NDF	OCT 11, 2004
	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020			
	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020			
	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020			
	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020			
	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020			
	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020			
	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020			
	020541 001	ANASTROZOLE;ARIMIDEX				I-363	SEP 05, 2005
	020883 001	ARGATROBAN;ARGATROBAN	5925760	AUG 04, 2017		I-352	APR 03, 2005
	021436 001	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
	021436 002	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
	021436 003	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
	021436 004	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
	021436 005	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
	021436 006	ARIPIPRAZOLE;ABILIFY				NCE	NOV 15, 2007
>ADD>	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
>ADD>	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
>ADD>	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
>ADD>	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
>ADD>	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007
>ADD>	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA				NCE	NOV 26, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020702 001	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
						I-350	OCT 18, 2005
						PED	APR 18, 2006
	020702 002	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
						I-350	OCT 18, 2005
						PED	APR 18, 2006
	020702 003	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
						I-350	OCT 18, 2005
						PED	APR 18, 2006
	020702 004	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
						I-350	OCT 18, 2005
						PED	APR 18, 2006
>ADD>	021470 001	AZELAIC ACID;FINACEA	4713394	JAN 17, 2006	U-492	NDF	DEC 24, 2005
	020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
	020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
>ADD>	020934 001	BETAMETHASONE VALERATE;LUXIQ	6126920	MAR 01, 2016	U-484		
	021055 001	BEXAROTENE;TARGRETIN	5962731	OCT 05, 2016	U-475		
	021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21, 2012	U-446		
	020873 001	BIVALIRUDIN;ANGIOMAX	5196404	MAR 23, 2010			
	020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6465464	JUN 28, 2015	U-394	NPP	DEC 20, 2004
			6465464*PED	DEC 28, 2015	U-394	PED	JUN 20, 2005
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6465464	JUN 28, 2015	U-395	NPP	DEC 20, 2004
			6465464*PED	DEC 28, 2015	U-395	PED	JUN 20, 2005
	021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
			5643602*PED	JAN 01, 2015		PED	APR 02, 2005
	020441 002	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
			4907583	MAR 13, 2007			
			4668218*PED	OCT 11, 2006			
			4907583*PED	SEP 13, 2007			
	020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
			4907583	MAR 13, 2007			
			4668218*PED	OCT 11, 2006			
			4907583*PED	SEP 13, 2007			
	020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
			4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
	020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
			4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
	020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
			4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
	020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
			6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
						PED	APR 26, 2005
						PED	APR 01, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020746 002	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 002	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020358 004	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
		5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2002
		5559148*PED	NOV 24, 2015	U-264	PED	AUG 04, 2006
021408 001	BUTENAFINE HYDROCHLORIDE;MENTAX-TC				NP	OCT 17, 2005
019881 001	BUTOCONAZOLE NITRATE;GYNAZOLE-1	5266329	NOV 30, 2010	U-457		
		4551148	NOV 05, 2002			
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		
	021222 001	CEFDITOREN PIVOXIL;SPECTRACEF	4839350	JUN 13, 2006		I-364	AUG 21, 2005
			4918068	JUN 13, 2006			
			5958915	OCT 14, 2016			
	020998 003	CELECOXIB;CELEBREX	5466823	NOV 30, 2013		I-284	DEC 23, 2002
			5563165	NOV 30, 2013		NCE	DEC 31, 2003
			5760068	JUN 02, 2015	U-19	I-338	OCT 17, 2004
			5760068	JUN 02, 2015	U-299		
			5972986	OCT 14, 2017	U-299		
	020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
	019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
			4525358*PED	DEC 25, 2007		PED	APR 21, 2006
	019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
			4525358*PED	DEC 25, 2007		PED	APR 21, 2006
	020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
			4525358*PED	DEC 25, 2007		PED	APR 21, 2006
	021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP				NP	OCT 07, 2005
>ADD>	021441 001	CHLORPHENIRAMINE MALEATE;ADVIL ALLERGY SINUS				NP	DEC 19, 2005
>ADD>	019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
>ADD>			4670444*PED	JUN 09, 2004			
>ADD>	020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U-223		
>ADD>			4670444*PED	JUN 09, 2004	U-223		
>ADD>	020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003			
>ADD>			4844902	FEB 11, 2008			
>ADD>			4670444*PED	JUN 09, 2004			
>ADD>			4844902*PED	AUG 11, 2008			
	020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
						PED	JAN 17, 2004
	020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
						PED	JAN 17, 2004
	020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
						PED	JAN 17, 2004
	021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
						PED	JAN 17, 2004
>ADD>	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM	6126920	MAR 01, 2016	U-484	I-374	DEC 20, 2005
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6429210	JUN 10, 2019		I-349	FEB 27, 2005
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10, 2014			
	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10, 2014			
>ADD>	020287 004	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021165 001	DESLORATADINE;CLARINEX	6100274	JUL 07, 2019			
	021312 001	DESLORATADINE;CLARINEX				NCE	DEC 21, 2006
	075863 001	DESOGESTREL;KARIVA				PC	JUN 04, 2002
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021191 001	DIMYRISTOYL LECITHIN;IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
			6280705	JUL 30, 2013			
			6287539	JUL 30, 2013			
			5605673	FEB 25, 2014			
			5626833	MAY 16, 2014	U-458		
			5639443	JUN 17, 2014			
			5695741	DEC 09, 2014	U-458		
			5720938	FEB 24, 2015			
			5798091	AUG 25, 2015	U-458		
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6419953	DEC 18, 2018			
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
			4988731	JAN 29, 2008			
>ADD>	020449 001	DOCETAXEL;TAXOTERE				I-379	NOV 27, 2005
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-278		
			5707980	AUG 17, 2010	U-278		
			5861386	AUG 02, 2008	U-278		
			5869473	AUG 02, 2008	U-278		
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-321		
			5707980	AUG 17, 2010	U-321		
	021098 001	DROSPIRENONE;YASMIN	5569652	OCT 29, 2013	U-1		
	021319 001	DUTASTERIDE;AVODART	5565467	OCT 15, 2013			
			5846976	DEC 08, 2015	U-476		
			5998427	OCT 15, 2013	U-477		
	020972 001	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
	020972 002	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
	020972 003	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
	021360 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5633169	SEP 02, 2014	U-248		
			5811423	AUG 07, 2012	U-256		
	021360 002	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-248		
			5811423	AUG 07, 2012	U-256		
>ADD>	021016 001	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
>ADD>	021016 002	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
	020796 001	ENTACAPONE;COMTAN	5446194	AUG 29, 2012			
			5135950	OCT 31, 2010			
			4963590	NOV 27, 2007			
			5112861	MAY 12, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021437 001	EPLERENONE;INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
			6410054	DEC 08, 2019	U-3		
			6410524	NOV 05, 2019	U-467		
			4559332	APR 09, 2004			
>ADD>	021437 002	EPLERENONE;INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
			6410054	DEC 08, 2019	U-3		
			6410524	NOV 05, 2019	U-467		
			4559332	APR 09, 2004			
>ADD>	021437 003	EPLERENONE;INSPRA	6495165	DEC 08, 2019	U-3	NCE	SEP 27, 2007
			6410054	DEC 08, 2019	U-3		
			6410524	NOV 05, 2019	U-467		
			4559332	APR 09, 2004			
	020738 006	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	NCE	DEC 22, 2002
			5656650	AUG 12, 2014	U-3		
	021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5656650	AUG 12, 2014	U-3		
	021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5656650	AUG 12, 2014	U-3		
	020718 001	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
			5747447	MAY 05, 2015			
	020718 002	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
			5747447	MAY 05, 2015			
	021323 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
			RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
						I-366	AUG 29, 2005
						PED	MAR 01, 2006
	021323 002	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
			RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
						I-366	AUG 29, 2005
						PED	MAR 01, 2006
	021323 003	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
			RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
						I-366	AUG 29, 2005
						PED	MAR 01, 2006
>ADD>	021365 001	ESCITALOPRAM OXALATE;LEXAPRO				NP	AUG 14, 2005
>ADD>						I-366	AUG 29, 2005
>ADD>						PED	FEB 14, 2006
>ADD>						PED	MAR 01, 2006
>ADD>	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
>ADD>			5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
>ADD>			4786505	APR 20, 2007	U-373		
>ADD>			4853230	APR 20, 2007	U-373		
>ADD>			5714504	FEB 03, 2015	U-373		
>ADD>			5877192	MAY 27, 2014	U-373		
>ADD>			5690960	NOV 25, 2014	U-373		
>ADD>			6166213	OCT 09, 2018			
>ADD>			6191148	OCT 09, 2018			
>ADD>			6369085	MAY 25, 2018			
>ADD>			6428810	NOV 03, 2019	U-469		
>ADD>			4738974*PED	OCT 19, 2005	U-373		
>ADD>			4786505*PED	OCT 20, 2007	U-373		
>ADD>			4853230*PED	OCT 20, 2007	U-373		
>ADD>			5690960*PED	MAY 25, 2015	U-373		
>ADD>			5714504*PED	AUG 03, 2015	U-373		
>ADD>			5877192*PED	NOV 27, 2014	U-373		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>			5900424*PED	NOV 04, 2016	U-373		
>ADD>			6147103	OCT 09, 2018			
>ADD>			6147103*PED	APR 09, 2019			
>ADD>			6166213*PED	APR 09, 2019			
>ADD>			6191148*PED	APR 09, 2019			
>ADD>			6369085*PED	NOV 25, 2018			
>ADD>			6428810*PED	MAY 03, 2020	U-469		
>ADD>	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U-373	NP	FEB 20, 2004
>ADD>			5900424	MAY 04, 2016	U-373	PED	AUG 20, 2004
>ADD>			4786505	APR 20, 2007	U-373		
>ADD>			4853230	APR 20, 2007	U-373		
>ADD>			5714504	FEB 03, 2015	U-373		
>ADD>			5877192	MAY 27, 2014	U-373		
>ADD>			5690960	NOV 25, 2014	U-373		
>ADD>			6147103	OCT 09, 2018			
>ADD>			6166213	OCT 09, 2018			
>ADD>			6191148	OCT 09, 2018			
>ADD>			6369085	MAY 25, 2018			
>ADD>			6428810	NOV 03, 2019	U-469		
>ADD>			4738974*PED	OCT 19, 2005	U-373		
>ADD>			4786505*PED	OCT 20, 2007	U-373		
>ADD>			4853230*PED	OCT 20, 2007	U-373		
>ADD>			5690960*PED	MAY 25, 2015	U-373		
>ADD>			5714504*PED	AUG 03, 2015	U-373		
>ADD>			5877192*PED	NOV 27, 2014	U-373		
>ADD>			5900424*PED	NOV 04, 2016	U-373		
>ADD>			6147103*PED	APR 09, 2019			
>ADD>			6166213*PED	APR 09, 2019			
>ADD>			6191148*PED	APR 09, 2019			
>ADD>			6369085*PED	NOV 25, 2018			
>ADD>			6428810*PED	MAY 03, 2020	U-469		
	020655 001	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 002	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 003	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			
	020538 005	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 006	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 007	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 008	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020992 001	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		I-359	JUN 21, 2005
	021187 001	ETHINYL ESTRADIOL;NUVARING	5989581	APR 08, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021241 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN LO	4616006	SEP 26, 2003	U-112	NP	AUG 22, 2005
			6214815	JUN 09, 2019	U-112		
			4530839	SEP 26, 2003	U-112		
			4544554	SEP 26, 2003	U-112		
			4628051	SEP 26, 2003	U-112		
	021445 001	EZETIMIBE;ZETIA	5846966	SEP 21, 2013	U-474	NCE	OCT 25, 2007
			RE37721	JUN 16, 2015	U-473		
	075753 002	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	075753 003	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6399632	MAY 11, 2012	U-468		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6399632	MAY 11, 2012	U-468		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6399632	MAY 11, 2012	U-468		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6399632	MAY 11, 2012	U-468		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6399632	MAY 11, 2012	U-468		
	075442 001	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 002	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 003	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
>ADD>						NPP	JAN 03, 2006
>ADD>						PED	JUL 03, 2006
	018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
>ADD>						NPP	JAN 03, 2006
>ADD>						PED	JUL 03, 2006
	018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
>ADD>						NPP	JAN 03, 2006
>ADD>						PED	JUL 03, 2006
	018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
>ADD>						NPP	JAN 03, 2006
>ADD>						PED	JUL 03, 2006
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC				I-362	JUL 29, 2005
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				D-75	JUN 12, 2005
	018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM				D-75	JUN 12, 2005
	020121 001	FLUTICASONE PROPIONATE;FLONASE				D-76	MAY 23, 2005
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	6242003	APR 13, 2020			
	021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003			
	021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
	020235 001	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 002	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 003	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020882 001	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	020882 002	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	021129 001	GABAPENTIN;NEURONTIN	6054482	APR 25, 2017		I-354	MAY 24, 2005
			6054482*PED	OCT 25, 2017			
	020131 001	GADOTERIDOL;PROHANCE	5474756	DEC 12, 2012	U-480		
			5846519	DEC 08, 2015			
			6143274	DEC 12, 2012	U-480		
	021061 001	GATIFLOXACIN;TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
	021061 002	GATIFLOXACIN;TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
	021062 001	GATIFLOXACIN;TEQUIN	5880283	DEC 05, 2015			
	021062 002	GATIFLOXACIN;TEQUIN	5880283	DEC 05, 2015			
>ADD>	021062 003	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
>ADD>			5880283	DEC 05, 2015		D-69	OCT 12, 2004
>ADD>	021062 004	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
>ADD>			5880283	DEC 05, 2015		D-69	OCT 12, 2004
	020622 001	GLATIRAMER ACETATE;COPAXONE	6342476	MAY 24, 2014	U-441		
			6362161	MAY 24, 2014	U-441		
	021460 001	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
	021460 002	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
	021460 003	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
	021178 001	GLYBURIDE;GLUCOVANCE				I-368	SEP 30, 2005
	021178 002	GLYBURIDE;GLUCOVANCE				I-368	SEP 30, 2005
	021178 003	GLYBURIDE;GLUCOVANCE				I-368	SEP 30, 2005
	020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-369	AUG 16, 2005
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-369	AUG 16, 2005
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 20, 2007	U-105		
>ADD>	021282 001	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U-489		
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
			4743450	FEB 24, 2007		PED	JUN 28, 2003
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
			4344949	OCT 03, 2002	U-3		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
	020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
	020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009			
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
	020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6348216	JUN 10, 2017			
	021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
			5071643*PED	JUN 10, 2009			
			5360615	DEC 10, 2008			
			5360615*PED	JUN 10, 2009			
	021373 001	IBUPROFEN;CHILDREN'S ADVIL COL				NP	AUG 01, 2003
						PED	FEB 01, 2004
	075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
	075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
>ADD>	021335 001	IMATINIB MESYLATE;GLEEVEC				I-376	DEC 20, 2005
>ADD>	021335 002	IMATINIB MESYLATE;GLEEVEC				I-376	DEC 20, 2005
	020986 001	INSULIN ASPART;NOVOLOG	5618913	APR 08, 2014			
			5866538	JUN 20, 2017			
	021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5547930	SEP 28, 2013			
			5834422	SEP 28, 2013	U-471		
			5948751	JUN 19, 2017			
			5840680	SEP 28, 2013	U-471		
			5618913	APR 08, 2014			
>ADD>	021425 001	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005			
>ADD>	021425 002	IOPROMIDE;ULTRAVIST (PHARMACY	4364921	MAR 06, 2005			
	019710 003	IOVERSOL;OPTIRAY 160	4396598	DEC 30, 2002	U-31		
	019710 002	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002	U-30		
			4396598	DEC 30, 2002	U-29		
	019710 004	IOVERSOL;OPTIRAY 300	4396598	DEC 30, 2002	U-29		
			4396598	DEC 30, 2002	U-30		
			4396598	DEC 30, 2002	U-464		
	019710 001	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002	U-28		
			4396598	DEC 30, 2002	U-29		
			4396598	DEC 30, 2002	U-463		
	019710 005	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002	U-62		
			4396598	DEC 30, 2002	U-464		
			4396598	DEC 30, 2002	U-465		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	6403569	APR 28, 2020	U-449		
018662 002	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 003	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 004	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
020657 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019			
020966 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019			
019700 001	KETOROLAC TROMETHAMINE;ACULAR				M-16	FEB 08, 2005
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE				M-16	FEB 08, 2005
020564 001	LAMIVUDINE;EPIVIR				D-2	JUN 24, 2005
020564 003	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
		5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE;EPIVIR				D-2	JUN 24, 2005
020406 001	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452	M-12	JUL 31, 2005
020406 002	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452	M-12	JUL 31, 2005
021428 001	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
021428 002	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U-126		
		5013743	FEB 12, 2010	U-452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020597 001	LATANOPROST;XALATAN	6429226	SEP 06, 2009	U-260	I-375	DEC 20, 2005
	021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014			
			5733950	OCT 03, 2008			
			5739176	OCT 03, 2008			
			4938763	OCT 03, 2008			
			5278201	JAN 11, 2011			
			5324519	OCT 20, 2011			
	021379 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014		NP	JUL 24, 2005
			5733950	OCT 03, 2008			
			5739176	OCT 03, 2008			
			4938763	OCT 03, 2008			
			5278201	JAN 11, 2011			
			5324519	OCT 20, 2011			
	021088 001	LEUPROLIDE ACETATE;VIADUR	6375978	DEC 17, 2018			
			6395292	JAN 30, 2017			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6451289	MAR 21, 2021			
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	6451289	MAR 21, 2021			
	020837 003	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332	I-347	JAN 30, 2005
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
			6083993	JAN 05, 2010	U-332		
			6451289	MAR 21, 2021			
	020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2021	U-433		
			6429230	JAN 18, 2021	U-433		
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
						I-372	OCT 30, 2005
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
						I-372	OCT 30, 2005
	020634 003	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
						I-357	APR 08, 2003
						I-372	OCT 30, 2005
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
						I-372	OCT 30, 2005
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
						I-372	OCT 30, 2005
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
						I-372	OCT 30, 2005
	021342 001	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 002	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 003	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 004	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 005	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 006	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
	021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
>ADD>	020612 001	LIDOCAINE;LIDODERM	5589180	MAR 05, 2016	U-485		
>ADD>			5441738	MAY 01, 2012	U-485		
>ADD>			5827529	JUN 10, 2011	U-486		
>ADD>			5709869	DEC 23, 2016	U-487		
>ADD>			5601838	MAY 18, 2010	U-488		
	021226 001	LOPINAVIR;KALETRA	6458818	NOV 07, 2017			
	020470 001	LORATADINE;CLARITIN-D 24 HOUR	5314697	OCT 23, 2012			
	020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009			
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
			6129930	SEP 20, 2013	U-448		
			6406715	OCT 31, 2017	U-450		
	021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
			6129930	SEP 20, 2013	U-448		
			6406715	OCT 31, 2017	U-450		
	021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
			6129930	SEP 20, 2013	U-448		
			6406715	OCT 31, 2017	U-450		
>ADD>	021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
			6080778	MAR 23, 2018	U-456		
>ADD>	021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
			6080778	MAR 23, 2018	U-456		
>ADD>	021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
			6080778	MAR 23, 2018	U-456		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
			6080778	MAR 23, 2018	U-456		
	019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005
	019643 003	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005
	019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005
	020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011			
	076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				PC	NOV 03, 2002
	020938 002	MELOXICAM;MOBIC				NCE	APR 13, 2005
	020922 001	MEQUINOL;SOLAGE	6353029	AUG 24, 2020			
>ADD>	020855 001	MESNA;MESNEX	5252341	JUL 16, 2011		NDF	MAR 21, 2005
>ADD>			5262169	JUL 16, 2011			
	013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
	013217 003	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
>ADD>	021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>			5741803	APR 21, 2015	U-493		
>ADD>			6288095	FEB 11, 2017	U-493		
>ADD>			5965584	JUN 19, 2016	U-493		
>ADD>			6166042	JUN 19, 2016	U-493		
>ADD>	021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>			5741803	APR 21, 2015	U-493		
>ADD>			6288095	FEB 11, 2017	U-493		
>ADD>			5965584	JUN 19, 2016	U-493		
>ADD>			6166042	JUN 19, 2016	U-493		
>ADD>	021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U-493		
>ADD>			5741803	APR 21, 2015	U-493		
>ADD>			6288095	FEB 11, 2017	U-493		
>ADD>			5965584	JUN 19, 2016	U-493		
>ADD>			6166042	JUN 19, 2016	U-493		
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018			
	021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801	JUL 12, 2002		NP	AUG 01, 2003
			4612008	SEP 16, 2003			
			4783337	SEP 16, 2003	U-372		
			5082668	SEP 16, 2003			
	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020			
	021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
			6228398	MAY 01, 2019	U-472		
	021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
			6228398	MAY 01, 2019	U-472		
	021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
			6228398	NOV 01, 2019	U-472		
>ADD>	019815 003	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
	020415 001	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 002	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 003	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	021208 001	MIRTAZAPINE;REMERON SOLTAB				M-18	APR 09, 2005
	021208 002	MIRTAZAPINE;REMERON SOLTAB				M-18	APR 09, 2005
	021208 003	MIRTAZAPINE;REMERON SOLTAB				M-18	APR 09, 2005
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX				I-360	JUL 17, 2005
						PED	JAN 17, 2006
>ADD>	020829 002	MONTELUKAST SODIUM;SINGULAIR				I-378	DEC 31, 2005
>ADD>	020830 001	MONTELUKAST SODIUM;SINGULAIR				I-378	DEC 31, 2005
>ADD>	020830 002	MONTELUKAST SODIUM;SINGULAIR				I-378	DEC 31, 2005
	021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012		NDF	JUL 26, 2005
			5565473*PED	AUG 03, 2012		PED	JAN 26, 2006
						NCE	FEB 20, 2003
						PED	AUG 20, 2003
>ADD>						I-378	DEC 31, 2005
	021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232		
	020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U-232		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
			5256664	APR 28, 2012			
			4338317*PED	SEP 16, 2003			
			5256664*PED	OCT 28, 2012			
	020778 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
	020779 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
	020381 001	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
	020381 002	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
	020381 003	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
	020381 004	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
	020381 005	NIACIN;NIASPAN TITRATION ST	6406715	OCT 31, 2017	U-450		
			6129930	SEP 20, 2013	U-354		
	021330 001	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
	021330 002	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
	020076 004	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 005	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 006	NICOTINE;HABITROL				D-71	NOV 12, 2002
>ADD>	020356 001	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD>	020356 002	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD>	020356 003	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
>ADD>	020356 004	NISOLDIPINE;SULAR	4703038	OCT 07, 2005	U-3		
	021498 001	NITAZOXANIDE;ALINIA				NCE	NOV 22, 2007
						ODE	NOV 22, 2009
>ADD>	021134 001	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021134 002	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
>ADD>	021134 003	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
	020555 001	NIZATIDINE;AXID AR	4375547	APR 12, 2002			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	6395292	JAN 30, 2017			
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	019810 001	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019		M-19	JUL 12, 2005
						PED	JAN 12, 2006
	019810 002	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019		M-19	JUL 12, 2005
						PED	JAN 12, 2006
	019810 003	OMEPRAZOLE;PRILOSEC	6166213	OCT 09, 2018		M-19	JUL 12, 2005
			6166213*PED	APR 09, 2019		PED	JAN 12, 2006
	020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009			
	021492 001	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
			5338874	APR 07, 2013			
			5290961	JAN 12, 2013			
	021492 002	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
			5338874	APR 07, 2013			
			5290961	JAN 12, 2013			
>ADD>	020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA				NE	OCT 17, 2005
	021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
			4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	5997903	DEC 07, 2016		I-356	APR 19, 2005
020987 002	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		I-356	APR 19, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					NCE	FEB 02, 2005
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
		6121291	MAR 17, 2017	U-286		
		6121291	MAR 17, 2017	U-431		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5811436	SEP 22, 2015		PED	NOV 17, 2002
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U-285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6062927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		5789449	JAN 06, 2009	U-286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U-286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6133289*PED	NOV 19, 2015	U-286		
		6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	SEP 24, 2010			
021302 001	PIMECROLIMUS;ELIDEL	6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			
		6423722*PED	DEC 26, 2018			
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5030447	JUL 09, 2008		I-304	JAN 18, 2003
		5180589	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U-335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		I-281	JUN 09, 2003
		5180589*PED	JAN 09, 2009		PED	DEC 09, 2003
		5622985*PED	OCT 22, 2014	U-335	D-51	JAN 18, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					I-286	JAN 18, 2003
					PED	JUL 18, 2003
					I-287	FEB 10, 2003
					PED	AUG 10, 2003
					I-304	JAN 18, 2003
					PED	JUL 18, 2003
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004
			5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				I-371	NOV 08, 2005
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003			
			6458811	MAR 10, 2017			
	020741 001	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006		I-367	OCT 21, 2005
			6143769	SEP 05, 2006			
			RE37035	MAR 14, 2009			
	020741 002	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	I-367	OCT 21, 2005
			6143769	SEP 05, 2006			
			RE37035	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	I-367	OCT 21, 2005
			6143769	SEP 05, 2006			
			RE37035	MAR 14, 2009			
>ADD>	021511 001	RIBAVIRIN;COPEGUS				NP	DEC 03, 2005
	020903 001	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U-454		
			6177074*PED	MAY 01, 2017	U-454		
			6461605	NOV 01, 2016	U-478		
			6461605*PED	MAY 01, 2017	U-478		
			6472373	SEP 21, 2017	U-479		
			6472373*PED	MAR 21, 2018	U-479		
	020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
	020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U-353	NCE	MAR 27, 2003
			6015801	JUL 17, 2018	U-353	I-292	APR 14, 2003
						I-291	APR 14, 2003
						D-73	MAY 17, 2005
						D-74	MAY 17, 2005
	020272 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 004	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 005	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 007	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 008	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020588 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020692 001	SALMETEROL XINAFOATE;SEREVENT				I-348	MAR 22, 2005
020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021209 001	SECRETIN;SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699	AUG 13, 2012		I-355	MAY 16, 2005
			5248699*PED	FEB 13, 2013			
			5744501	JAN 06, 2009	U-461		
			5789449	JAN 06, 2009	U-460		
	020478 001	SEVOFLURANE;ULTANE	6444859	JAN 27, 2017		M-17	MAR 30, 2004
			6444859*PED	JUL 27, 2017		PED	SEP 30, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
			6469012	OCT 22, 2019	U-155		
	020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
			6469012	OCT 22, 2019	U-155		
	020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
			6469012	OCT 22, 2019	U-155		
	019766 001	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
						PED	APR 18, 2006
	019766 002	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
						PED	APR 18, 2006
	019766 003	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
						PED	APR 18, 2006
	019766 004	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
						PED	APR 18, 2006
	019766 005	SIMVASTATIN;ZOCOR				I-350	OCT 18, 2005
						PED	APR 18, 2006
>ADD>	021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U-291		
			5308847	MAY 03, 2011	U-292		
			5403833	APR 04, 2012	U-293		
			5989591	MAR 11, 2018			
	021196 001	SODIUM OXYBATE;XYREM				ODE	JUL 17, 2009
						NCE	JUL 17, 2007
	020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
	020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U-160		
>ADD>	020132 001	SUMATRIPTAN SUCCINATE;IMITREX	5863559	JAN 26, 2016	U-72		
>ADD>			6020001	MAR 02, 2012	U-444		
			6368627	MAR 02, 2012	U-444		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020132 002	SUMATRIPTAN SUCCINATE;IMITREX	5863559	JAN 26, 2016	U-72		
>ADD>			6020001	MAR 02, 2012	U-444		
			6368627	MAR 02, 2012	U-444		
>ADD>	020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5863559	JAN 26, 2016	U-72		
>ADD>			6020001	MAR 02, 2012	U-444		
			6368627	MAR 02, 2012	U-444		
	017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002		M-20	AUG 30, 2005
			4536516*PED	FEB 20, 2003		PED	MAR 01, 2006
	017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
			4536516*PED	FEB 20, 2003			
	021184 003	TAZAROTENE;AVAGE	5089509	JUN 13, 2011	U-481	NP	SEP 30, 2005
	020600 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-193		
			5089509	JUN 13, 2011	U-481		
	020600 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-193		
			5089509	JUN 13, 2011	U-481		
	021184 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-481		
	021184 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U-481		
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
	021200 001	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
	021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U-466	NCE	JUL 24, 2007
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
						PED	FEB 11, 2005
						PED	FEB 11, 2007
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
						PED	FEB 11, 2005
						PED	FEB 11, 2007
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
						PED	FEB 11, 2005
						PED	FEB 11, 2007
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
			5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
						PED	FEB 11, 2005
						PED	FEB 11, 2007
	020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U-445		
			4680291	JUL 14, 2004	U-445		
	021318 001	TERIPARATIDE ACETATE;FORTEO				NP	NOV 26, 2005
>ADD>	021015 001	TESTOSTERONE;ANDROGEL	6503894	AUG 30, 2020	U-490		
>ADD>	021454 001	TESTOSTERONE;TESTIM	5023252	JUN 11, 2008	U-483		
	020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U-440		
	020785 001	THALIDOMIDE;THALOMID	6315720	OCT 23, 2020	U-442		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
			5958951	JUN 10, 2017			
			5866590	APR 29, 2016			
	020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
			5958951	JUN 10, 2017			
			5866590	APR 29, 2016			
	020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
			5958951	JUN 10, 2017			
			5866590	APR 29, 2016			
	020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
			5958951	JUN 10, 2017			
			5866590	APR 29, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
			5958951	JUN 10, 2017			
			5866590	APR 29, 2016			
	021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
	021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
	021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
	020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
	021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
			5004758*PED	NOV 28, 2010			
	076110 001	TORSEMIDE;TORSEMIDE				PC	FEB 17, 2003
	076110 002	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
	076110 003	TORSEMIDE;TORSEMIDE				PC	DEC 07, 2002
	076110 004	TORSEMIDE;TORSEMIDE				PC	DEC 10, 2002
	021272 001	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
	021272 002	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
	021272 003	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
	021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
	020475 002	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NS	MAY 10, 2005
			5955109	SEP 21, 2016	U-134		
	021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
>ADD>						I-377	DEC 19, 2005
>ADD>	019415 004	UROFOLLITROPIN;FERTINEX	4589402	JUL 26, 2004	U-482		
>ADD>	019415 005	UROFOLLITROPIN;FERTINEX	4589402	JUL 26, 2004	U-482		
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			
	021341 002	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U-462		
	021341 003	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U-462		
	020593 001	VALPROATE SODIUM;DEPACON				D-72	JAN 24, 2005
	020665 001	VALSARTAN;DIOVAN				I-365	AUG 14, 2005
	020665 002	VALSARTAN;DIOVAN				I-365	AUG 14, 2005
	021283 001	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
	021283 002	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
	021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3	I-365	AUG 14, 2005
	021283 004	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
			6294197	JUN 18, 2017	U-3		
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
>ADD>			4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
>ADD>			4535186	DEC 13, 2007		PED	NOV 02, 2004
			6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
			6403120	MAR 20, 2017	U-451		
			6419958	MAR 20, 2017	U-459		
			6444708*PED	DEC 28, 2013			
			6444708	JUN 28, 2013			
			4535186*PED	JUN 13, 2008			
			5916923*PED	DEC 28, 2013	U-398		
			6274171*PED	SEP 20, 2017			
			6403120*PED	SEP 20, 2017	U-451		
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
>ADD>			4535186	DEC 13, 2007		PED	NOV 02, 2004
			6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
			6403120	MAR 20, 2017	U-451		
			6419958	MAR 20, 2017	U-459		
			6444708*PED	DEC 28, 2013			
			6444708	JUN 28, 2013			
			4535186*PED	JUN 13, 2008			
			5916923*PED	DEC 28, 2013	U-398		
			6274171*PED	SEP 20, 2017			
			6403120*PED	SEP 20, 2017	U-451		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
>ADD>			4535186	DEC 13, 2007		PED	NOV 02, 2004
			6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
			6403120	MAR 20, 2017	U-451		
			6419958	MAR 20, 2017	U-459		
			6444708*PED	DEC 28, 2013			
			6444708	JUN 28, 2013			
			4535186*PED	JUN 13, 2008			
			5916923*PED	DEC 28, 2013	U-398		
			6274171*PED	SEP 20, 2017			
			6403120*PED	SEP 20, 2017	U-451		
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6419958*PED	SEP 20, 2017	U-459	I-325	MAY 02, 2004
>ADD>			4535186	DEC 13, 2007		PED	NOV 02, 2004
			6274171	MAR 20, 2017			
			5916923	JUN 28, 2013	U-398		
			6403120	MAR 20, 2017	U-451		
			6419958	MAR 20, 2017	U-459		
			6444708*PED	DEC 28, 2013			
			6444708	JUN 28, 2013			
			4535186*PED	JUN 13, 2008			
			5916923*PED	DEC 28, 2013	U-398		
			6274171*PED	SEP 20, 2017			
			6403120*PED	SEP 20, 2017	U-451		
	021119 001	VERTEPORFIN;VISUDYNE	4883790	JAN 20, 2007			
	020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002			
			4307100*PED	JAN 08, 2003			
	021266 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021266 002	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021267 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021036 001	ZANAMIVIR;RELENZA	6294572	DEC 15, 2014			
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
	020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
			4831031	MAR 02, 2007		NDF	JUN 21, 2005
			6110918	MAR 26, 2017			
			6232304	APR 01, 2017			
	021223 001	ZOLEDRONIC ACID;ZOMETA				I-361	FEB 22, 2005
	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012		NCE	NOV 25, 2002
	020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES

NEW DOSING SCHEDULE

D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372 NOSOCOMIAL PNEUMONIA
I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION

MISCELLANEOUS EXCLUSIVITY CODES

M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22 CHANGE IN TIME TO ONSET OF ACTION

PATENT USE CODES

U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439 TREATMENT OF OBESITY
U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID

DRUG

U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

U-444 METHOD OF TREATING

U-445 USE AS AN ANTIMYCOTIC AGENT

U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER

U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING

U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)

U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS

U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN

U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15

U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN

U-458 METHOD OF USE OF IMAGENT

U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE

U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE

U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA

U-463 VENOGRAPHY

U-464 PERIPHERAL ARTERIOGRAPHY

U-465 CT IMAGING OF THE HEAD

U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME

U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION

U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS

U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE

U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS

U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES

U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL

U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA

U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B

U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY

U-480 CONTRAST AGENT FOR MRI

U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-

LIKE ACTIVITY

U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....

U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND

U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION

U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE

U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA

U-489 EXPECTORANT

U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-491 METHOD OF DELIVERING A DRUG TO THE LUNG

U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID

U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

For privacy protection, check the box below:

Γ Do not make my name available to other mailers.

Please choose method of payment:

Γ Check payable to Superintendent of Documents
Γ GPO Deposit Account ΓΓΓΓΓΓ-Γ

Γ VISA or MasterCard
ΓΓΓΓΓΓΓΓΓΓΓΓΓΓΓΓ

_____
(Credit card expiration date)

_____
(Authorizing Signature)

Thank you for your order!

(10/01)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.